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Abstract
Classiﬁcation methods for longitudinal data bear the potential to identify classiﬁers that
are superior to those based on cross-sectional data. Recently, the univariate longitudinal
quadratic discriminant analysis (longQDA) was proposed for such purposes. Its key idea
is to use marginal means and covariance matrices of linear mixed models as group-speciﬁc
plug-in estimators for the discriminant rule. This dissertation investigates some of the
unaddressed issues as model selection and several multivariate extensions. A complemen-
tary software implementation in R is presented which fulﬁlls state-of-the-art design and
user requirements. Longitudinal biomarker data from diagnostic studies that are assessed
for their potential to classify patients as therapy-resistant or not serve as motivating
applications.
First, we compare two model selection criteria for determining the most appropriate uni-
variate linear mixed model structure for each group and quantify the corresponding bias
of an incorrect decision. The ﬁrst criterion selects the model structure that yields the
best classiﬁcation performance. The second selects the model with the minimal Bayesian
information criterion and performs better in our simulation study. The bias of an incorrect
decision turns out to be higher for longer data proﬁles and more complex longitudinal mod-
els with random eﬀects. Subsequently, we present multivariate extensions of longQDA.
Two multivariate mixed model classes with a parsimonious parametrization are proposed:
multivariate random eﬀects models and covariance pattern models with a Kronecker pro-
duct structure. With a special set-up of the data, estimation algorithms implemented
for the univariate case are used for the ﬁrst model class. The restricted maximum likeli-
hood estimation of Kronecker product models is accomplished by a numerical constraint
optimization algorithm.
Finally, we introduce the R package longQDA for executing quadratic discriminant analysis
with longitudinal data. Beyond the statistical methodology presented in this dissertation,
the entire process of data analysis up to the reporting of the results is supported. The
software implementation follows the modern object-orientated concept with S4 classes
and fulﬁlls conceptual requirements such as a user-friendly handling, a good run-time
performance and easy extensibility. The latter quality criterion is demonstrated for two
features: the functionalities for multivariate data settings and its use in simulation studies.

Zusammenfassung
Klassiﬁkationsmethoden für Longitudinaldaten bergen das Potenzial bessere Klassiﬁkato-
ren zu identiﬁzieren als es mit Querschnittsdaten möglich wäre. Die univariate longitu-
dinale quadratische Diskriminanzanalyse (longQDA) wurde kürzlich dafür vorgeschlagen.
Die Hauptidee ist, marginale Mittelwerte und Kovarianzmatrizen von linearen gemischten
Modellen als gruppen-speziﬁsche Plug-in-Schätzer für die Diskriminanzregel zu verwen-
den. Diese Dissertation untersucht noch nicht bearbeitete Themen wie die Modellselekti-
on und verschiedene multivariate Erweiterungen. Sie stellt eine Software-Implementierung
in R vor, die moderne Design- und User-Anforderungen erfüllt. Als motivierende Anwen-
dungsbeispiele werden longitudinale Biomarkerdaten aus diagnostischen Studien verwen-
det. Es soll deren Potential bewertet werden, Patienten als therapieresistent oder nicht
resistent zu klassiﬁzieren.
Zuerst werden zwei Modellselektionskriterien verglichen, um die Struktur des linearen ge-
mischten Modells für jede Gruppe zu bestimmen und die entsprechende Verzerrung einer
inkorrekten Entscheidung zu quantiﬁzieren. Das erste Kriterium wählt die Modellstruk-
tur, die die beste Klassiﬁkations-Performance liefert. Das zweite wählt das Modell mit
dem minimalen Bayesschen Informationskriterium und erweist sich in einer Simulations-
studie als das bessere Kriterium. Die Verzerrung durch eine inkorrekte Entscheidung ist
für längere Datenproﬁle und komplexere longitudinale Modelle mit zufälligen Eﬀekten
höher. Anschließend werden multivariate Erweiterungen der longQDA vorgestellt. Zwei
multivariate Klassen der gemischten Modelle mit sparsamer Parametrisierung werden vor-
geschlagen: multivariate Modelle mit zufälligen Eﬀekten und Modelle mit einer Kronecker-
Produkt-Struktur in der Kovarianzmatrix. Mit einer speziellen Datensatzstruktur können
Schätzalgorithmen, die für den univariaten Fall entwickelt wurden, für die erstgenann-
te Modellklasse verwendet werden. Die restringierte Maximum-Likelihood-Schätzung der
Kronecker-Produkt-Modelle erfolgt mit einem numerischen Optimierungsalgorithmus un-
ter Nebenbedingungen.
Zuletzt wird das R-Paket longQDA für die quadratische Diskriminanzanalyse mit Longitu-
dinaldaten präsentiert. Über die statistische Methoden dieser Dissertation hinaus unter-
stützt es den gesamten Datenanalyse-Prozess bis hin zur Dokumentation der Ergebnisse.
Die Software-Implementierung beruht auf dem modernen objektorientierten Konzept von
S4 und überzeugt durch Benutzerfreundlichkeit, eine gute Laufzeit-Performanz und ein-
fache Erweiterungsmöglichkeiten. Das letztgenannte Qualitätskriterium wird anhand von
zwei Features dargestellt, der Funktionalität für multivariate Daten und dem Einsatz in
Simulationsstudien.
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1 Introduction
It appears to me a most excellent thing for the physician to cultivate Prognosis;
for by foreseeing and foretelling, in the presence of the sick, the present, the
past, and the future, [...], he will be the more readily believed to be acquainted
with the circumstances of the sick; so that men will have conﬁdence to intrust
themselves to such a physician. And he will manage the cure best who has
foreseen what is to happen from the present state of matters.
Hippokrates (300 B.C.)
Already in ancient times, correct patient prognoses were indicative for professional medical
work of high quality. The developments in the diagnostics ﬁeld are nowadays so advanced
that we operate at a more microbiological level: Body liquids or genes are searched for
so called biomarkers to aid in diagnosis, prognosis or treatment issues. This is a typical
area for the statistical application of supervised learning algorithms such as discriminant
analysis. One aim is to determine the biomarker that discriminates best between patient
groups, another one is to predict the group membership for future patients: Once a model
has been ﬁnalized and the discriminant function has been derived, how well can we predict
to which group a particular patient belongs?
In most applications in the literature (e.g. in Pepe, 2003; Zhou et al., 2002), biomarkers
are measured only once for each patient. This may be a feasible approach for the most
common case where the diagnosis of a patient is of interest. But if the eﬀect of a therapy
or any other physical process or time-dependent response is of interest, we are faced
with a time-changing phenomenon. Then it is more appropriate to consider longitudinal
proﬁles instead of using just one single measurement of a biomarker: We expect that
characteristics of a (disease) process are reﬂected in turn in the proﬁles of a predictive
biomarker. In fact, the deﬁnition of a biomarker implies repeated measurements over
time: "A biomarker is a molecule that indicates an alteration of the physiological state
of an individual in relation to health or disease state, drug treatment, toxins, and other
challenges of the environment. By this deﬁnition, a biomarker is not static, it is changing
over time." (Zolg and Langen, 2004). Research questions about change are of interest.
Consequently, time needs to be handled as a predictor and longitudinal data analysis is
the method of choice.
2Marshall and Barón (2000) and Tomasko et al. (1999) introduced the longitudinal
quadratic discriminant analysis (longQDA) for such purposes. It extends the Bayesian
classiﬁcation method quadratic discriminant analysis (QDA, McLachlan, 1992) in
that the group parameters for the discriminant rule are estimated by linear mixed
models (Verbeke and Molenberghs, 2000; Weiss, 2005). Also known as multilevel
models or hierarchical linear models, these models are especially adequate for longitudinal
data with their inherent time dependencies. For non-linear time structures which are
more probable for long biomarker proﬁles, the estimation may be easily adapted (De la
Cruz-Mesia and Marshall, 2006).
The longitudinal data structure induces an issue that is irrelevant in discriminant analysis
for cross-sectional data: the selection of the most appropriate model for the biomarkers.
The high ﬂexibility of linear mixed models allows for many model structures, especially
for the covariance structure. For the standard modelling setting where the sole aim is
the estimation of the linear mixed model and eventually the testing of hypotheses, Singer
and Willett (2003) stress the importance of the selection of the respective covariance
structure. This issue is even of higher importance for longQDA. The estimation of the
mean and of the covariance parameters are of equal interest as both are plugged in the
discriminant function. In the standard setting, however, when the estimation of the model
is the sole analysis goal, the focus is more on the mean structure than on the covariance
parameters which determine "only" the precision and consequently the signiﬁcance of the
statistical tests. Furthermore, there is an interest in the eﬀects of an incorrect model
structure on the assessment of the biomarker performance. A comprehensive simulation
study was carried out to address these issues dependent on the length of the biomarker
proﬁles. Model selection was either based on various performance measures, i.e. the ﬁnal
results of longQDA, or on the Bayesian information criterion when estimating the mixed
models, independent of the discriminant analysis task. This issue is either not addressed
in the literature (Marshall and Barón, 2000; Brant et al., 2003) or was only based on the
minimal error rate (Tomasko et al., 1999; Wernecke et al., 2004).
A further topic of this dissertation is the extension to multivariate longQDA where mul-
tivariate mixed models yield group-speciﬁc sample estimators. Note that in this context,
univariate and multivariate always refers to the number of biomarkers, the outcomes of
the mixed models. Strictly speaking, so called univariate mixed models are multivariate in
the usual sense since a vector of repeated measurements is modelled, but all of the same
outcome. Multivariate mixed models are presented in the following which extend the uni-
variate mixed models which turned out to be appropriate for our biomarker settings. These
are mainly multivariate random coeﬃcients models with at least one random intercept.
Regarding alternative models, the suitability of multivariate covariance pattern models are
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elaborated. The appealing idea of these models is to parameterise the covariance matrix
parsimoniously as a Kronecker Product of the auto- and the cross-covariance. Both vari-
ants of multivariate mixed models are applied to data from a diagnostic biomarker study.
Simulated data serve as examples for achieving a superior performance by combining lon-
gitudinal biomarkers.
Beside the methodological development, statisticians are more and more faced with soft-
ware development. A wide-spread application of statistical methods is closely related to
the availability of comfortable state-of-the art software implementations. Therefore, our
R package called longQDA implements the longitudinal quadratic discriminant analysis with
Monte Carlo cross validation, all performance measures and full ﬂexibility in model selec-
tion. The software implementation follows object-orientated programming paradigms and
fulﬁlls requirements as user friendliness and easy extensibility and supports the reporting
of analysis results. In a wider scope, it serves as an example for the implementation of a
statistical method in compliance with requirements of users with statistical knowledge.
To summarize, the main focus of this dissertation is primarily on the following points:
 extend the knowledge in model selection issues in univariate longQDA: assess the
performance not only by standard diagnostic measures such as the area under the
receiver operating characteristic (ROC) curve but also by the predictive Brier score
and contrast their usability in model selection with the Bayesian information crite-
rion (BIC)
 propose a multivariate longQDA based on multivariate random eﬀects models or
covariance pattern models with a parsimonious Kronecker Product structure
 provide a software solution as an R package, which is comfortable to use and easy
to extend due to the S4 implementation
The structure of this thesis follows those topics. The next chapter introduces longitudi-
nal quadratic discriminant analysis to the reader and establishes the terminology in the
diagnostic context. Performance measures are discussed to assess the classiﬁcation po-
tential of biomarkers. One application data set with a univariate longitudinal biomarker
is presented and analysed by means of longQDA. Then the main topics given above are
elaborated in Chapter 3-5, respectively. Chapter 6 concludes with the summary and the
outlook.

2 Univariate Longitudinal QDA and
Performance Measures
This chapter covers the main subject of the dissertation. First and foremost, this is
the longitudinal QDA (longQDA). It extends the classic QDA for cross-sectional data in
that the plug-in estimators for the discriminant rule are the resulting marginal means and
covariances of modeling the longitudinal data by mixed models. Section 2.1 introduces
univariate longQDA and especially mixed models that are appropriate for longitudinal
biomarkers. In Section 2.2, several measures are presented to assess the predictive classi-
ﬁcation performance of biomarkers. This includes performance measures as the area under
the receiver operating characteristic (ROC) curve which are most common in diagnostics
as well as the Brier score and its subcomponents which are currently recommended for
various statistical applications (Gneiting and Raftery, 2007; Gerds et al., 2008). Some
notes follow about Monte Carlo cross validation which is a procedure for robust estimation.
In Section 2.3, the univariate longQDA was applied to real data of HIV patients (taken
from May and DeGruttola, 2007). This serves as one example for commonly encountered
data in longitudinal diagnostic studies and illustrates the beneﬁt for classiﬁcation when
measuring one biomarker longitudinally, i.e. several times during the study.
2.1 Univariate Longitudinal QDA
As in a QDA setting for cross-sectional data, there are two patient groups k = 0; 1
deﬁned by the Gold Standard (reference classiﬁcation) and the indicator function zi [1]
deﬁnes the membership of patient i to group k = 1 where i = 1; : : : ; n[1]. Thus, there are
N = n[0]+n[1] patients in the study. As all applications deal with biomarkers indicative for
therapy response, group 1 consists always of resistant patients and group 0 of non-resistant
patients. The key characteristic for longQDA is that biomarkers are not only measured
once, but several times during a longitudinal diagnostic study, leading to one biomarker
vector wi = (wi1; : : : ; wip)T for patient i . Given group k , a p-variate conditionally normal
density f (wi j zi [1] = k) is assumed for the p-times repeatedly measured biomarker wi ,
i.e. wi j zi [1] = k  N(i [k]; Vi [k]). To account for the repeated biomarker measurements,
an obvious approach is to estimate the mean i [k] and the covariance matrix Vi [k] by a
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linear mixed model. Let w((n[k]p)1) = (w1; : : : ;wn[k])
T be the (n[k]  p)  1-dimensional
vector containing observations of i = 1; : : : ; n[k] patients with measurements taken at
j = 1; : : : ; p visits at time ti j for group k . To ease readability, the group index k indicating
that the biomarker density is deﬁned conditionally on zi [1] = k 8i = 1; : : : ; n[k] is omitted
in all mixed models from now on. For patient i , a linear mixed model is deﬁned for the
univariate response variable wi in each group as
wi(p1) = Xi(pu)(u1) + Zi(ps)bi(s1) + i(p1) (2.1)
where bi  N(0(s1);D(ss)); i  N(0(p1);Ri(pp)). The parameters bi and i are
independent and their covariance matrices are assumed to be positive deﬁnite. Further,
Xi is a (pu) matrix of known covariates, modelling how the biomarker evolves over time
for subject i , and  is a u-dimensional vector of unknown population-speciﬁc regression
parameters.
The marginal normal distribution of wi has the mean i = Xi and the covariance matrix
Vi = ZiDZ
T
i +Ri . Combining the n[k] patient-speciﬁc regression models (Eq. (2.1)), the
model is given by
w = X + Zb +  (2.2)
where the vectors w ; b;  and the matrix X are obtained from stacking the vectors wi ; bi ; i
and the matrix Xi , respectively, underneath each other. The matrix Z is block-diagonal
with blocks of Zi on the main diagonal and zeros elsewhere. Due to the commonly
assumed independence between patients in mixed models, R is a covariance matrix with
a block-diagonal structure of n[k] sub-matrices Ri . This is consequently also true for V ,
hence w  N(X; V ).
Biomarkers are measured at the beginning of the study and at pre-deﬁned scheduled
visits thereafter. As individual visit times ti usually vary from that time schedule and
have diﬀerent time lags in between, mixed models that can incorporate non-equidistant
measurements need to be selected. The selection comprises random coeﬃcients models
that assume a random intercept for each patient (RI) or a random intercept and a linear
random slope (RIS) or extend the RI model by assuming a continuous AR(1) structure
for the residual matrix (RICAR1). Pure covariance pattern models were not considered,
the focus was on mixed model structures (MMS) that allow for variations at an individual
level, at least at baseline. The number of measurements is usually rarely larger than ten
and thus models with more complicated stochastic dependencies as proposed by Taylor
et al. (1994) or Munoz et al. (1992) were not considered.
For clarity, here are the parameters of the considered covariance structure in univariate
longQDA:
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RI: s = 1, i.e. Zi = (1; : : : ; 1)T ; D = d2I ,
Ri = ﬀ
2 I
RIS: s = 2, i.e. Zi =

1 ti1
...
...
1 tip
, D =
(
d2
I
dIS
dIS d
2
S
)
,
Ri = ﬀ
2 I
RICAR1: s = 1, i.e. Zi = (1; : : : ; 1)T ; D = d2I ,
Ri = (rj j 0)i = ﬀ
2[ﬃ(ti j ti j 0)1(j 6= j 0) + 1(j = j 0)]
with 0 < ﬃ < 1 and j; j 0 = 1; : : : ; p.
The matrix I is the p-dimensional identity matrix, d2
I
resp. d2
S
is the variance of the random
intercept resp. of the linear slope and dIS is the covariance between the intercept and the
linear slope.
Note that the RIS model should always be parameterized to allow for a correlation between
the random intercepts and the random slopes as the correlation parameter changes due
to a time shift and thus should not be constrained (Weiss, 2005, p.260f.).
The aim in quadratic discriminant analysis is to ﬁnd a quadratic discriminant function
m(wi) for the classiﬁcation of patients into groups deﬁned by a Gold Standard. The
discriminant function m(wi) for longQDA is the same as for QDA, the log-ratio of
f (wi j zi [1] = 1) to f (wi j zi [1] = 0). Future patients are classiﬁed according to the fol-
lowing discriminant rule: If m(wi)  ﬁ 0, where ﬁ 0 is a selected cut-oﬀ value, then patient
i with biomarker measurements wi is assigned to group k = 1. If m(wi) < ﬁ 0, the patient
is assigned to group k = 0.
Now let [1] be the prior probability that a patient belongs to the group with biomarker
density f (wi j zi [1] = 1) prior to observing wi , and set [1] = 1   [0]. For normal distri-
butions, the optimal discriminant rule, in the sense of minimizing the expected probability
of misclassiﬁcation, is given by ﬁ 0 = log([0]=[1]). This is also known as the Bayesian
decision rule (Johnson and Wichern, 2002). As the posterior probability is proportional to
the product of the likelihood and the prior probability (resp. equal to after multiplication
by the normalising constant), the classiﬁcation rule is based on the posterior probability
pi [1] with
pi [1] = P (z^i [1] = 1jwi) =
exp
[
  12(wi   [1])
T V  1
i [1] (wi   [1])
]

[
jVi [1]j
]
 
1
2
 [1]
1∑
k=0
exp
[
  12(wi   [k])
T V  1
i [k] (wi   [k])
]

[
jVi [k]j
]
 
1
2
 [k]
: (2.3)
The posterior probabilities p[1] = (p1[1]; : : : ; pn[1][1])
T constitute a univariate measure
which summarizes the predictive classiﬁcation information of the longitudinal biomarker
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proﬁles. They form the basis for the overall assessment of the biomarker performance
which is covered in the next section.
To prevent an overoptimistic estimation of the biomarker performance, Monte Carlo cross
validation (MCCV) with sampling without replacement (Shao, 1993) is applied. The
principle of any cross validation procedure is to split the data repeatedly in two disjunct
samples called training and test set. The training set is used for estimation purposes
whereas the performance is then independently assessed with the test set. The repetition
of this procedure reduces any possible systematic bias due to a possibly non-representative
partitioning of the data by chance. The results are summarized over all repetitions. The
approach is termed Monte Carlo cross validation as the samples are taken randomly, with
a ﬁxed number of repetitions (e.g. 50, independent of the size of the sample). Due to
the random drawing, it is assured that data of one patient are used for training as well as
for testing. For longitudinal data, all observations of one patient were sampled at once
to preserve the correlation structure (Goldstein, 2003). Thus, patients and not single
observations were sampled. The mixed model estimators for the discrimination rule were
evaluated in the training sets and the rule was applied to the samples in the test sets
yielding estimations for the performance measures. By the way, to preserve the group
proportions, it is important to split the data sample into the training and test set for
each group separately. Results are reported in terms of median estimates over all MCCV
samples, and the empirical 10 and 90 percentiles are used as non-parametric conﬁdence
intervals (for theoretical justiﬁcations see Efron and Tibshirani, 1993).
2.2 Classiﬁcation Performance Measures
To assess the performance of a biomarker to predict the group membership, we aim for
a small number of performance measures providing the most comprehensive summary.
For this purpose, measures that are either based on the receiver operating characteristic
(ROC) curve (Pepe, 2003; Zhou et al., 2002) or on the Brier score (see e.g. Gneiting
and Raftery, 2007) are presented in the following and contrasted with respect to their
properties.
First, the common classiﬁcation approach in diagnostics is elucidated. In the typical set-
ting, a medical test is expected to give either a positive or a negative test result. To fulﬁll
this requirement of a binary test result, continuous test results need to be dichotomized so
that a test is said to be positive if the result exceeds or is equal to a selected threshold ﬁ.
When biomarker data are assessed by classiﬁcation methods as longQDA which yield a
group-speciﬁc posterior probability for each patient, the probabilities for one group may
take over the role of the continuous test results. By deﬁnition, these are the probabilities
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for group k = 1 as the test positivity is generally deﬁned for the group with larger test
results. In other words, ﬁ is the parameter which determines at what value the posterior
probability is dichotomized to yield a binary prediction z^i [k] corresponding to a positive
resp. negative test result.
Usually, medical tests are imperfect in that the test results resp. the posterior probabilities
of both groups overlap yielding misclassiﬁcations. This means that patients with false
positive test results have posterior probabilities that are larger than or equal to ﬁ but are
members of group 0. Patients with false negative results are characterized by posterior
probabilities which are smaller than ﬁ but are members of group 1. Therefore, the
group-speciﬁc probabilities that a patient is correctly classiﬁed may serve as performance
measures.
The sensitivity is deﬁned as P (pi [1]  ﬁj zi [1] = 1) and the speciﬁcity as P (pi [1] <
ﬁj zi [1] = 0). They are also denoted as true positive and true negative fraction. These
measures are estimated by the sample proportion of correctly classiﬁed patients of all
patients in group 1 resp. group 0 according to the Gold Standard. This approach implies
a decision given a 0-1-loss function (Friedman et al., 2009, Section 2.4) weighting all
misclassiﬁcations equally by 1. Both measures assess the local (and not the global)
performance of a diagnostic test as they are threshold-speciﬁc. Varying ﬁ on the scale
of the posterior probabilities yields all possible threshold-speciﬁc sensitivity and speciﬁcity
pairs. A local performance criterion for a diagnostic test may be the maximisation of
sensitivity and speciﬁcity. However, each measure can only be maximised at the expense
of the other if the densities of the posterior probabilities overlap. Decreasing the thresholds
ﬁ increases the sensitivity. When the speciﬁcity is favoured over the speciﬁcity, ﬁ should
be decreased. The ROC curve is a graph that displays this trade-oﬀ (Figure 2.1).
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Figure 2.1: Histograms of simulated posterior probabilities for group 1 (left) and corre-
sponding ROC curve (right).
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The sensitivities are plotted on the y-axis as a function of the false positive fraction (1-
speciﬁcity) over the entire range of possible thresholds. To assess the performance at
a global level, the most commonly used summary measure in diagnostic settings is the
area under the ROC curve (AUC). The AUC equals one for perfect classiﬁcation and
0:5 for biomarkers with no discriminatory power. The AUC corresponds to an average
performance over all possible decisions. This is a quite artiﬁcial construct with limited
expressiveness.
A further performance measure is the Brier score (BS) which will be considered in details.
In the two-group case, it is deﬁned as
BS = 1 
1
N
N∑
i=1
(p^i [1]   zi [1])
2:
The score measures the discrepancy between the observed real group membership and
the estimated posterior probability of the classiﬁcation method using a squared error loss
function. To ease the comparability of the performance measures, the BS is scaled as
such that a maximum score of 1 is indicative for the best classiﬁcation performance. It
reaches its minimum at 0 in the unlikely case that all patients are misclassiﬁed with a
group-speciﬁc probability equal to zero. The BS equals one minus the Gold Standard's
variance ﬀ2z[1] for a constant prediction with a probability equal to the prior [1]. This
provides a threshold of the BS and assesses a prediction based solely on the a priori
knowledge.
Ikeda et al. (2002) study the relationship between AUC and BS but could not identify
a linkage between the two. This is not surprising as there are diﬀerences regarding the
content. The AUC and the sensitivity and speciﬁcity are performance measures that
indicate how eﬀective the classiﬁcation rule is in assigning a patient to the correct group
and are therefore called accuracy measures by Hand (2001). The performance is only
evaluated in terms of correct and misclassiﬁed patients without respect to the probability
with which the patient is classiﬁed into a certain group. The BS, however, provides
information about the relative severities of misclassiﬁcations by placing diﬀerent weights
on misclassiﬁed as well as on correctly classiﬁed patients. This score overcomes the
shortcomings of the AUC which gives no indication of the degree of conﬁdence one
should place in a classiﬁcation. A distinction should be made, for example, between the
classiﬁcation of one patient with a high probability for one group, say 0:99, and another
one with a much lower probability near 0:5. In an assessment by the AUC, however, both
are treated the same.
A more detailed view based on the decompositions of the Brier score proposed by Sanders
(1963), Murphy (1973) and Yates (1982) illustrate that the BS enables a more com-
prehensive assessment of the biomarker performance. For Sanders' decomposition, the
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posterior probabilities for one group (here for k = 1) are categorized into say 5 cells
c = 1; : : : ; 5 (The number of cells depends on the desired precision and the size of the
patient sample.). The patients in cell c are deﬁned by Jc := fi = 1; : : : ; Nj pi(1) 2 Mcg
with Mc = [ c 15 ;
c
5); c = 1; : : : ; 4 and M5 = [
4
5 ; 1]. Thus, jJc j = nc and N =
∑5
c=1 nc .
With this discretisation of the posterior probabilities, the BS is partitioned as follows:
BS = 1 
1
N
5∑
c=1
∑
i2Jc
(p^i [1]   zi [1])
2
= 1 
( 1
N
5∑
c=1
nc z[1]c(1  z[1]c) +
1
N
5∑
c=1
nc(^p[1]c   z[1]c)
2
)
= 1  (BSD + BSC)
where z[1]c is the proportion of nc patients who are members of group 1 deﬁned by the
Gold Standard and p[1]c is the corresponding expected proportion. The latter is estimated
by the mean posterior probability of cell c , averaged over nc patients. The measure
BSD assesses the discrimination performance and BSC the calibration performance (a.k.a.
precision). According to Gurney and Swensen (1995), calibration values indicate the ability
of the classiﬁcation rule to assign numeric probabilities, discrimination values indicate the
ability to distinguish outcomes (e.g. resistant vs. non-resistant patients). Murphy (1973)
partitions the discrimination component of Sanders further:
BSD = z[1](1  z[1]) 
1
N
5∑
c=1
nc(z[1]c   z[1])
2
where z[1] is the proportion of patients in group 1 in the sample. He proposes this
decomposition as the variance of the Gold Standard is determined "by nature" and does
not depend on the performance of the biomarker which should actually be assessed. The
second term is called Murphy's discrimination component BSDM and is preferred over BSD.
Its upper bound is the Gold Standard's variance ﬀ2z[1] , which is the ﬁrst term of BSD.
It is especially important to take the calibration into account when decisions are made on
an individual basis, whether a clinician wants to know with which probability a patient is
classiﬁed into one of the groups or whether classiﬁcation rules based on diﬀerent model
assumptions or biomarkers are compared by the statistician. In both cases, the posterior
probabilities should be interpretable in a frequentistic sense. Diamond (1992) points out
that the optimization of one component often goes at the expense of the other due to
diﬀerent implied scales of the measures: The discrimination supports a categorical pre-
dicted result (or one that can be at least discretized in two categories without much loss),
whereas the calibration is maximised at the expense of discrimination. Therefore good
calibration does not imply good discrimination, and vice versa. For example, a classiﬁca-
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tion rule that predicts the membership to group 1 with a constant probability equal to
the group proportion z[1], i.e. without adding any additional information to improve the
prediction, has a good calibration but a bad discrimination. One example for a rule with
perfect discrimination but poor calibration would be the following. Given group propor-
tions of 2:1, a rule predicts with uniformly distributed pi [1] 2 [0; 0:2] 8i 2 1; : : : n(0) and
pi [1] 2 [0:21; 1] 8i 2 1; : : : n(1), resulting in two separated probability densities. The BS
takes both performance aspects into account whereas the AUC is only a measure for the
discriminative power of a classiﬁer.
A related limitation of the AUC becomes obvious when considering the quality require-
ment for a classiﬁcation rule (also known as scoring rule) to be strictly proper (Gneiting
and Raftery, 2007; Hand, 1997). A strictly proper classiﬁcation rule is characterized by
attaining its maximum expected value given the posterior probability distribution if and
only if the true probabilities for the patient's group membership are used. The BS has
the desirable property to be a strictly proper rule but the AUC does not. The AUC fulﬁlls
only the weaker condition of non-strictly properness: The true probabilities may yield the
same performance as others, not necessarily a higher one. For example, the AUC also
reaches its maximum if all patients are classiﬁed into the correct group, but with uncertain
posterior probabilities close to 0:5.
Another decomposition of the Brier Score (Yates, 1982) is based on the covariance de-
composition and does not require a discretisation of the posterior probabilities. It provides
performance measures which are more common in statistics. According to the well known
decomposition of the mean squared error MSE = variance+ bias2, the decomposition is
BS = 1 
(
ﬀ2z[1] + ﬀ
2
p[1]
  2ﬀz[1];p[1] + (p[1]   z[1])
2
)
= 1 
(
z[1](1  z[1]) + ﬀ
2
p[1]
+ ﬀ2p[1];min   2(p[1j z[1]=1]
 p[1j z[1]=0])z[1](1  z[1]) + (p[1]   z[1])
2
)
where ﬀ2p[1] = ﬀ
2
p[1]
 ﬀ2p[1];min is the "excess" variability with the conditional minimum vari-
ance ﬀ2p[1];min = (p[1j z[1]=1]   p[1j z[1]=0])
2z[1](1  z[1]), p[1] is the estimated overall mean
posterior probability for group k = 1; p[1j z[1]=1] and p[1j z[1]=0] are, respectively, the mean
posterior probabilities for group k = 1 resp. k = 0 deﬁned by the Gold Standard. Re-
garding the variance of the posterior probabilities, we should aim for a classiﬁcation rule
with a minimal variance ﬀ2p[1] . But the only way ﬀ
2
p[1]
reaches its minimum possible value
zero is when the posterior probabilities are the same for all patients and then the covari-
ance ﬀz[1];p[1] is zero as well. Thus the proper objective to minimize ﬀ
2
p[1]
is to condition
on the relationship between the Gold Standard and the biomarker ﬀz[1];p[1] . The con-
ditional minimum prediction variance given ﬀz[1];p[1] is ﬀ
2
p[1];min
. The ratio between the
excess variation and the conditional minimum prediction variance QVar = ﬀ2p[1]=ﬀ
2
p[1];min
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should be small and is inversely proportional to the 2-sample t-test for comparing the
group-speciﬁc predictions p[1j z[1]=1] and p[1j z[1]=0] (Spiegelhalter, 1986). Besides QVar,
the covariance ﬀz[1];p[1] between the Gold Standard and the posterior probabilities serves
as performance measure. It is advisable to standardize this covariance to yield the point
biserial correlation z[1];p[1] . Note the smaller range compared to correlation coeﬃcients
for two continuous variables. The range depends on z[1], the limits are given in Grad-
stein (1986). The separation of the posterior probability distributions of the two groups
may be assessed by Diﬀp[1] = p[1j z[1]=1]   p[1j z[1]=0]. The bias (p[1]   z[1]) indexes a per-
formance characteristic labelled calibration-in-the-large, CalL, which reﬂects the ability of
the biomarker to match mean posterior probabilities to the proportion of patients in group
k = 1 deﬁned by the Gold Standard. It is interpreted as the "baseline knowledge" about
group membership.
All in all, the Brier score with its derived performance measures allows for a more profound
assessment of the biomarker performance than the ROC curve related measures by taking
the actual location and shape of the group-speciﬁc posterior probability distributions in
account in various ways. The AUC is reported as it is the most commonly used measure
in diagnostic medicine. Other authors (Spiegelhalter, 1986; Harrell, 2006) make similar
compromises regarding their choice of performance measures.
2.3 Application of Longitudinal QDA:
HIV Therapy Resistance Data
The application of longQDA is illustrated with data of one biomarker that is indicative
for HIV therapy resistance. The data were recently presented in the literature (May and
DeGruttola, 2007) and are freely available. The aim is to classify patients based on
their viral load either as resistant or non-resistant to speciﬁc HIV treatments (Nevirapine,
Delavirdine and Efavirenz) and thus to replace the need of phenotype or genotype data.
The group with the worse condition is denoted by k = 1, hence resistant patients are
members of group k = 1 and non-resistant patients of group k = 0. The presence of
resistance is assumed to be perfectly determined by the presence of the reported K103N
mutation of HIV (although this is possibly idealistic for a test assay based on phenotype
or genotype data). Using this Gold Standard, there are 292 patients with no resistance
and 64 who exhibited the mutation. The viral load is measured by the amount of HIV
RNA and up to 6 measurements (at baseline, after 2, 4, 8, 16 and 24 weeks) are avail-
able for each patient. The analysis was restricted to patients with complete data to
enable a fair comparison of the results between single visits with the same data base.
Biomarker data of 59 non-resistant and 26 resistant patients were considered. This im-
plies a non-informative drop-out and a missing at random mechanism which was assumed
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for simplicity. Otherwise, other methods need to be applied (Hogan et al., 2004; Thiébaut
et al., 2005).
For all QDA and longQDA analyses, 50-fold MCCV was applied and patients were ran-
domly allocated to the training or the test set according to a group-wise ratio of 2:1. The
priors were ﬁxed to the group proportions of the entire dataset (not the one reduced to
the complete cases), assuming that these are good estimations for the "prevalence" of
therapy resistance. So [1] was 0:18 and hence the lower bound for the BS 0:852, the
range of the biserial correlation [ 0:683; 0:683].
The biomarker measurements were log10-transformed (labelled LBM1). The resulting
group-speciﬁc proﬁles on this scale are depicted in Figure 2.4 below (ignore the colouring).
Proﬁles of non-resistant patients decrease quadratically whereas those of the resistant
group have a rather unchanged, more linear shape from the third visit on. At baseline,
the non-resistant patients have a wider range of initial biomarker values but the variation
during the treatment is higher for the resistant ones. Besides, an atypical subgroup is
present in the non-resistant group whose proﬁles do not decline over time and resemble
rather the proﬁles of patients who were classiﬁed as resistant by the Gold Standard.
A comparison of the biomarker levels at group level show that from the ﬁfth visit on, the
ranges of the boxplots do not overlap at all (Figure 2.2(a)), indicating a good separation
between the groups. The variances of the viral load measurements are especially high
from the third visit on in both groups.
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Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6
LB
M
1
N = 59 N = 59 N = 59 N = 59 N = 59 N = 59
N = 26 N = 26 N = 26 N = 26 N = 26 N = 26(a) Boxplots are given for the scheduled
visit; for non-resistant patients in black, for
resistant patients in red.
Visit 1 2 3 4 5 6
1
. . . 0:59 0:50 0:42 0:27 0:26
2 0:55
. . . 0:66 0:50 0:46 0:38
3 0:57 0:45
. . . 0:85 0:74 0:71
4 0:35 0:36 0:73
. . . 0:88 0:85
5 0:33 0:42 0:67 0:83
. . . 0:95
6 0:22 0:36 0:56 0:79 0:92
. . .
(b) Autocorrelations for non-resistant patients are given in
the upper, for resistant patients in the lower triangle.
Figure 2.2: Boxplots and autocorrelations of log-transformed HIV RNA
The empirical autocorrelations were estimated for all patients with complete measure-
ments (Table 2.2(b)). Also for correlations of visits more than one lag apart, they are of
medium or large size, higher than 0:6 from the third visit on. At the ﬁrst and second visit,
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this is only true for those with lag 1. Both groups have autocorrelations of similar size
but they are more or less higher in the non-resistant group (one exception: coeﬃcient of
ﬁrst and ﬁfth visit). As the time dependencies in the biomarker data are of considerable
size, they should be adequately taken into account by using mixed models to estimate the
group-speciﬁc parameters.
2.3.1 Biomarker Performance at Single Visits by QDA
Before applying longQDA, the data are further explored by examining the performance
of the biomarker at single visits. This provided insight into which visits contribute most
to the longitudinal performance. Except for the calibration performance, an improvement
in performance is observed over time (Table 2.1(a)). For the calibration it is vice versa,
the worst is achieved at visit 5 or 6. The performance of the 3rd visit is for most of the
measures as weak as at baseline and there are only small performance diﬀerences between
visit 5 and 6.
(a) Comparing QDA with single visits.
Visit AUC BS BS
[ ]
C BSDM z[1];p[1] ln(Q
[ ]
Var
)
1 :55 [:43; :66] :79 [:77; :80] :003 [:001; :024] :01 [:00; :01] :09 [ :04; :25] 8 [7; 11]
2 :69 [:53; :78] :81 [:78; :82] :009 [:010; :028] :02 [:01; :05] :30 [ :07; :41] 5 [5; 7]
3 :61 [:51; :73] :79 [:76; :81] :007 [:001; :045] :01 [:00; :03] :14 [ :04; :39] 6 [5; 9]
4 :66 [:56; :78] :81 [:78; :82] :011 [:003; :039] :03 [:01; :05] :27 [ :10; :42] 5 [4; 7]
5 :71 [:60; :85] :83 [:78; :85] :030 [:007; :096] :08 [:05; :12] :41 [ :23; :59] 3 [3; 4]
6 :77 [:64; :87] :84 [:77; :86] :026 [:009; :102] :08 [:05; :13] :49 [ :27; :62] 3 [2; 3]
(b) Comparing longQDA with 3, 4, 5 and 6 visits.
# of Visits AUC BS BS
[ ]
C BSDM z[1];p[1] ln(Q
[ ]
Var
)
3 :66 [:55; :77] :80 [:74; :83] :033 [:008; :091] :04 [:02; :07] :24 [:04; :43] 4 [4; 6]
4 :65 [:55; :74] :80 [:75; :83] :027 [:005; :072] :03 [:01; :06] :26 [:04; :42] 4 [3; 7]
5 :74 [:62; :84] :82 [:76; :86] :024 [:008; :080] :06 [:03; :09] :40 [:23; :57] 3 [2; 4]
6 :75 [:66; :85] :80 [:72; :86] :056 [:020; :135] :08 [:05; :12] :44 [:28; :60] 2 [1; 3]
Table 2.1: Selected performance measures comparing (long)QDA, given as median with
the 10th and 90th percentile. For all performance measures indicated by [ ],
lower values are indicative for a better performance. For the others, it is
vice versa. The results of the bias for CalL are similar to those of BSC as
is the diﬀerence of the group-speciﬁc average posterior probabilities to the
discrimination measures. They are therefore omitted in the table.
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2.3.2 Longitudinal Biomarker Performance by longQDA
As the exploratory analysis showed how the initial biomarker levels vary across patients,
the mixed models were conﬁned to those with at least a random intercept. Therefore,
RI, RIS and RICAR1 are considered as mixed model structures (MMS). For simplicity,
the same MMS is always applied for both groups. Time was included as a ﬁxed and
random linear eﬀect in the mixed model and an additional quadratic ﬁxed time eﬀect
for longQDA analyses involving at least four visits. When estimated the model without
the ﬁxed quadratic time eﬀect, a worse ﬁt resulted. However, the performance of the
biomarker did not change remarkably. A restricted maximum likelihood (REML) approach
was used to estimate the group-speciﬁc covariance parameters. The longitudinal variant
of QDA was applied including either the ﬁrst g = 3; 4; 5 or 6 visits.
The results of longQDA with regard to the number of measurements per patient were
assessed and the performance of the diﬀerent mixed model structures (MMS) were com-
pared. The MMS were selected based on the BIC (see (3.1) for the deﬁnition) which
turned out to be the better approach in our simulation study (presented in Chapter 3).
Including the ﬁrst 3 visits, RI was selected as the best model, whereas the RIS model was
the favoured structure for data including 4, 5 or 6 visits. The estimated model parameters
of the RIS model based on the complete biomarker data are listed in Table 2.2.
0 1 2 dI dS dIS ﬀ
2
non-resistant patients 4.5 -13.2 18.7 0.46 8.15 0.32 0.32
resistant patients 4.3 -7.7 13.5 0.22 4.43 0.30 0.28
Table 2.2: Group-speciﬁc estimates based on RIS model for 6 visits
Mean group proﬁles and biomarker proﬁles simulated according to the resulting marginal
distribution are depicted in Figure 2.3. The simulated proﬁles resemble the observed ones
depicted in Figure 2.4 (ignore colouring) quite well.
The classiﬁcation performance of the biomarker, dependent on the number of visits in-
cluded in longQDA, is shown in Table 2.1(b). Nearly all performance measures indicate an
increase in performance over time, especially for 5 and 6 measurements. This is consistent
with our ﬁndings from the analyses based on single visits where the ﬁfth and sixth one
performed best. However, the calibration measures are worse when using longer biomarker
proﬁles. In general, the biomarker performance with 5 or 6 measurements is as well only of
medium size. This may be due to the subgroup in the non-resistant group who have quite
ﬂat proﬁles similar to the resistant patients. According to their high predicted posterior
probabilities for being resistant, this subgroup was identiﬁed by longQDA as being rather
resistant than non-resistant.
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Figure 2.3: Simulated biomarker proﬁles based on the marginal mixed model parameters
for 6 visits (non-resistant patients in black on the left, resistant patients in
red on the right). The bold lines are the estimated means.
In Figure 2.4, the biomarker proﬁles were coloured according to the results gained by
longQDA with 6 visits. Overall, the posterior probabilities match well with our previous
ﬁndings that therapy resistance is characterized by a rather ﬂat proﬁle and non-resistance
by a clear decrease in viral load over time. Patients in the resistant group are harder to
classify correctly due to their more heterogeneous proﬁles.
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Figure 2.4: Individual observed biomarker proﬁles coloured according to the predicted pos-
terior probabilities to be resistant, estimated by longQDA with all 6 visits
(non-resistant patients on the left, resistant patients on the right).
To put emphasis on the gain in performance by using longitudinal measurements, the in-
crease in classiﬁcation certainty over time is examined at last and the individual posterior
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probabilities for being resistant based on 1, 3, 4, 5 and all 6 visits are compared in Fig-
ure 2.5. Note that the probability at baseline was only included there as reference point
at which the patients were still untreated and should therefore not be used as a prediction
for therapy response. Using more and more repeated measurements and waiting some
time, the predictions improve: For the "real" non-resistants with a low probability for
being resistant, the posterior proﬁles tend downwards. The resistants, in contrast, exhibit
increasing posterior proﬁles over time, both reﬂecting an increase in classiﬁcation cer-
tainty. The equivalent estimations of QDA using only the last cross-sectional biomarker
measurement (green dots) were included as reference. The posterior probabilities of QDA
tend to be more central for the non-resistant patients and lower for the resistant ones.
This involves also a lower separation of the probabilities' distributions.
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Figure 2.5: Increase in classiﬁcation certainty with increasing number of measurements
(non-resistant patients in black on the left, resistant patients in red on the
right). The green dots are the estimated posterior probabilities by QDA when
using only the data of the 1st, 3rd, 4th, 5th and 6th visit.
3 Model Selection in Longitudinal QDA
3.1 Introduction
In this chapter, the importance of selecting an appropriate mixed model structure is exam-
ined when estimating the group-speciﬁc parameters of the discriminant rule. The model
selection is an even more important issue in longQDA than in the case where the sole
interest is in the estimation of mixed models: In longQDA, all estimated parameters ﬁnd
their way in the discriminant rule, none of them are nuisance parameters. For simplicity,
the issue is elaborated for univariate longQDA. It is assumed that the model selection
approach may be transferable to the multivariate case.
In Section 3.2, the eﬀects of ﬁtting various mixed models are exampliﬁed with the HIV
therapy resistance data of Section 2.3. For real data, the true model structure is un-
known. However, in simulations, the true, underlying model structure can be ﬁxed. The
detailled setup of the simulation study is described in Section 3.3. In the simulation, two
diﬀerent selection approaches are compared, one where the model was selected based on
having the highest performance measures, and another where the selection was based on
BIC (Subsection 3.4.1). Within the ﬁrst approach, all performance measures introduced in
Section 2.2 are considered to ﬁgure out whether some are more appropriate than others.
In Section 3.4.2, the importance of model selection is assessed for longQDA by quanti-
fying the bias of an incorrect model structure. The simulation results are summarized in
Section 3.4.3.
3.2 Motivation
To demonstrate the eﬀects of diﬀerent model structures with a practical example and to
put emphasis on the model selection issue, the biomarker proﬁles of the application data
set are modelled by RI, RIS, RICAR1 and QDA. Classic QDA ignores the time structure in
the data: The order of the visits as well as the actual individual visit times are not taken
into account and the covariance matrices are totally unstructured. The abbreviation
(M)MS in contrast to MMS refers in the following to model structures which do not
necessarily include only mixed models. The estimated performance measures for 5 visits
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are given in Table 3.1, the estimated posterior probabilities are displayed in Figure 3.1.
These results are quite diﬀerent and depend on the chosen (M)MS, especially at the
individual level. So there is a need for a reliable model selection criterion.
(M)MS AUC BS BS
[ ]
C BSDM z[1];p[1] ln(Q
[ ]
Var
)
RI :74 [:63; :85] :80 [:70; :87] :075 [:020; :135] :08 [:05; :12] :50 [:32; :65] 1 [1; 2]
RIS :74 [:62; :84] :82 [:76; :86] :024 [:008; :080] :06 [:03; :09] :40 [:23; :57] 3 [2; 4]
RICAR1 :72 [:61; :86] :81 [:73; :87] :058 [:017; :135] :09 [:05; :12] :45 [:28; :60] 2 [2; 3]
QDA :68 [:57; :82] :79 [:73; :85] :039 [:015; :092] :05 [:02; :09] :33 [:28; :56] 3 [2; 4]
Table 3.1: Selected performance measures comparing (M)MS of longQDA. They are given
as median with 10th and 90th percentile.
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Figure 3.1: Diﬀerences between predicted posterior probabilities due to the (M)MS selec-
tion in longQDA (non-resistant patients in black on the left, resistant patients
in red on the right).
With real data, the "true", underlying model structure is not known. However in simula-
tion studies, this lack can be overcome and the following research questions are addressed:
 Which is the most appropriate approach for choosing the model structure in the
estimation step of longQDA?
 How important is the selection of the correct mixed model? How much performance
loss occurs by just applying QDA, ignoring the time structure? How large are the
eﬀects of an incorrect structure on the results, at the global as well as at the
individual level?
For the ﬁrst issue, two approaches are compared. An heuristic approach would be to ﬁt
the longitudinal biomarker data by diﬀerent mixed models and to select that structure
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for the two groups which yielded the best classiﬁcation performance. This approach was
chosen by Tomasko et al. (1999) and Wernecke et al. (2004) based on the error rate.
Independent of the appropriateness of the approach to use a performance measure as
selection criterion, it is recommendable to refrain from the error rate as misclassiﬁcations
are treated equally for both groups (Pepe, 2003). Another approach would be to select
the model with the best ﬁt according to the BIC in the estimation step of longQDA.
The use of the BIC to select the best covariance structure of various linear mixed models
is common practice and either favoured over AIC (Littell et al., 2000) or leads to the
same decisions (Gurka, 2006). Two things are noteworthy when using BIC under REML
estimation as we did. First, BIC comparisons are only allowed for models with the same
ﬁxed eﬀects (Weiss, 2005, p.18). This is the case for all our models. Second, there is
some controversy regarding the correct form of the BIC (Gurka, 2006; Greven, 2007).
There are concerns regarding the sample size (N   u in the penalizing term for REML
instead of N for ML in the case of u ﬁxed eﬀects) and the number of parameters (O for
REML or u+O for ML). Consequently, the computation of the BIC diﬀers from software
to software. However, whenever only models with the same ﬁxed eﬀects are compared
within the same software, the absolute value of the BIC does not matter. We use the
BIC as implemented in the R packages nlme and lme4:
BIC =  2  lREML + (u +O)  log(N   u); (3.1)
where lREML is the restricted log-likelihood and O is the number of unique parameters in
the covariance matrix Vi .
The advantage of the BIC approach is the separation of the model selection from the
actual goal of the analysis, the classiﬁcation. Further on, this decision is based on diﬀerent
data: The estimation step is performed on the training  and the classiﬁcation on the
test sets. The importance of choosing the correct mixed model and not applying QDA
is a second issue and assessed by the diﬀerences between the performance measures at a
global level and between the estimated posterior probabilities at an individual level.
3.3 Simulation Setup
As the ﬁndings might depend on the number of visits and the assumed model structure,
data with 3, 6 and 10 visits were simulated according to a RI, RIS or a RICAR1 struc-
ture. These "true" covariance structures are denoted by *, i.e. there are RI*, RIS* and
RICAR1*. The structures were again assumed to be the same in both patient groups.
The biomarker measurements were simulated according to the implied marginal densities
of the mixed models with the following parameters:
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RI* TTT
Non-resistant:
[0] = (4:0; 4:4)
T , D[0] = 0:79; ﬀ2[0] = 0:77
Resistant:
[1] = (4:0; 1:5)
T , D[1] = 0:55; ﬀ2[1] = 0:51
RIS* TTT
Non-resistant:
[0] = (4:0; 4:4)
T , D
0
[0] =
(
d2
I[0] IS[0]
IS[0] d
02
S[0] = d
2
S[1]=d
2
I[1]
)
=(
0:39 0:35
0:35 17:1
)
;
ﬀ2[0] = 0:55
Resistant:
[1] = (4:0; 1:4)
T , D
0
[1] =
(
0:25 0:47
0:47 16:3
)
; ﬀ2[1] = 0:39
(Note the special notation of D
0
: It contains the variance of the intercept d2
I
as usual but the slope's variance standardized by the variance of the intercept
in the diagonal and the correlation IS in the oﬀ-diagonal. Thus the assumed
correlation between the random intercept and the random slope may directly
be read oﬀ and compared to the variances on the same scale.)
RICAR1* TTT
Non-resistant:
[0] = (4:2; 4:8)
T , D[0] = 0:58; ﬀ2[0] = 1:24; ﬃ[0] = 0:0008
Resistant:
[1] = (4:1; 1:6)
T , D[1] = 0:47; ﬀ2[1] = 0:69; ﬃ[1] = 0:0001
These are the estimates of the HIV application data set when using 50-fold MCCV. The
data set comprised all complete cases with 6 visits.
The models under consideration for the simulated data were RI, RIS, RICAR1 and QDA.
The models were always ﬁtted with the same structure for both groups. For the mixed
models, a linear ﬁxed time eﬀect as given by the true model was part of the model and
an unstructured mean proﬁle was ﬁtted for QDA as usual. The parameters of the "true"
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models are ﬁxed by the simulation design and were not estimated. The classiﬁcation
rule, however, had to be evaluated in the test sets for the "true" as well as for the
examined models to assess the biomarker performance. The best performance is expected
for the MMS matching the underlying "true" model. Our approach provided the induced
deviations when estimating the mean vector and the covariance matrix with the correct
resp. the incorrect model structures.
To explore the eﬀect of an incorrect model selection with increasing number of visits,
biomarker data measured at 10 visits were generated and the performance was assessed
using all visits as well as only the ﬁrst 3 and the ﬁrst 6 by deleting the subsequent visits.
The individual times of the visits were simulated according to the empirical ones of the
HIV data. The empirical study times between visits for patient i ; i = 1; : : : ; N were
approximated by the following distributions (after mapping them to [0; 1]):
ti1;ti2  0:12  N(1 = 0:05; ﬀ
2
1 = 0:001) + 0:76  N(0:5; 0:05)
+0:12  N(0:95; 0:001)
ti2;ti3  N(0:25; 0:006)
ti3;ti4  0:7  N(0:45; 0:004) + 0:3  N(0:95; 0:004)
ti4;ti5  N(0:45; 0:004)
and ti j ;ti(j+1)  N(0:45; 0:0045) for visit number j = 5; : : : ; 9:
The last time diﬀerence (between the 5th and the 6th visit) served also for simulating the
individual visit times from visit 7 up to visit 10.
The resulting biomarker trajectories are depicted in Figure 3.2. The proﬁles of the non-
resistant group decrease continuously over time whereas the median biomarker level of
the resistant group remain quite stable.
Taken together, this resulted in nine simulation scenarios given by the combination of
RI*, RIS* or RICAR1* with 3, 6 or 10 visits where the eﬀect of choosing an RI, RIS,
RICAR1 or QDA structure was studied. A 50-fold MCCV was applied in the simulation
study and patients were randomized per group either to the training or the test set with a
ratio of 2:1. The prevalence was ﬁxed to 0:18 for the resistant group as in the application
and the group sample size was tripled to get stable results in terms of sample sizes. As a
result, our simulation sample consists of 177 non-resistant and 78 resistant patients. The
results are based on 25 simulation repetitions and an increase to 50 repetitions yielded
just the same results up to small numerical diﬀerences.
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Figure 3.2: Simulated biomarker proﬁles according to RIS* (top), RI* (middle) and
RICAR1* (bottom) with 10 individual visit times. The sample consists of
30 randomly selected non-resistant patients on the left and 30 randomly se-
lected resistant patients on the right.
3.4 Simulation Results
Note for the interpretation of our ﬁndings in the following that the results of RI*, RIS*
and RICAR1* should not be compared: The simulated data led to diﬀerent performance,
e.g. due to the higher variability and its increase over time in any RIS model compared
to RI and RICAR1 structures. With 6 visits, for example, RI* yielded a Brier score of
0:866 [0:841; 0:891], RIS* of 0:827 [0:808; 0:845] and RICAR1* of 0:851 [0:827; 0:868]
(given as median with 10th and 90th percentile over all MCCV samples). When biomarker
proﬁles were simulated according to RI* or RICAR1*, the performance measures improved
remarkably over time - especially for RI* - due to less variation between the proﬁles over
time. This yielded a very good performance for 10 measurements. In general, the eﬀect
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of assuming a wrong (M)MS is less an issue in the case of well separated groups. Then,
it is more unlikely that patients are misclassiﬁed just due to biased and therefore possibly
more similar model parameter estimates between the groups.
Expected convergence problems occurred for RI* when ﬁtting models with too complex
structures like RIS and RICAR1. For RIS, this was only the case for some of the MCCV
samples, whereas for RICAR1 no convergence was achieved at all. Hence the consid-
ered incorrect model structures are conﬁned to RIS and QDA for RI*. For RIS*, the
simulation scenario with 3 visits was excluded from the assessment for model selection
as the longitudinal structure of the simulated RIS* models, represented by the random
linear slopes, could not be captured based on 3 measurements. This was reﬂected by the
estimated mixed model parameters of RIS, which diﬀered clearly from the true ones of
RIS* resp. by the estimated performance measures of RIS, which did not match up with
those of RIS*. There were also convergence problems: In about a fourth of the compar-
isons, the RICAR1 models did not converge for at least one of the groups. For all other
simulation scenarios, the MMS matching to the one underlying the simulated biomarker
data achieved the same performance as the corresponding MMS*. This conﬁrmed that
the estimation of the mixed model parameters went well, without any critical information
loss with regard to the classiﬁcation.
3.4.1 Criterion for Model Selection: Highest Performance Measure or BIC?
First, a heuristic approach was applied, selecting the model which yielded the best perfor-
mance measure. As it was unclear which performance measure is the most suitable for this
purpose, we assessed as well whether all performance measures presented in Section 2.2
support the correct model selection. The results for 10 visits are displayed in Table 3.2.
For RI* with 10 visits, the classiﬁcation performance was very good, resulting in small
diﬀerences between the (M)MS. For this scenario, all examined performance measures
did not uniquely point to the correct model: RI and RIS achieved the same results as
RI*, only the measures of QDA correctly indicated a worse performance. Using the ﬁrst 6
visits, where the classiﬁcation is worse than for 10 visits, yielded the same indistinguishable
results. For three visits, the performance measures of all (M)MS were practically the same
and therefore of no use for model selection purposes.
For RIS* with 10 biomarker measurements, the performance was uniquely best for the RIS
model according to AUC, BS, BSC , BSDM and the correlation z[1];p[1] . The calibration
component CalL was not helpful in that the QDA structure gave similar small values as
the RIS model. Absolutely inadequate as selection criteria were the performance measures
Diﬀp[1] = p[1][z[1]=1]   p[1][z[1]=0] and QVar: They indicated that RI and RICAR1 are the
correct covariance structures instead of RIS. The same applies to RIS* with 6 visits. The
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other performance measures such as AUC etc. , which were adequate in the case of 10
visits, exhibited another problem: The measures of all (M)MS were so similar in size that
there is no single best one.
For RICAR1* with 10 biomarker measurements, AUC, BS, BSDM and the cor-
relation z[1];p[1] indicated correctly the highest performance for RICAR1. For 6
measurements, this was only the case for AUC and z[1];p[1] . Inadequate as selection
criteria are Diﬀp[1] for 6 and 10 visits and QVar for 6 visits suggesting RI as best model
as well as CalL for 10 visits with QDA as best one. No unique optimal model due to
similar performance may be selected based on BSC , QVar and CalL for 6 and 10 visits,
and additionally by BSDM for 6 visits. For biomarker proﬁles of length 3, all performance
measures exhibited this problem of too similar sizes.
What about the BIC? There is strong evidence for the approach of selecting the model
with the minimal BIC to work. For all assumed MMS* with 10 visits, the model with the
same covariance structure as MMS* yielded the minimal BIC in all simulation repetitions,
all MCCV samples and both patient groups. For RI*, RIS* and RICAR1* with 6 visits and
for RI* with 3 visits, the selection was also successful in nearly all comparisons between the
ﬁtted MMS. For RICAR1* with 3 visits, the BIC of RICAR1 was at least in the majority
(44%) of all comparisons the minimal one.
3.4.2 Global and Individual Eﬀects of an Incorrect (M)MS
The eﬀects of an incorrect (M)MS are assessed at the global as well as at the individual
level. The global level is assessed in terms of the performance measures. All of them are
based on the predicted posterior probability for each patient to be resistant to the therapy.
The individual level is directly assessed by these posterior probabilities. This is obviously
a stricter assessment than at the global level but it gives a more detailed picture about
the implications at the patient level.
For biomarker proﬁles of length 3, no eﬀects of using various model structures were
observed for RI*, RIS* or RICAR1*, neither at the global nor at the individual level.
Thus the assessment was restricted to 6 and 10 visits. At the global level, considerable
diﬀerences between the performance measures were only observed for 10 visits under
RIS* (Table 3.2, second block). Incorrect model structures are characterized by worse
median performance measures but also by high variances over all MCCV samples. For the
BS, for example, the maximum deviation was observed for RI where the median score was
0:07 smaller and the conﬁdence interval did not overlap with that of RIS*. The smallest
median AUC resulted with QDA, it is 0:79 instead of 0:87. For 10 visits under RI* or
RICAR1*, the groups are so well separated that an incorrect estimation of the model
parameters was not an issue.
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(a) Non-resistant patients
Figure 3.3: Proﬁles of individual predicted posterior probabilities comparing the (M)MS
RI, RIS, RICAR1 and QDA. The true MMS was RI* in the ﬁrst row, RIS* in
the second and RICAR1* in the third row. The proﬁles were based on data
from 6 visits in the left column of each subﬁgure and on data from 10 visits
in the right column.
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(b) Resistant patients
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For 6 visits under RI*, RIS* or RICAR1*, the diﬀerences in the discrimination rule induced
by the (M)MS were probably too small to have an eﬀect on the performance measures.
Further on, the eﬀects were assessed at the individual level. In Figure 3.4(a), the median
posterior probabilities of all MCCV samples that were predicted for one therapy-resistant
patient under each assumed model are represented by circles on one line. The ﬁrst mark
of each line gives the posterior probability estimated by the model with the true covariance
structure.
The deviations from this benchmark were much more pronounced for the resistant than for
the non-resistant group (cf. Figure 3.4(a) and 3.3(a)). For RI* and 6 visits, QDA tended
to predict lower posterior probabilities to be resistant, which are at most 0:1 smaller in
size. For 10 visits, the very good classiﬁcation performance of RI* did not lead to any
diﬀerences between the (M)MS. Under RIS*, the highest deviations occured especially for
RI and and also for RICAR1. They were of unacceptable size for therapy-resistant patients
with 6 resp. 10 biomarker measurements: The probabilities of the RI models were about
0:4 resp. 0:5 higher than predicted under RIS, and those of the RICAR1 models deviated
about 0:4 for both proﬁle lengths. For both groups, RI and RICAR1 overestimated the
probabilities to be part of the same group as according to the Gold Standard. QDA
overestimated these probabilities for the non-resistant patients but underestimated them
for the resistant ones. But this was diﬀerent for 6 visits where the incorrect structure QDA
resulted hardly in any bias. Spuriously high predicted probabilities to be resistant to the
therapy, like e.g. under RI and RICAR1, implied a falsely low uncertainty in classiﬁcation
whereas spuriously low probabilities, like e.g. for QDA with 10 visits, reﬂected a falsely
high uncertainty. Both are undesirable eﬀects. Assuming an RICAR1* structure, the
implications for the patients were at most critical when ﬁtting RI models. The posterior
probabilities of the resistants were incorrectly higher  similar in size as under RIS*.
High deviations for single patients were due to unstable estimation, they disappeared by
increasing the number of simulation repetitions.
3.4.3 Summary
As the simulations showed, an incorrect model structure had at ﬁrst eﬀects at the
individual level resulting in incorrectly low or high uncertainty in classiﬁcation. The
QDA structure was always one of the incorrect models which was identiﬁed in the
simulations. There was no eﬀect when the group separation in the scenario was very
good. Eﬀects at the global level were only observed for the most complex structure
RIS* with longer proﬁles of length 10. This means that the selection of the correct
structure was especially important for models that assumed a time-variant longitudinal
data structure and the deviations in the results enlarged with increasing length of the
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proﬁles. Therefore, it is important to have an objective model selection criterion. The
BIC approach was found to perform much better than the performance measures. The
decision for a speciﬁc model structure should not be based on the model with the best
performance measure as they were too similar in size for most scenarios (especially
those with 3 and 6 visits). Additionally, if they diﬀered, only few of them as AUC,
BS and z[1];p[1] were able to select the correct model. These ﬁndings suggest to use
the BIC as model selection criterion as already done in the application in Section 2.3.
At the beginning of this section, the inﬂuence of the assumed model structure on the
estimations were shown for the HIV therapy resistance data. The direction of the bias
was similar in the simulation study (cf. Figure 3.1 on the right with the left plot in the
middle of Figure 3.4(a) for resistant patients and Figure 3.1 on the left with the left plot
in the middle of Figure 3.3(a) for non-resistant patients.).
In the multivariate case when the performance of biomarker combinations are assessed,
the model selection process is even more important. The selection of an incorrect model
structure does not only result in a wrong assessment of a biomarker combination but also
inﬂuences the search for the best biomarker combination. Possible multivariate extensions
for the longitudinal QDA are the topic of the next chapter.
Remark
This chapter is based on Kohlmann, M., Held, L., Grunert, V.P. (2009). Classiﬁcation of
Therapy Resistance Based on Longitudinal Biomarker Proﬁles. Biometrical Journal 51,
610  626.

4 Multivariate Extensions of Longitudinal
QDA for Biomarker Combinations
4.1 Introduction
In Chapter 2, statistical methods were proposed to assess the diagnostic value of single
longitudinal biomarkers. In this chapter, longQDA is extended to the multivariate case
to assess biomarker combinations. This opens up further opportunities: In addition to
the potential to improve the classiﬁer by using repeated measurements like in univariate
longQDA, the combination of biomarkers may also yield to a better performance.
Multivariate longitudinal data are sometimes referred to as doubly multivariate
data (Timm, 2002) as they exhibit two multivariate features, one is the longitudinal
nature, the repeated measurements over time, the other the set of variables, the
biomarkers. From a diagnostic point of view, the two features complement one another
well. The longitudinal measurements contain information about the development of
disease processes whereas biomarkers may be qualitatively selected to cover various
aspects of the disease. The biomarkers are, for example, characteristic for the
inﬂammation process or for the degradation process triggered by the disease. Combining
biomarkers in one diagnostic test is advantageous for the patient as only one blood
sample is required to determine the level of several biomarkers. Moreover, with the
technical development of multi-test diagnostic platforms about the same amount of
blood serum is required for the measurement of one biomarker as for the simultaneous
measurement of a biomarker panel.
So statistical models need to be established to allow the assessment of a biomarker panel
with longitudinal proﬁles. For multivariate longQDA, the key point is the estimation of
the multivariate group-speciﬁc means and covariance matrices. Multivariate linear mixed
models are considered for the plug-in estimation and three diﬀerent classes of model
structures are examined. One is characterized by the independence assumption for the
biomarkers (Section 4.2.1), the other two are appropriate for correlated biomarkers: multi-
variate random eﬀects models (Section 4.2.2) and multivariate covariance pattern models
(Section 4.2.3). Having established appropriate models, the subsequent proceeding is the
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same as in the univariate case. For model selection, we rely on the simulation results show-
ing the appropriateness of the BIC and use it as selection criteria for multivariate models,
too. In Section 4.3, the established multivariate longQDA is applied to biomarker data
which are examined for their ability to predict drug resistance for patients with rheuma-
toid arthritis (RA). The chapter ends with exemplary simulated data settings where the
classiﬁcation performance of biomarker panels exceeds the performance of their single
components (Section 4.4).
4.2 Multivariate Linear Mixed Models
We have measurements wi =
(
w
[1]T
i ; : : : ;w
[q]T
i
)T
of ` = 1; : : : ; q biomarkers, collected
at ti j ; j = 1; : : : ; p time points from i = 1; : : : ; n[k] patients in each patient group k = 0; 1.
In applications from medical diagnostics, all biomarker levels are usually determined from
the same blood sample taken at one time. So for each patient, the time points are identical
for all biomarkers. As above, the subscripts k = 0; 1 indicating that the estimation is
performed group-wise are omitted in the following.
The multivariate mixed model is deﬁned as
wi(pq1) = Xi(pquq)(uq1) + Zi(pqsq)bi(sq1) + i(pq1)
where
bi  N(0(sq1);D(sqsq))
i  N(0(pq1);Ri(pqpq)):
Due to the fact that all measurements are determined from one blood sample, the matrix
Zi (and also the time-related columns of Xi) consists of q submatrices on the diagonal
and each submatrix equals the design matrix of the univariate model (see p. 6 for the
deﬁnition).
So the biomarker measurements of one patient are distributed as
wi  N(i = Xi; Vi = Z
T
i DZi +Ri):
The n[K] patient-speciﬁc regression models are then combined as described for the uni-
variate case in Eq. (2.2).
The models can also be expressed exclusively in terms of matrices. Then the response
matrix has q columns: Wi =
(
w
[1]T
i ; : : : ;w
[q]T
i
)
. The matrices of ﬁxed and random
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eﬀects as well as the residuals' error matrix have q columns as well. The matrices Xi ;Zi ;D
and Ri are the same as in the vector notation. This implies, however, a less ﬂexible
structure, requiring for all biomarkers the same dimension of ﬁxed and random eﬀects.
The multivariate modeling for biomarker proﬁles is of higher complexity compared to the
univariate one due to the increased number of covariance parameters in Vi , in particu-
lar due to the correlations. Aside from the autocorrelations between the measurements
of one biomarker being referred to as the within correlation of the biomarkers, the be-
tween correlation of the biomarkers need to be considered. These correlations between
the biomarkers (cross-correlations) are time-dependent, too. We distinguish two forms:
one between the biomarkers measured at the same time point and the other between
measurements of (distinct) biomarkers measured at diﬀerent time points. The latter is
a particular feature for multivariate longitudinal data, the ﬁrst is well-known from the
analysis of cross-sectional multivariate data.
Suppose q = 2 biomarkers were measured at p = 3 time points. The corresponding
covariance matrix Vi is
Vi(66) =
(
A B
C E
)
=

v
[1]2
11 v
[1]
21 v
[1]
31 v
[1;2]
11 v
[1;2]
21 v
[1;2]
31
v
[1]
21 v
[1]2
22 v
[1]
32 v
[1;2]
12 v
[1;2]
22 v
[1;2]
32
v
[1]
31 v
[1]
32 v
[1]2
33 v
[1;2]
13 v
[1;2]
23 v
[1;2]
33
v
[1;2]
11 v
[1;2]
12 v
[1;2]
13 v
[2]2
11 v
[2]
21 v
[2]
31
v
[1;2]
21 v
[1;2]
22 v
[1;2]
23 v
[2]
21 v
[2]2
22 v
[2]
32
v
[1;2]
31 v
[1;2]
32 v
[1;2]
33 v
[2]
31 v
[2]
32 v
[2]2
33

; (4.1)
where the unique parameters to be estimated are printed in blue. On the block-diagonal
are the covariance matrices of each biomarker, namely A and E. They contain the
variances on the diagonal and the symmetric autocovariances on the oﬀ-diagonal. The
oﬀ-diagonal matrices B and C are the covariance matrices containing the within-time
cross-correlations on their diagonal and the between-time cross-correlations on their oﬀ-
diagonal. The diagonals of B and C are equal and the lower triangular matrix of C equals
the upper triangular matrix of B. Note that the matrices B and C are not symmetric,
caused by the asymmetric property of the between-time cross-correlations. In other words,
biomarker w [1]i measured at time point ti j is diﬀerently related to biomarker w
[2]
i measured
at time ti j 0 than biomarker w
[1]
i measured at time ti j 0 is related to biomarker w
[2]
i measured
at time ti j .
Due to the large number of parameters, parsimonious multivariate extensions of mixed
models are needed that are eﬀective when the number of observations is not large enough
to estimate an unstructured covariance matrix. Furthermore, the possible problem of
instability resulting from overparameterising the covariance matrix may be circumvented
if a useful representation of the underlying correlation structures is found.
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There is the usual distinction between random eﬀects models and covariance pattern
models. For the ﬁrst, the random eﬀects bi are assumed to capture most of the variation
within the patient and between the biomarkers and a simple covariance structure as Ri =
(qq) 
 I(pp) is assumed for the residuals where  is an unstructured matrix. In a
pure covariance pattern model, there are no random eﬀects bi . The dependencies in the
data are modeled by a more complex structure for Ri than in the random eﬀects model
and thus Vi = Ri . Parsimonious multivariate random eﬀects models as well as covariance
pattern models are presented in the following.
But ﬁrst, the diﬀerences between those two model classes are depicted with respect to
the auto- and cross-correlations. In Figure 4.1, one arrow represents one correlation
parameter, assuming that no restrictions are placed on the models.
Figure 4.1: Correlation scheme of bivariate mixed models. On the top: covariance pat-
tern model, on the bottom: random eﬀects model. Blue arrows symbolize
autocorrelations, green arrows within-time cross-correlations and red arrows
between-time cross-correlations.
The implications of the change from the univariate to the multivariate model are clear:
The number of correlations increase as the blue ones are extended by the red and green
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types. The random eﬀects models (below) induce a more parsimonious structure than the
covariance pattern models (above). The diﬀerence between the number of parameters in-
creases with q and is thus more pronounced in the multivariate case. It will be investigated
in Subsection 4.2.3 that strict assumptions are required for covariance pattern models to
ensure a reasonable relation between the number of parameters and the sample size and
hence to enable the estimability of the models. The following presentation is restricted
to the bivariate case considering q = 2 biomarkers without loss of generality. Models
for q > 2 biomarkers require an extended approach and are therefore shortly discussed in
Chapter 6.
4.2.1 Models with Uncorrelated Random Eﬀects
The independence assumption of the biomarkers leads us back to the univariate case, only
the blue arrows of both schemes in Figure 4.1 are modelled. Whether the autocorrelations
of the biomarkers for longQDA are modelled only by random eﬀects (RIind or RISind)
or additionally by time-dependent residuals (RICAR1ind), the approach is the same: It is
suﬃcient to model each biomarker separately and then the results are combined as follows
to assess the combined biomarker performance. Treating the q = 2 biomarkers w [1];w [2]
as independent, the mean and the covariance matrices are estimated separately as the
joint density can be factorized as
P (k = Kjw [1];w [2]) / [K]  f (w
[1]j k = K)  f (w [2]j k = K)
for group K.
It follows with Equation (2.3) that the corresponding posterior probability p[1;2]
i [K]
based
on 2 biomarkers is
p
[1;2]
i [K]
=
exp
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[`]
i [K]
: (4.2)
That is, the results of the univariate mixed models as given by Equation (4.2) are used in
that the posterior probabilities of the univariate RI, RIS, RICAR1 model are combined to
yield the posterior probabilities of the biomarker pair.
The implied marginal covariance matrix Vi of Equation (4.1) has only non-zero entries in
the matrices on the block diagonal, all entries in the oﬀ-diagonal are assumed to be zero,
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including the cross-correlations:
Vi(66) =

v
[1]2
11 v
[1]
21 v
[1]
31 0 0 0
v
[1]
21 v
[1]2
22 v
[1]
32 0 0 0
v
[1]
31 v
[1]
32 v
[1]2
33 0 0 0
0 0 0 v
[2]2
11 v
[2]
21 v
[2]
31
0 0 0 v
[2]
21 v
[2]2
22 v
[2]
32
0 0 0 v
[2]
31 v
[2]
32 v
[2]2
33

:
The selection of the assumed univariate mixed model structure is guided by the model
with the smallest BIC as examined in Chapter 3. There is a high ﬂexibility with regard to
the model structure as it can even diﬀer across biomarkers. This is especially favourable
for q > 2.
4.2.2 Models with Correlated Random Eﬀects
The models presented in this section are direct extensions of the univariate mixed models
with an RI or RIS structure (Chapter 2, p. 6) and denoted as RIcorr resp. RIScorr. They
are increasingly common in medical applications (Mickey et al., 1994; Shah et al., 1997;
Chakraborty et al., 2003; Beckett et al., 2004). The random eﬀects are now assumed to
be correlated, resulting in the following covariance matrices D. For the RIcorr model, the
covariance matrix of the random intercepts is
D =
(
d
[1]2
I
d
[1;2]
II
d
[1;2]
II
d
[2]2
I
)
:
For the RIScorr model, the (4 4)-covariance matrix D of the random eﬀects is
D =

d
[1]2
I
d
[1]
IS
d
[1;2]
II
d
[2;1]
IS
d
[1]
IS
d
[1]2
S
d
[1;2]
IS
d
[1;2]
SS
d
[1;2]
II
d
[1;2]
IS
d
[2]2
I
d
[2]
IS
d
[2;1]
IS
d
[1;2]
SS
d
[2]
IS
d
[2]2
S
 :
The covariances d [1;2]
II
and d [1;2]
SS
of the random eﬀects allow for the possibility that the
average levels of the intercepts resp. the slopes are correlated. Models with constraints
between the biomarkers, i.e. where the random intercepts are correlated and the random
slopes are not or vice versa, have not been considered.
For the residuals, a simple covariance structure as Ri = (qq)
 I(pp) is assumed where
 is an unstructured matrix. The covariance parameter ﬀ[1;2] contains the correlation
between the residuals of two biomarkers measured at the same point in time. For the
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validity of this model, both biomarker measurements need to be recorded simultaneously.
We assume  also in the application later on  that conditional on the random eﬀects the
error components are uncorrelated, thus ﬀ[1;2] = 0 and Ri = diag(ﬀ[1]2; ﬀ[2]2)
 I. This is
a reasonable assumption for q biomarkers which come from diﬀerent test assays and was
also suggested in the literature (Shah et al., 1997).
Assuming p = 3 measurements at (ti1; ti2; ti3), the overall covariance matrix Vi of the
RIScorr model is
Vi = ZiDZ
T
i +Ri
=

1 ti1 0 0
1 ti2 0 0
1 ti3 0 0
0 0 1 ti1
0 0 1 ti2
0 0 1 ti3

D 

1 1 1 0 0 0
ti1 ti2 ti3 0 0 0
0 0 0 1 1 1
0 0 0 ti1 ti2 ti3

+

ﬀ[1]2 0 0 ﬀ[1;2] 0 0
0 ﬀ[1]2 0 0 ﬀ[1;2] 0
0 0 ﬀ[1]2 0 0 ﬀ[1;2]
ﬀ[1;2] 0 0 ﬀ[2]2 0 0
0 ﬀ[1;2] 0 0 ﬀ[2]2 0
0 0 ﬀ[1;2] 0 0 ﬀ[2]2

:
The single entries in Vi have a complex structure, e.g. the (1; 1)-entry is d
[1]2
I
+ d
[2]2
I
+
2ti1
(
d
[1]
IS
+ d
[2]
IS
+ d
[1;2]
II
+ d
[1;2]
IS
+ d
[2;1]
IS
)
+ t2i1
(
d
[1]2
S
+ 2d
[1;2]
SS
+ d
[2]2
S
)
+ ﬀ[1]2.
A special case of the multivariate random eﬀects models is the latent variable approach. If
the random eﬀects are perfectly correlated, that is if b[1]i = g b
[2]
i , where g is a constant,
then this model is equivalent to assuming a common latent variable with a multivariate
normal distribution (see e.g. Gueorguieva (2001)).
Statistical software for ﬁtting linear mixed models (R packages nlme,lmer, SAS proc
mixed) are not designed for multivariate mixed models but can be used with a customized
set-up of the dataset (see Subsection 5.3.1 for details). Mickey et al. (1994) and Shah
et al. (1997) use the EM algorithm for estimation, treating the random eﬀects as missing
data, Schafer and Yucel (2002) follow the same approach but extend the algorithm to cope
with "real" missing data. For a discussion of the RIScorr model including interpretation
guidance and pitfalls confer Fieuws and Verbeke (2004).
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4.2.3 Covariance Pattern Models with Kronecker Product Structure
Covariance pattern models are mixed models with no random eﬀects but a residual covari-
ance matrix with a complex time-dependent structure. As described above, multivariate
covariance patterns need parsimonious structures to avoid that maximally pq(pq+1)2 dis-
tinct parameters of the covariance matrix need to be estimated. As far as we know, the
only multivariate extension that has been proposed (among others by Galecki, 1994), is
the product covariance model. Its name is due to the speciﬁc assumption that the covari-
ance matrix Vi is factorised as a Kronecker product and it is referred to in the following as
the model with the Kronecker product structure (KPS). The matrix is separated into the
matrix  describing the variance of and the covariance of the biomarkers independently
from time and into 	 containing the within-covariance which is assumed to be the same
for all biomarkers.
For q = 2 and p = 3, without any constraints on 	, the covariance matrix is
Vi =  
 	 =
(
[1]2 [1;2]
[1;2] [2]2
)


  
2
11  12  13
 21  
2
22  23
 31  32  
2
33

=

[1]2 211 
[1]2 12 
[1]2 13 
[1;2] 211 
[1;2] 12 
[1;2] 13
[1]2 21 
[1]2 222 
[1]2 23 
[1;2] 21 
[1;2] 222 
[1;2] 23
[1]2 31 
[1]2 32 
[1]2 233 
[1;2] 31 
[1;2] 32 
[1;2] 233
[1;2] 211 
[1;2] 12 
[1;2] 13 
[2] 211 
[2]2 12 
[2]2 13
[1;2] 21 
[1;2] 222 
[1;2] 23 
[2]2 21 
[2]2 222 
[2]2 23
[1;2] 31 
[1;2] 32 
[1;2] 233 
[2]2 31 
[2]2 32 
[2]2 233

In the top schema of Figure 4.1, p. 36, the blue arrows (representing the autocorrelations)
are captured by the covariance pattern of	 in this model. The variances of the biomarkers
are the entry-wise product of the diagonal entries of  and 	. The green arrows are the
product of the between-biomarker covariance and the within-biomarker variances. The
red arrows representing the cross-correlations are the autocorrelations scaled (through
multiplication) by the between-biomarker correlation.
As both matrices,  and	, are symmetric, the covariance matrix of the second biomarker,
denoted as submatrix E in Equation (4.1), is proportional to the covariance matrix of the
ﬁrst biomarker. The product-covariance model sets
E = ﬂ1A =
[2]2
[1]2
A
with the scale variance parameter ﬂ1. For the cross-covariance matrix B = C, there is
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also a proportional relationship in that
C = ﬂ2	 = 
[1;2]	
with the scale cross-covariance parameter ﬂ2. Weiss (2005) notes that in the product
covariance model, the within-time cross-correlations always have higher absolute values
than the between-time cross-correlations which is a reasonable assumption. This becomes
obvious when comparing the within-time cross-correlation
corr(w [`]i j ; w
[`0]
i j ) =
[1;2] 211

[1][2] 211
=
[1;2]
[1][2]
with the between-time cross-correlation
corr(w [`]i j ; w
[`0]
i j 0
) =
[1;2] 12
[1] 11[2] 22
=
 12
 11 22
 corr(w [`]i j ; w
[`0]
i j )
and realizing that the ﬁrst term of the last equation is a correlation and therefore less
than one in absolute value. A further implied assumption is the symmetry of the cross-
correlations.
For univariate covariance pattern models, common covariance structures include com-
pound symmetry (CS), autoregressive (AR), banded, Toeplitz, unstructured (UN) and
others (Verbeke and Molenberghs, 2000). In the bivariate, an unstructured covariance
pattern is assumed for  and for 	 either compound symmetry (CS), an continuous au-
toregressive process of order 1 (CAR1) or an unstructured (UN) pattern. These structures
are denoted as UN
 CS, UN
 CAR1 and UN
 UN.
Caution is advised when implementing the Kronecker product structure as some indeter-
mination may result (Galecki, 1994): The non-identiﬁability arises from the fact that if
 
 	 is the overall covariance matrix, then there exists a continuum of other pairs of
covariance matrices, e.g. c   and 	=c (c > 0), which results in the same Kronecker
product. The covariance matrix 	 is then rescaled to yield  11 = 1, assuring the identi-
ﬁability of the matrices  and 	. The remaining entries of the overall covariance matrix
may then be interpreted as ratios on the scale of  11. Further on, the covariance matrix 	
equals the correlation matrix for homogeneous variance structures like CS and CAR1.
Together with this constraint, the covariance matrix 	 is as follows for the three consid-
ered model structures:
 CS:
The constraint implies that ﬀ2 = 1   2 and therefore
	 = ﬀ2I +  2J = (1   2)I +  2J
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where I is the p-dimensional identity matrix and J a p-dimensional matrix of 1's.
For p = 3 for example, it is
 1  
2  2
 2 1  2
 2  2 1
 :
 CAR1:
The constraint implies that ﬀ2 = 1 and therefore
	 =
[
ﬀ2   jti j ti(j+h)j
]
=
[
 jti j ti(j+h)j
]
with  2 [0; 1].
The time points j and j + h are h lags apart for the hth superdiagonal and h = 0 for
the diagonal of the matrix. Thus, the matrix will be diﬀerent for each individual i if
the individual times between biomarker measurements vary from patient to patient.
 UN:
The constraint implies that ﬀ21 = 1. This is the only condition which is placed on
the covariance matrix 	 in the unstructured case.
For p = 3 for example, 	 =
 1  12ﬀ2  13ﬀ3 12ﬀ2 ﬀ22  23ﬀ2ﬀ3
 13ﬀ3  23ﬀ2ﬀ3 ﬀ
2
3
 :
The number of parameters in the covariance matrix to be estimated are q(q+1)2 + 1 for
UN
 CS and UN
 CAR1 and q(q+1)2 +
p(p+1)
2   1 for UN
 UN.
For the proposed model structures, the time component, the distinctive feature of lon-
gitudinal data compared to cross-sectional ones, is only partially taken into account: for
CS and UN by the order of the biomarker measurements, for CAR1 by the time distance
between the measurements. The ﬁrst models assume equidistant visits and modifying the
time scale has no eﬀect whatsoever on the estimated model parameters. This is a general
limitation of covariance pattern models.
In the univariate case, the marginal representation of a mixed model with a random
intercept equals that of a covariance pattern model with a compound symmetry struc-
ture (Verbeke and Molenberghs, 2000). Due to the strong assumptions underlying a
covariance pattern model with a KPS, the equivalence between the multivariate RI model
(with uncorrelated residual variances as above) and the UN 
 CS structure is only valid
under the following three assumptions:
ﬀ2 = 2
[1]2 =
ﬀ[1]2
2
[2]2 =
ﬀ[2]2
2
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Estimation
The computational beneﬁts of the Kronecker product structure become evident when
considering the model estimation. But at ﬁrst, a general outline of the estimation is given.
The full log-likelihood function lML is based on the marginal model w  N(X; V ())
where  = (o); o = 1; : : : ; O is a vector containing the distinct covariance parameters to
be estimated. Maximising the likelihood (omitting constant terms)
lML(w j; ) =  
1
2
log jV ()j  
1
2
(w  X)TV () 1(w  X) (4.3)
with respect to  for ﬁxed  yields
^() = (XTV () 1X) 1XTV () 1w : (4.4)
As it is a well-known result (Verbeke and Molenberghs, 2000) that a full maximum like-
lihood approach provides biased estimates for the covariance parameters , a restricted
maximum likelihood (REML) approach (Patterson and Thompson, 1971) is preferred.
REML corrects for the loss of degrees of freedom when estimating  and therefore pro-
duces less biased variance parameters than ML. There are several derivations available
for mixed models (Patterson and Thompson, 1971; Harville, 1977; Verbyla, 1990). The
conditional derivation given by Verbyla (1990) is presented in the following.
Let the matrix M = [M1;M2]T be a non-singular matrix where M1 and M2 are pq  uq
and pq  (pq   uq) matrices respectively. The submatrices are chosen to satisfy the
following conditions
MT1 X = I(uquq) and M
T
2 X = 0:
Transforming w by these matrices, the new partitioned response vector is(
MT1 w
MT2 w
)
=
(
w1
w2
)
 N
[(

0
)
; ﬀ2
(
MT1 V M1 M
T
1 V M2
MT2 V M1 M
T
2 V M2
)]
and consequently, the distribution of w2 is independent on . The joint likelihood of w1
and w2 can be factorized into the conditional and the marginal likelihood as
LREML(; ;w1;w2) = L
REML(; ;w1jw2)  L
REML(;w2): (4.5)
The log-likelihood of the conditional distribution of w1jw2 omitting constant terms is
lREML(; ;w1jw2) =
1
2
(
log jXTV  1Xj   T1X
TV  1X1
)
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where 1 = w1  w2 with w

2 =M
T
1 V M2(M
T
2 V M2)
 1
w2. This conditional likelihood
is independent from the choice of M, it only depends on X. The score vector for  is
sREML() = XTV  1X1;
yielding the same estimate for ^ as under ML (Eq. (4.4)). The log-likelihood of the
marginal distribution of w2 is the likelihood of observing the sample residuals (not the
sample data) and, ignoring constants, can be rewritten as
lREML(;w2) =  
1
2
(
log jV j+ log jXTV  1Xj+ ^TV  1^
)
=  
1
2
(
log jV j+ log jXTV  1Xj+ wTPw
)
(4.6)
where ^ = w   X^ and P = V  1   V  1X(XTV  1X) 1XTV  1.
The score vector sREML() = (sREML(1); : : : ; sREML(O))T contains the entries
sREML(o) =  
1
2
tr
(
P
@Vi
@o
)
+
1
2
wTP
@Vi
@o
Pw : (4.7)
for o = 1; : : : ; O. A detailed derivation of the REML results is found in Taylor (2005).
In the multivariate setting, the estimation can be a computionally intensive estimation as
Vi of size pq  pq needs to be diﬀerentiated and inverted (cf. Equations (4.4)(4.7)).
Due to the assumed Kronecker product structure, however, it is not and involves only the
less dimensional diﬀerentiation and inversion of qq and 	pp. Here,  = (; ) and
contains all distinct covariance parameters of  resp. 	. We have
@Vi
@o
=
 @@o 
	 if o 2  
 @	
@o
if o 2  
and
V  1i = ( 
	)
 1 =  1 
	 1:
When assuming a covariance structure such as CS or CAR1 for	, the estimation formulae
are even more simpliﬁed. The resulting partial derivatives and the inverse for those two
structures are
 CS:
@	
@ 
=  2 I + 2 J
	 1 =
1
(1   2)
I  
 2
(1   2)(1 + (p   1) 2)
J
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 CAR1:
@	
@ 
=
[
jti j   ti(j+h)j   
(jti j ti(j+h)j 1)
]
	 1 =
1
1   2jti j ti(j 0+1)j
 diag(1; 1; : : : ; 1; 0) +
1
1   2jti j ti(j 0 1)j
 diag(0; 1; : : : ; 1; 1)
 
 jti j ti j 0 j
1   2jti j ti j 0 j
J
where J is a tridiagonal matrix with zeros on the diagonal and ones on the ﬁrst
super- and the ﬁrst subdiagonal.
As can be seen in Equation (4.5), the estimation of  which is based on the second fac-
tor does not depend on . Therefore, the selected approach for the REML estimation
was to ﬁrst get an estimate for  by numeric constrained optimization according to Equa-
tions (4.6) and (4.7) and second, to compute ^ according to Equation (4.4). The numeric
constrained optimization was done by the R function optim based on the L-BFGS-B algo-
rithm (see Kohlmann (2005) and the references therein). Besides the likelihood function
and the gradient function, start values and constraints for the parameters were given.
The partial derivatives under UN
UN were derived by the R package Ryacas (Goedman
et al., 2008).
Other alternatives for the numerical computation would have been a Fisher-Scoring al-
gorithm as presented by O'Brien and Fitzmaurice (2005).The L-BFGS-B algorithm was
opted for as no information matrix needs to be computed. For the simpler case where the
mean is assumed to be unstructured and estimated by the average value over w , the esti-
mation of  does not longer depend on . Dutilleul (1999) proposes a ﬂip-ﬂop algorithm,
estimating  by iterating between the estimation of  for ﬁxed 	 and vice versa. Further,
a likelihood ratio test was derived to test whether the covariance matrix is separable with
a KPS (Lu and Zimmerman, 2005; Mitchell et al., 2006; Roy and Khattree, 2003). The
ﬂip-ﬂop algorithm is faster than a Fisher-Scoring algorithm (for comparisons see Lu and
Zimmerman, 2005) and even faster, non-iterative methods have recently been proposed
by Werner et al. (2008).
4.3 Application of Multivariate longQDA: RA Therapy
Resistance Data
The application data set for multivariate longQDA is again about therapy resistance, but
this time with respect to a drug for patients suﬀering from rheumatoid arthritis. Seven
biomarkers (coded as BM1 up to BM7) were repeatedly measured throughout the study,
ﬁrst at the beginning of the study, then 1, 4 and 6 months thereafter. The drug was
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administered at the beginning of the study (after the blood sample was taken) and two
weeks later. A patient was deﬁned as non-resistant according to an improvement after
6 months based on the ACR50 criteria (Felson et al., 1993) involving criteria such as
the status of the joints, disease activity and pain intensity. This deﬁnition is the Gold
Standard, the reference classiﬁcation. The study population under treatment comprises
55 non-resistant and 110 resistant patients with complete data of all 4 visits.
The biomarker proﬁles were transformed to better meet the normality assumptions of
longQDA, biomarker 1 to 6 by ln(x + 10), biomarker 7 by the variance-stabilizing arcsine
transformation suitable for proportions. The individual proﬁles as well as their group-wise
summary are displayed in Figure 4.2. Biomarker 1 to 4 exhibit a downwards pattern over
time for both groups whereas for biomarker 5 to 7, there are only few dynamics over time.
The heterogeneity is especially peculiar for biomarker 2. At visit 1, the measurements had
not been aﬀected by the drug yet. Given that there is no selection bias present regarding
the individual medication history, the classiﬁcation at this point in time assesses what
could be termed 'predisposition' for being resistant. Except for biomarker 5, the non-
resistant patients had higher initial biomarker levels than the resistant ones and the group
diﬀerence in relation to the variance was highest for biomarker 4. During the treatment,
all biomarker proﬁles except that of biomarker 1 decreased more for non-resistant patients
over time.
The autocorrelations (squares on the diagonal of Figure 4.3(a) and 4.3(b)) were high,
similar in both groups and higher than the cross-correlations (squares on the oﬀ-diagonal).
For none of the biomarkers, a pattern that cross-correlations at the same time points dif-
fered structurely from those at diﬀerent time points was observed. The cross-correlations
indicated two conceptual groupings of biomarkers: biomarker 6 and 7 with relations to
1, and biomarker 2 to 5. Between biomarkers of those groups, the cross-correlations
were negligible in size. There was a slight tendency for resistant patients to have higher
correlated biomarkers. This was in accordance with the smaller decrease of the proﬁles
over time.
The model selection for the estimation of the group-speciﬁc mean and covariance was
based on the minimal BIC as exposed in Chapter 3. For the univariate assessment, RI,
RIS and RICAR1 structures were ﬁtted and for the bivariate, the structures presented in
Section 4.2.1-4.2.3: RIind, RISind, RICAR1ind, RIcorr, RIScorr, UN
CS, UN
CAR1 and
UN
UN. A ﬁxed intercept and a ﬁxed linear slope (with study time measured in months)
were always part of the mixed model. In each group, the model structure that was selected
in the majority of the 50 MCCV loops was determined. If the selected structure diﬀered
between non-resistant and resistant patients, the results of the structure with the highest
overlap between the groups were reported. This is analogous to the approach applied
previously.
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Figure 4.2: Individual proﬁles of biomarker indicative for RA therapy resistance (in black
non-resistant, in red resistant patients)
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Figure 4.3: Auto- and cross-correlations of transformed biomarkers
For 3 as well as for 4 visits, RIS was selected for BM1 (3 visits: in 88% of the MCCV
loops for non-resistant, in 100% for resistant patients; 4 visits: 94%, 100%), RI for the
BM2, 4-7 (3 visits: 92% and more, 65% and more; 4 visits: 65% and more, 65% and
more). There were two discrepancies with diﬀering model structures: The RIS structure
was selected in 86% and RI only in 14% for BM4 in the resistant group with 3 visits and
also in 52% RIS versus 34% RI for BM2 in the non-resistant group with 4 visits. For
BM3, RI was selected in most of the MCCV loops with 3 visits (98%, 50%), but RICAR1
with 4 visits (46%, 62%).
In the bivariate longQDA, RISind was chosen for all pairs with BM1, RIind for pairs with
BM5, BM6 or BM7 (except RIcorr for BM3 with BM5 and BM5 with BM6 for 4 visits)
and RIcorr for the pairs BM2 with BM3 or BM4, BM3 with BM4 and BM6 with BM7
for 3 and 4 visits. For 3 visits, the model selection was not always consistent for both
groups in that RIind was rather appropriate for the non-resistant patients. This matches
with the simulation results of Section 3.4 that a correct selection of the model structure
is more diﬃcult for shorter biomarker proﬁles. The selection of the MMS for the other
biomarker combinations was unambiguous with more than 50% frequency in both groups.
The distinction between a MMS with or without cross-correlations matches with the
empirical cross-correlations illustrated in Figure 4.3. The RIcorr structure was selected
for models with empirical cross-correlations of more than 0.25. Unsurprisingly, RIScorr
did not converge in all of the MCCV samples for the biomarker pairs with low empirical
cross-correlations. Sometimes there were convergence problems with UN
UN which is
inﬂexible due to the combination of the maximum degrees of freedom for the estimation
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of the autocorrelations and the minimal proportionality structure between the biomarkers.
None of the Kronecker product structures was selected as the most appropriate one in
this application.
As an example, the diﬀerences of the ﬁxed mean proﬁles and the covariance parame-
ters between the empirical and those of the diﬀerent MMS are illustrated in Figure 4.4
resp. Figures 4.5 and 4.6 for the biomarker pair BM3 and BM4.
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Figure 4.4: Empirical and estimated ﬁxed mean proﬁles of BM3 and BM4
The estimated linear mean proﬁle was the same for all model structures except that of
UN
UN and matched well with the empirical equivalent in both groups. The mismatch
of the empirical proﬁles to the estimated proﬁles for UN
UN was a ﬁrst evidence for the
inappropriateness of this covariance structure. It was more pronounced for BM4 than for
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BM3 where it even led to a falsely high diﬀerence between the proﬁles of the two patient
groups.
The empirical autocorrelation parameters of the non-resistant patient group were high for
BM3 and higher between visit 1 and 2 and visit 3 and 4, and decreased slightly for BM4
with an increasing time diﬀerence between the visits (Figure 4.5). The cross-correlations
were low and smallest between BM3 at visit 1 and 2 and BM4 at visit 3 and 4.
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Figure 4.5: Empirical and estimated auto- and cross-correlations of BM3 and BM4 with
variance parameters printed on the diagonal, non-resistant patients
The biomarker measurements of the resistant group (Figure 4.6) exhibited high time-
independent autocorrelations for BM3 and BM4, the cross-correlations at the same visit
were of similar size as the autocorrelations but smaller for diﬀerent visits.
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Figure 4.6: Empirical and estimated auto- and cross-correlations of BM3 and BM4 with
variance parameters printed on the diagonal, resistant patients
The illustrations of the Kronecker product structures in the second row show the special
proportionality assumption of BM3 to BM4 resp. to the covariance between them: The
patterns of the estimates are the same. This simplifying assumption yielded mainly to
underestimation within both groups. Especially for UN
CS, the pattern of the empirical
correlations were lost. All KPS structure estimates show lower diﬀerences between the
group parameters than there were in the data. The RIcorr structure is more parsimonious
than RIScorr but captured the most important patterns in the correlations. However,
RIScorr outperformed the other MMS regarding the replication of the empirical correlation
pattern. The autocorrelation parameters of RIind were similar to the one of RIcorr. But
this was not the case for RISind and RIScorr, the estimation of cross-correlations in the
latter resulted also in a more precise estimation of the autocorrelations. The estimated
RICAR1ind parameters were very similar to those of RIind but the empirical ones did also
not exhibit a AR(1) pattern.
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This ranking of the structures based on the correlations applies to the variance parameters
as well. The models without cross-correlations did not have so highly overestimated
variances as the Kronecker product structures. Moreover, unrealistic model structure
simpliﬁcations carried the danger to decrease or increase the empirically observed group
diﬀerences and thus the classiﬁcation performance. The BIC selected RIind in 82%, RIcorr
in 10% and RICAR1ind in 8% of the 50 MCCV samples for the non-resistant group and
RIcorr in 100% for the resistant group. Compared to the visual ranking, the BIC takes
the ﬁt and the number of parameters of the models into account, penalising models with
too many parameters.
In the following, the univariate longitudinal classiﬁcation performance of the biomarkers
for the ﬁrst 3 and 4 visits is presented in comparison to the cross-sectional one of QDA at
visit 1. At the ﬁrst visit, biomarker 1 and 4 had the best cross-sectional performance with
an median AUC of 0:62, a BS of 0:785 and a correlation with the Gold Standard of 0:2
(see Table 4.1 for the corresponding conﬁdence intervals and Figure 4.7, ﬁrst row of the
cubes). (The prior probabilities were estimated by the group proportions in all analyses,
i.e.  = (1=3; 2=3). This yielded [ 0:77; 0:77] as limits of the biserial correlation. The
reference limit of the Brier Score is 0:778.)
Perf. Measure Biomarker Visit 1 (QDA) 4 visits (longQDA)
AUC BM 1 0.63 [0.53;0.67]
BM 4 0.62 [0.54;0.71] 0.67 [0.58;0.76]
BM 4,5 0.65 [0.57;0.76]
BS BM 1 0.785 [0.766;0.789]
BM 4 0.786 [0.769;0.794] 0.792 [0.755;0.812]
BM 4,5 0.786 [0.756;0.806]
z[1];p[1] BM 1 0.20 [0.03;0.26]
BM 4 0.19 [0.07;0.29] 0.27 [0.11;0.42]
BM 4,5 0.22 [0.09;0.39]
Table 4.1: Performance measures of biomarkers indicative for RA therapy response. They
are given as median with 10th and 90th percentile of 50-fold MCCV results.
The group-wise distributions of the estimated posterior probabilities were hardly separated
(Figure 4.8(a) and (b)). When using 3 or 4 visits with longQDA, BM2, BM3, BM4 and
BM6 gained in performance, BM1, BM5 and BM7 lost. Only BM4 achieved a clearly
higher performance than the cross-sectional reference (median AUC: 0:67, BS 0:792,
correlation 0:27).
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Figure 4.7: Univariate performance of biomarkers, displaying the dependence on the num-
ber of visits included in the assessment. The reference grid marks the best
cross-sectional performance of BM4, the cube of the BS has a second one at
the reference limit of 0:778.
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Also at the individual posterior probability level (Figure 4.8(c)), an improvement was
observed. But the biomarker was still of minor quality for predicting therapy resistance.
The group-wise estimated mixed model parameters for the non-resistants were [0] =
(3:92; 0:176); d2[0]I = 0:25; ﬀ
2
[0] = 0:26 and [1] = (3:71; 0:088); d
2
[1]I = 0:30; ﬀ
2
[1] =
0:28 for the resistants. In both groups, the total residual variance was twice as high as
the variance of the random intercept, yielding an intraclass correlation of about one third.
Figure 4.8: Histograms of posterior probabilities for resistant (red) and non-resistant pa-
tients (gray). (a) BM1, QDA with data of visit 1; (b) BM4, QDA with data
of visit 1; (c) BM 4, longQDA with data of 4 visits; (d) BM4 and BM5, QDA
with data of visit 1; (e) BM4 and BM5, longQDA with data of 4 visits.
In the following, the performance of biomarker pairs is considered. The best ones were
achieved by combinations with the best univariate biomarker BM4 (Figure 4.9). At the
ﬁrst visit, the pair of BM4 and BM5 achieved a slightly better performance with QDA
with a median AUC of 0:65, a BS of 0:786 and a correlation of 0:22 than BM4 as a
single marker (Table 4.1 and Figure 4.8(d) vs. (b)). But it was still worse than the uni-
variate longitudinal performance of BM4. This remained also the best performance when
combining biomarkers over time with longQDA (Figure 4.9 and Figure 4.8(e) vs. (c)).
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Figure 4.9: Bivariate performance of biomarkers, displaying the dependence on the number
of visits included in the assessment. The lower reference grid marks the best
cross-sectional performance of the pair BM4,BM5, the higher one the best
longitudinal one of BM4.
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4.4 Improvement by Multivariate Modelling: Some Examples
For the application data, there was no additional gain in performance by combining
biomarkers. Therefore, exemplary scenarios where such an improvement has been achieved
are presented in the following. For this purpose, bivariate biomarker data were simulated
according to a random coeﬃcients model with RIcorr structure (denoted as RIcorr*).
This is the simplest bivariate model in that only one additional parameter needs to be
estimated comparing the bivariate model with the two univariate models. It is the cor-
relation [1;2]
II
between the random intercepts of each biomarker. The univariate, i.e. the
biomarker-speciﬁc parameters were assumed to be the same. Thus, both biomarkers yield
the same univariate classiﬁcation performance and a potential gain is only triggered by
the bivariate modelling. As above, the residuals between the variables were assumed to
be independent.
There were 4 simulation scenarios and their parameters are given in Table 4.2. In scenario 1
to 3, the parameters diﬀered only with regard to [1;2]
[k]II
. The diﬀerence of the group-
speciﬁc correlations of the random intercepts was smallest for scenario 1 with 0.2 ([1;2]
[0]II
=
0:8; 
[1;2]
[1]II
= 0:6). The diﬀerence was increased to 0.6 for scenario 2 ([1;2]
[1]II
= 0:2) and
further to 1.6 for scenario 3 ([1;2]
[1]II
=  0:8). The fourth scenario exhibits a data setting
where the correlations diﬀered as slightly as in scenario 1 but the ﬁxed slopes as well
as the residual variances diﬀered in addition by 0.1 each ([0]1 =  0:05; [1]1=0:05 and
ﬀ2[0] = 0:3; ﬀ
2
[1] = 0:2).
Parameter Scenario Group 0 Group 1
0 1,2,3,4 -3.70 -3.70
1 1,2,3 - 0.05 - 0.05
4 -0.05 -0.05
dI 1,2,3,4 - 0.15 - 0.15

[1;2]
II
1,4 -0.80 -0.60
2 -0.80 -0.20
3 -0.80 -0.80
ﬀ2 1,2,3 -0.20 -0.20
4 -0.30 -0.20
Table 4.2: Group-speciﬁc parameter settings of simulated RIcorr* models
Biomarker data with 4 visits measured at baseline, 1, 4, and 6 months thereafter were
simulated. The population comprised twice the sample sizes of the application data, 110
non-resistant and 220 resistant patients. We applied 50-fold MCCV and did 25 simulation
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repetitions. For each simulation scenario, two classiﬁcation performances were evaluated
to illustrate the potential gain: the univariate performance by a random coeﬃcient model
including the measurements of one biomarker and the corresponding bivariate performance
including both biomarkers.
The histograms of the estimated posterior probabilities for group 1 are shown in Fig-
ure 4.10 and the resulting performance measures AUC, BS and z[1];p[1] are listed in Ta-
ble 4.3 for each simulation scenario. The limits of the latter two are the same as for the
application data. Note that the univariate results of scenario 2 and 3 were the same as
for scenario 1 and were therefore omitted.
Figure 4.10: Histograms of posterior probabilities for resistant (red) and non-resistant
patients (gray), simulated bivariate biomarker data. (a) Sc. 1, RI; (b) Sc. 1,
RIcorr; (c) Sc. 2, RIcorr (d) Sc. 3, RIcorr; (e) Sc. 4, RI; (f) Sc. 4, RIcorr.
Scenario MMS AUC BS z[1];p[1]
1 RI :50 [:42; :57] :776 [:767; :782] :00 [ :13; :13]
1 RIcorr :52 [:44; :60] :773 [:760; :785] :03 [ :11; :17]
2 RIcorr :59 [:51; :68] :782 [:767; :798] :16 [ :03; :30]
3 RIcorr :79 [:73; :84] :835 [:812; :853] :50 [ :41; :58]
4 RI :81 [:75; :87] :844 [:818; :867] :55 [ :44; :64]
4 RIcorr :87 [:82; :92] :873 [:848; :897] :66 [ :56; :73]
Table 4.3: Selected performance measures demonstrating the beneﬁt of multivariate mod-
elling. They are given as median with 10th and 90th percentile.
Comparing the univariate performance of scenario 1 with the corresponding bivariate per-
formance ((a) vs. (b)), a performance of very minor quality was achieved in both cases. A
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diﬀerence between the correlation parameters of 0.2 was not suﬃcient for an improvement
and a diﬀerence of 0.6 as in scenario 2 was only slightly better ((a) vs. (c)). Scenario 3
exhibited an extreme improvement by bivariate modelling ((a) vs. (d)). A diﬀerence of
1.6 yielded an AUC of 0:79 [0:73; 0:84] vs. 0:5 [0:42; 0:57], a BS of 0:835 [0:812; 0:853]
vs. 0:776 [0:767; 0:782] and also a clearly higher biserial correlation of 0:50 [0:41; 0:58]
vs. 0:00 [ 0:13; 0:13].
But a very high diﬀerence is not the only possible scenario to yield an improvement by
bivariate modeling. Another possible parameter setting is illustrated by scenario 4. The
diﬀerence between the correlation parameters was with 0.2 as small as in scenario 1 but
two further parameters diﬀered slightly between the groups. This yielded quite a good
univariate classiﬁcation performance but it was also further improved by combining the
biomarkers ((e) vs. (f)).
5 Software Implementation:
The R package longQDA
For a wide-spread application of statistical methods, an implementation in a state-of-the-
art software environment like R (Ihaka and Gentleman, 1996; R Development Core Team,
2008) is indispensable nowadays. The package longQDA provides the necessary general
framework for executing quadratic discriminant analysis with longitudinal data. All
univariate and multivariate models presented in Chapter 2 to 4 have been implemented. It
comprises about 3500 eﬀective lines of code (determined by LineStats, Fridman (2005))
and is available on request from the Biostatistics Department of Roche Diagnostics
GmbH, Penzberg.
In the next section, an application of longQDA is shown for the HIV therapy resistance data
set. The results of these analyses have already been presented in Chapter 2. The package
longQDA contains these data as an exemplary data set with a univariate biomarker. The
implementation of the software follows the object-orientated concept of S4 classes (Cham-
bers, 1998, 2006), which is provided by the R package methods. This conceptual approach
determined the software design and is presented in the subsequent section. One of the
main advantages of object-oriented programming (OOP) is easy extensibility and this is
demonstrated for two features of the software, the multivariate version of longQDA and
the generation and analysis of simulated data with the option to use parallel computing.
Further possible extensions may be, for example, mixed models with a mixture density
for the random eﬀects. Appendix B complements this section by help ﬁles of the most
important functions in longQDA.
5.1 Application: Analyzing Univariate Biomarker Data with
longQDA
The package longQDA provides functionality for the entire data analysis process, from the
descriptive and explorative analysis of longitudinal data up to the comparison of results,
e.g. when contrasting longQDA with diﬀerent model assumptions or longQDA to QDA.
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In the following, the main functionality of longQDA is demonstrated with the data set
called AIDS2, which contains one biomarker that is indicative for a patient's response
to HIV therapy. The following exemplary features of the analysis steps are presented:
describing and exploring longitudinal data, deﬁning subanalyses, performing those sub-
analyses by QDA or univariate longQDA, comparing analysis results and, last but not
least, documenting the results.
The documentation is facilitated by a sequential report generation during the entire data
analysis process. In every analysis step, the output may be redirected into a report and a
preview with the results of these analyses may be displayed. At any time during the analysis
process, further additional plots or comments may be added to the report. Having ﬁnished
the analysis, the user generates a report ﬁle (in tex or pdf format) which documents the
analyses and contains all the output: plots, tables and comments.
5.1.1 Report Setup
Prior to the actual data analysis, it is recommended to set up the report. The constructor
function Report instantiates a report. In the subsequent stages of the analysis, the report
object is ﬁlled with the names of the output ﬁles and the generated output ﬁles are saved
to the location speciﬁed in the argument folder.
> rep1 <- Report(folder = "C:/AIDS2/")
An instance of class Report is a list with four entries, one for the exploratory analysis,
one for the analysis setup, one for the longQDA analyses and one for the comparison of
results (for more details, refer to B):
> str(rep1)
Formal class 'Report' [package "longQDA"] with 2 slots
..@ .Data :List of 4
.. ..$ :Formal class 'NamedList' [package "longQDA"] with 2 slots
.. .. .. ..@ .Data : list()
.. .. .. ..@ myname: chr "Exploratory Analysis"
.. ..$ :Formal class 'NamedList' [package "longQDA"] with 2 slots
.. .. .. ..@ .Data : list()
.. .. .. ..@ myname: chr "Analysis Setup"
.. ..$ :Formal class 'NamedList' [package "longQDA"] with 2 slots
.. .. .. ..@ .Data : list()
.. .. .. ..@ myname: chr "Analysis"
.. ..$ :Formal class 'NamedList' [package "longQDA"] with 2 slots
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.. .. .. ..@ .Data : list()
.. .. .. ..@ myname: chr "Comparisons"
..@ folder: chr "C:/AIDS2/"
5.1.2 Data Import and Creation of the LongData Object
After the report object has been created, the data set 'AIDS2' is imported. As it is
contained in the package, it is easily loaded by
> data(AIDS2)
Otherwise, data can be imported to R in the usual way.
A short description of the data set is obtained by calling ?AIDS2 to display the corre-
sponding help entry. Here is a short overview of the data set:
> head(AIDS2)
PATID TIMEDAY VISIT CENSOR BM1 SDURN GROUP GROUPVAR
1 1 0 1 1 20161 0.00000000 1 non-resistant
2 1 14 2 1 9699 0.03835616 1 non-resistant
3 1 29 3 1 442 0.07945205 1 non-resistant
4 1 42 4 1 310 0.11506849 1 non-resistant
5 2 0 1 1 172748 0.00000000 1 non-resistant
6 2 8 2 1 40921 0.02191781 1 non-resistant
> str(AIDS2)
'data.frame': 1506 obs. of 8 variables:
$ PATID : int 1 1 1 1 2 2 2 2 2 2 ...
$ TIMEDAY : int 0 14 29 42 0 8 37 64 99 162 ...
$ VISIT : int 1 2 3 4 1 2 3 4 5 6 ...
$ CENSOR : int 1 1 1 1 1 1 1 1 1 3 ...
$ BM1 : int 20161 9699 442 310 172748 40921 290 188 49 8 ...
$ SDURN : num 0.0000 0.0384 0.0795 0.1151 0.0000 ...
$ GROUP : int 1 1 1 1 1 1 1 1 1 1 ...
$ GROUPVAR: Factor w/ 2 levels "non-resistant",..: 1 1 1 1 1 1 1 1 1 1 ...
The variables of the data set are PATID, the patient identiﬁcation number, TIMEDAY
and SDURN, the study time in days resp. years, VISIT, the number of the visit ranging
from 1 to 6, CENSOR, information about the censoring, BM1, the measurements of the
biomarker HIV RNA, and GROUP and GROUPVAR, the information about the group mem-
bership according to the Gold Standard formatted as an integer resp. a factor variable.
Then the raw data set needs to be formatted according to the implemented standard-
ized longitudinal data structure. For this purpose, the user speciﬁes the name(s) of the
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biomarker(s) and of other important variables like the study time. The scheduled visit
times and the coding of the groups need to be provided, too. The constructor function
LongData formats the raw data set to comply with the package-speciﬁc longitudinal data
structure and stores important metainformation about the data which is repeatedly needed
in the subsequent analysis steps.
> d <- LongData(rawdata=AIDS2, name=dsname, markerlabels="BM1",
+ scheduledtimes=c(0, 2, 4, 8, 16, 24)/52,
+ groups=c("non-resistant" = 1, resistant = 2),
+ timename="SDURN")
The implemented standardized structure for longitudinal data is as follows:
> str(d)
Formal class 'LongData' [package "longQDA"] with 17 slots
..@ id2rows : int [1:356, 1:6] 1 5 11 13 16 22 28 31 33 38 ...
.. ..- attr(*, "dimnames")=List of 2
.. .. ..$ : chr [1:356] "1" "2" "3" "4" ...
.. .. ..$ : chr [1:6] "1" "2" "3" "4" ...
..@ visitindex : int 3
..@ timeindex : int 6
..@ markerlabels : Named chr "BM1"
.. ..- attr(*, "names")= chr "BM1"
..@ markerindices : int 5
..@ scheduledtimes : num [1:6] 0.0000 0.0385 0.0769 0.1538 0.3077 ...
..@ rawdata :'data.frame': 1506 obs. of 8 variables:
.. ..$ PATID : int [1:1506] 1 1 1 1 2 2 2 2 2 2 ...
.. ..$ TIMEDAY : int [1:1506] 0 14 29 42 0 8 37 64 99 162 ...
.. ..$ VISIT : int [1:1506] 1 2 3 4 1 2 3 4 5 6 ...
.. ..$ CENSOR : int [1:1506] 1 1 1 1 1 1 1 1 1 3 ...
.. ..$ BM1 : int [1:1506] 20161 9699 442 310 172748 40921 290 188 49 8 ...
.. ..$ SDURN : num [1:1506] 0.0000 0.0384 0.0795 0.1151 0.0000 ...
.. ..$ GROUP : int [1:1506] 1 1 1 1 1 1 1 1 1 1 ...
.. ..$ GROUPVAR: Factor w/ 2 levels "non-resistant",..: 1 1 1 1 1 1 1 1 1 ...
..@ name : chr "AIDS2"
..@ groupindex : int 7
..@ grouplabels : chr [1:2] "non-resistant" "resistant"
..@ groupcodes : num [1:2] 1 2
..@ groupcolors : chr [1:2] "black" "red"
..@ groupsymbols : num [1:2] 1 2
..@ grouppriors : num [1:2] 0.820 0.180
..@ fixedgrouppriors : logi FALSE
..@ idindex : int 1
..@ markertransformfn: chr(0)
Besides the data set with coded biomarker names (BM1, BM2,...) in the slot rawdata,
the original biomarker names are stored in the slot markerlabels with the coded
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names as names of the vector. (For this data set, the biomarker was already coded
so there is no diﬀerence between the coded and the original biomarker name.) The
slot markertransformfn is still empty, but later on, the function names used for the
biomarker transformation are stored there, it is e.g "log10". The slot scheduledtimes
contains the scheduled visit times from which the individual visit times usually diﬀer. The
metainformation of the data set comprises in addition the column numbers of the data
set containing important variables such as the patient identiﬁcation number (idindex),
the group (groupindex), the study time and the visits (timeindex and visitindex)
and that of the biomarker (markerindices). This allows a fast access to repeatedly
requested information by various methods. The same applies to the slot id2rows which
contains the row numbers of the data set for each patient at each visit. The other slots
contain information about the groups deﬁned by the Gold Standard. These are the prior
probability for each group (grouppriors), the labels (grouplabels), the symbols to
mark the group membership in plots (groupsymbols) and the numerical codes used in
the dataset (groupcodes). The user can choose either to use estimated group priors
according to the group proportions in the training sets or user-speciﬁed, ﬁxed group
priors in the analyses. The default is the ﬁrst and the choice of the user is saved in the
slot fixedgrouppriors. If ﬁxed group priors should be used, they can be provided in
the argument priors of LongData.
5.1.3 Exploratory and Descriptive Data Analysis
The ﬁrst step of the analysis is to explore and describe the longitudinal data. By calling
plotLongMarkers, plots of the biomarker proﬁles for the non-resistant and the resistant
patients are created (Figure 5.1).
> par(mfrow = c(1, 2)) # determines arrangement of plots
> plotLongMarkers(d)
Some patients have incomplete biomarker proﬁles due to missing visits or missing biomarker mea-
surements. These are the shorter or intermittent lines in the ﬁgure.
Next, completeCases is used to exclude all patients with less than 6 visits or missing biomarker
measurements. The biomarker is then transformed by the log10 function to ease the comparison
of the proﬁles between the two groups.
> d <- completeCases(d)
Records of 271 patients deleted due to incompleteness of the first
6 visits. Records of 0 patients deleted due to incomplete biomarker
measurements.
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> d <- transform(d, list(log10 = log10))
This yields a LongData object containing the reduced data set and the transformed
biomarker.
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Figure 5.1: Empirical biomarker proﬁles in each group, produced by plotLongMarkers.
Next, the median proﬁle and its variance are explored by boxplotLongMarkers,
the variation of the individual visit times around the scheduled ones are illustrated
by scatterVisitTimes and the autocorrelations within each group are estimated
by autoCorr. The user has two options here: Either the functions are separately
executed (with the advantage to control all parameters individually) or standardized
output is created by calling createReportFiles. In the latter case, the four functions
are executed with predeﬁned parameter settings, the output ﬁles are saved and the
location of the output ﬁles are automatically added in the Report object, updating the
object rep1.
This is achieved by
> rep1 <- createReportFiles(d, report = rep1)
The Report object's current structure is the following:
> str(rep1)
Formal class 'Report' [package "longQDA"] with 2 slots
..@ .Data :List of 4
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.. ..$ :Formal class 'NamedList' [package "longQDA"] with 2 slots
.. .. .. ..@ .Data :List of 1
.. .. .. .. ..$ :Formal class 'NamedList' [package "longQDA"] with 2 slots
.. .. .. .. .. .. ..@ .Data :List of 6
.. .. .. .. .. .. .. ..$ : chr "C:/AIDS2/AIDS2(completecases_6v)plotLongMarkers.pdf"
.. .. .. .. .. .. .. ..$ : chr "C:/AIDS2/AIDS2(completecases_6v)boxplotLongMarkers.pdf"
.. .. .. .. .. .. .. ..$ : chr "C:/AIDS2/AIDS2(completecases_6v)scatterVisitTimes.pdf"
.. .. .. .. .. .. .. ..$ : chr "C:/AIDS2/AIDS2(completecases_6v)statsVisitTimes.tex"
.. .. .. .. .. .. .. ..$ : chr "C:/AIDS2/AIDS2(completecases_6v)autoCorr.tex"
.. .. .. .. .. .. .. ..$ : chr "C:/AIDS2/AIDS2(completecases_6v)autoCorrPlots.pdf"
.. .. .. .. .. .. ..@ myname: chr "AIDS2(complete cases,6v)"
.. .. .. ..@ myname: chr "Exploratory Analysis"
.. ..$ :Formal class 'NamedList' [package "longQDA"] with 2 slots
.. .. .. ..@ .Data : list()
.. .. .. ..@ myname: chr "Analysis Setup"
.. ..$ :Formal class 'NamedList' [package "longQDA"] with 2 slots
.. .. .. ..@ .Data : list()
.. .. .. ..@ myname: chr "Analysis"
.. ..$ :Formal class 'NamedList' [package "longQDA"] with 2 slots
.. .. .. ..@ .Data : list()
.. .. .. ..@ myname: chr "Comparisons"
..@ folder: chr "C:/AIDS2/"
In most cases, it is the best to combine both options. Suppose additional plots of the
biomarker proﬁles are needed, in this case with transparent lines according to an alpha
transparency level of 0:3. The ﬁrst option may be used for this purpose by calling the
function manually. This yields Figure 5.2.
> par(mfrow = c(1, 2))
> plotLongMarkers(d, linealpha = 0.3)
At every time during the analysis, plots which are displayed in the current graphics device
may be included in the report. For this plot, it is achieved by
rep1 <- save2Report(rep1, section="expl",
subsection="AIDS2 (complete cases)",
name="PlotTrajTransparency",
text="Here are the biomarker trajectories
with a transparency value of $0.3$.")
The plot as well as the comment given by the argument text are added to the subsection
'AIDS2 (complete cases)'1 in the report section for the exploratory analysis for which the
results are saved in the rep1 list entry expl.
1The subsection to which the output is added need to exist already when using save2Report.
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Figure 5.2: Empirical transformed biomarker proﬁles in each group with transparent lines,
produced by plotLongMarkers.
This optional inclusion of any plot in the report may also be used for further explorative
analyses when plots have been produced by R functions implemented in other packages or
written by the user.
5.1.4 Analysis Setup
We move on to set up the discriminant analyses using the constructor function
AnalysisSetup. We specify to use 10-fold MCCV with training sets containing twice as
many patients as the test sets. The sub-analyses to be performed are speciﬁed in the
argument paths as lists with a speciﬁc structure.
> ana.setup <- AnalysisSetup(d, nMCsamples=10, ratiotrain=2/3,
+ paths=list(list(isLongitudinal=FALSE,
+ isMarkerComb=FALSE,
+ whichVisits=1,
+ isSingleVisit=TRUE),
+ list(isLongitudinal=TRUE,
+ isMarkerComb=FALSE,
+ whichVisits=(1:ncol(d@id2rows)),
+ modelparams=list(covstr="RIS",
+ timestr="quadratic"))))
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In the example above, the biomarker performance of the ﬁrst as well as that of all 6 visits
are of interest. So two analysis paths were deﬁned: Path 1 contains the settings for
evaluating the performance at baseline (1st visit) by QDA, path 2 describes the settings
for longQDA with linear mixed models including random intercepts and random linear
slopes (RIS), and up to quadratic ﬁxed time eﬀects.
One analysis path represents one sub-analysis and all analysis paths together form an
analysis tree. E.g. for a data set with 2 biomarkers (denoted as BM1 and BM2) which were
measured at 3 visits, a tree of maximal size is given in Figure 5.3. The paths are described
by the boolean variable isLongitudinal to indicate whether the longitudinal structure
of the data should be accounted for (i.e. choosing QDA or longQDA), by isMarkerComb
to decide for a univariate or multivariate biomarker assessment and by isSingleVisit
to indicate whether QDA should be executed with single cross-sectional or longitudinal
data handling them as multivariate cross-sectional data. The other parameters of the list
entries in paths determine the visits to be included in the sub-analysis and, if applicable,
the covariance structure and the order of the ﬁxed eﬀect of the time variable for the
mixed models in univariate longQDA.
Figure 5.3: Analysis tree illustrating the setup of univariate analysis paths. Multivariate
paths where isMarkerComb = TRUE are omitted. Created with yEd Graph
Editor (yWorks, 2008).
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The MCCV samples are then generated by calling AnalysisSetup and the analysis tree
is fully described. These analysis settings are saved to the report by
> rep1 <- createReportFiles(ana.setup, report = rep1)
To facilitate reproducible research, the analysis setup should be saved as a R object, e.g. to
the report folder, by
> saveRobject(ana.setup, reportfolder=rep1@folder,
name="AnaSetup_longQDA6visitslin")
This enables the user to reload these analysis settings by calling loadRobject and to
reproduce all analysis results at a later point in time. This functionality is also helpful
when the user needs to add further analysis paths. This way, a full comparability of the
results is ensured as the analysis is executed with exactly the same data set, same MCCV
samples and same performance measures parameters but diﬀerent (long)QDA settings.
The old settings are reloaded by loadRobject and only the paths are updated when
calling updateAnalysisSetup to yield the new analysis setup. All (long)QDA settings
that are speciﬁed in the argument paths of the constructor function AnalysisSetup may
be changed in the same-named argument of updateAnalysisSetup.
5.1.5 Analysis of all Analysis Paths
The method analyze is called to start the analysis which comprises the estimation of the
mean vector and the covariance matrix for each group (by mixed models for longitudinal
data, by the empirical analogues for QDA), the prediction of the posterior probabilities
based on the quadratic discriminant rule and the evaluation of the performance measures
for each analysis path.
> full.tree <- analyze(ana.setup)
Path 1
fit of QDA .........
Path 2
fit of RIS .........
The structure of the tree, containing all analysis results, has 4 hierarchical levels. The
ﬁrst one comprises the analysis paths, the second the visits, the third the biomarker
(combinations) and the forth level a list with entries for each MCCV sample. The structure
of the second path of full.tree is shown below:
5. Software Implementation: The R package longQDA 69
> full.tree[[2]]
$`Visit(s) 1;2;3;4;5;6`
$`Visit(s) 1;2;3;4;5;6`$`Markers BM1`
$`Visit(s) 1;2;3;4;5;6`$`Markers BM1`$`CV 1`
[...]
It is organized so that the results of each MCCV sample are contained in the leaf nodes
of the tree. One leaf node comprises a list with estimations of each part of analyze
described above and are saved in the list entries model, predict and performance:
> str(full.tree[[2]][[1]][[1]][[1]])
List of 3
$ model :Formal class 'RisModel' [package "longQDA"] with 5 slots
.. ..@ mean :List of 2
.. .. ..$ group1: Named num [1:3] 4.48 -13.08 18.92
.. .. .. ..- attr(*, "names")= chr [1:3] "(Intercept)" "SDURN" "I(SDURN^2)"
.. .. ..$ group2: Named num [1:3] 4.40 -8.46 14.01
.. .. .. ..- attr(*, "names")= chr [1:3] "(Intercept)" "SDURN" "I(SDURN^2)"
.. ..@ cov :List of 2
.. .. ..$ group1:List of 2
.. .. .. ..$ D: Named num [1:3] 0.558 7.378 0.447
.. .. .. .. ..- attr(*, "names")= chr [1:3] "DInt" "DSlope" "D_IS"
.. .. .. ..$ R: Named num 0.321
.. .. .. .. ..- attr(*, "names")= chr "sigQuad"
.. .. ..$ group2:List of 2
.. .. .. ..$ D: Named num [1:3] 0.343 6.279 0.477
.. .. .. .. ..- attr(*, "names")= chr [1:3] "DInt" "DSlope" "D_IS"
.. .. .. ..$ R: Named num 0.288
.. .. .. .. ..- attr(*, "names")= chr "sigQuad"
.. ..@ BIC :List of 2
.. .. ..$ group1: Named num 602
.. .. .. ..- attr(*, "names")= chr "CV1"
.. .. ..$ group2: Named num 262
.. .. .. ..- attr(*, "names")= chr "CV1"
.. ..@ modelparams:List of 2
.. .. ..$ covstr : chr "RIS"
.. .. ..$ timestr: chr "quadratic"
.. ..@ reshapefn : chr "minimize"
$ predict :List of 3
..$ class : Factor w/ 2 levels "1","2": 1 1 2 1 2 2 1 2 1 1 ...
..$ posterior : num [1:27, 1:2] 0.864 0.962 0.357 0.818 0.377 ...
.. ..- attr(*, "dimnames")=List of 2
.. .. ..$ : chr [1:27] "5" "88" "102" "104" ...
.. .. ..$ : chr [1:2] "1" "2"
..$ posteriorMV: num [1:27, 1:2] 0.004356 0.000370 0.000214 0.003271 ...
.. ..- attr(*, "dimnames")=List of 2
.. .. ..$ : chr [1:27] "5" "88" "102" "104" ...
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.. .. ..$ : chr [1:2] "1" "2"
$ performance:Formal class 'PerformanceMeasures' [package "longQDA"]
with 13 slots
.. ..@ auc : num 0.865
.. ..@ roc :Formal class 'performance' [package "ROCR"]
with 6 slots
.. .. .. ..@ x.name : chr "False positive rate"
.. .. .. ..@ y.name : chr "True positive rate"
.. .. .. ..@ alpha.name : chr "Cutoff"
.. .. .. ..@ x.values :List of 1
.. .. .. .. ..$ : num [1:101] 0 0 0 0 0 0 0 0 0 0 ...
.. .. .. ..@ y.values :List of 1
.. .. .. .. ..$ : num [1:101] 0 0 0 0 0 0 0 0 0 0 ...
.. .. .. ..@ alpha.values:List of 1
.. .. .. .. ..$ : num [1:101] 1.00 0.99 0.98 0.97 0.96 ...
.. ..@ bs : num 0.87
.. ..@ bsC : num 0.0237
.. ..@ bsD : num 0.100
.. ..@ bsDM : num 0.112
.. ..@ diffpig : num 0.332
.. ..@ pig2quer : num 0.559
.. ..@ corGSBM : num 0.618
.. ..@ deltaSigmaPostProb: num 0.196
.. ..@ sigmaMinPostProb : num 0.0234
.. ..@ ratioVarPostProb : num 8.4
.. ..@ calLarge : num 0.000395
Especially in the case of long computation times, it is recommended to save this object as
the analysis settings before by saveRobject. This enables the user to analyze the results
further, also in another R session later on.
> saveRobject(full.tree, reportfolder=rep1@folder,
+ name="fullTree_longQDA6visitslin")
The user is probably not interested in the results of a single MCCV loop but in the
summarized results of all MCCV samples. Therefore the method mccvSummary returns a
result tree where the leaf nodes contain summaries in form of matrices, lists etc. E.g. for
the second path, the result looks as follows:
> sum.tree <- mccvSummary(full.tree, ana.setup)
> str(sum.tree[[2]], 6)
List of 1
$ Visit(s) 1;2;3;4;5;6:List of 1
..$ Markers BM1:Formal class 'MccvSummary' [package "longQDA"] with 5 slots
.. .. ..@ modelEstimates:List of 2
.. .. .. ..$ group1:List of 3
.. .. .. .. ..$ estimates : num [1:10, 1:7] 4.48 4.56 4.52 4.42 4.52 ...
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.. .. .. .. .. ..- attr(*, "dimnames")=List of 2
.. .. .. .. ..$ BIC : Named num [1:10] 602 597 590 606 605 ...
.. .. .. .. .. ..- attr(*, "names")= chr [1:10] "CV1" "CV2" "CV3" "CV4" ...
.. .. .. .. ..$ modelparams:List of 2
.. .. .. ..$ group2:List of 3
.. .. .. .. ..$ estimates : num [1:10, 1:7] 4.40 4.29 4.39 4.38 4.32 ...
.. .. .. .. .. ..- attr(*, "dimnames")=List of 2
.. .. .. .. ..$ BIC : Named num [1:10] 262 238 250 261 251 ...
.. .. .. .. .. ..- attr(*, "names")= chr [1:10] "CV1" "CV2" "CV3" "CV4" ...
.. .. .. .. ..$ modelparams:List of 2
.. .. ..@ roccv :Formal class 'performance' [package "ROCR"] with 6 slots
.. .. .. .. ..@ x.name : chr "False positive rate"
.. .. .. .. ..@ y.name : chr "True positive rate"
.. .. .. .. ..@ alpha.name : chr "Cutoff"
.. .. .. .. ..@ x.values :List of 10
.. .. .. .. ..@ y.values :List of 10
.. .. .. .. ..@ alpha.values:List of 10
.. .. ..@ pmmatrix : num [1:10, 1:12] 0.865 0.569 0.612 0.763 0.789 ...
.. .. .. ..- attr(*, "dimnames")=List of 2
.. .. .. .. ..$ : chr [1:10] "CV 1" "CV 2" "CV 3" "CV 4" ...
.. .. .. .. ..$ : chr [1:12] "auc" "bs" "bsC" "bsD" ...
.. .. ..@ posterior2 :'data.frame': 85 obs. of 11 variables:
.. .. .. ..$ group: int [1:85] 1 1 1 1 1 1 1 2 1 1 ...
.. .. .. ..$ 1 : num [1:85] NA 0.136 NA NA NA ...
.. .. .. ..$ 2 : num [1:85] NA 0.0444 NA NA 0.3387 ...
.. .. .. ..$ 3 : num [1:85] NA NA NA NA NA ...
.. .. .. ..$ 4 : num [1:85] NA 0.104 NA NA 0.296 ...
.. .. .. ..$ 5 : num [1:85] NA 0.119 0.212 NA 0.354 ...
.. .. .. ..$ 6 : num [1:85] NA NA NA NA NA ...
.. .. .. ..$ 7 : num [1:85] NA NA NA NA 0.206 ...
.. .. .. ..$ 8 : num [1:85] NA NA 0.174 NA NA ...
.. .. .. ..$ 9 : num [1:85] NA NA NA 0.0798 NA ...
.. .. .. ..$ 10 : num [1:85] NA NA NA NA NA NA NA NA NA NA ...
.. .. ..@ analysisPath: chr "Path 2_Visit(s) 1;2;3;4;5;6_Markers BM1"
Based on this summary, default output ﬁles for each path are generated by calling
createReportFiles. This output includes the group-speciﬁc estimated model parame-
ters, a table with quantiles of the performance measures, ROC curves, histograms of the
performance measures of all MCCV samples, a back-to-back histogram of the predicted
posterior probabilities and a calibration curve for every analysis path.
> rep1 <- createReportFiles(sum.tree, ana.setup, report = rep1,
+ ROCaveragefn = "mean")
By default, all output of this section is summarized in a temporary pdf ﬁle. This preview,
named 'myReport.pdf', can be found in the report folder. As above, it is also possi-
ble to individualize the output by calling the internal output methods separately. Vide
the documentation (?createReportFiles) for all methods which are provided for this
purpose.
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Comments can be added to the report to a section resp. subsection. Further on, comments
can be saved together with a single plot as shown above. Below, the ﬁrst option is
demonstrated by adding a comment to the longQDA subanalysis (path 2):
> rep1 <- save2Report(rep1, section = "analysis", subsection = 2,
+ text = "longQDA includes 6 biomarker measurements per patient.")
5.1.6 Comparison of Analysis Paths
At the end of the exemplary data analysis, the results of all subanalyses are compared.
The subanalyses are selected by their leaf numbers which are returned by
> showLeafs(sum.tree)
Path 1
Visit(s) 1
Markers BM1 => 1
Path 2
Visit(s) 1;2;3;4;5;6
Markers BM1 => 2
As there are only 2 subanalyses, both of them are selected. A name for the comparison
as well as names for the analyses described by the analysis paths need to be provided.
> leafs6 <- selectResultLeafs(sum.tree, leafnumbers=(1:2),
+ compname="Baseline vs. all 6 visits",
+ pathnames=c("QDA, Baseline", "RIS, 6 vis."))
In addition, output ﬁles are generated by createReportFiles giving 2 plots with 2 ROC
curves for our example. One ROC curve is coloured according to the changing threshold of
the posterior probability, the other according to the path-speciﬁc colour (alterable by the
argument ROCcolors) and contains the legend for the ROC curves as well. In addition,
boxplots of the performance measures are plotted. A table with the frequencies of the
covariance structures (RI, RIS and RICAR1) which achieved the minimal BIC makes no
sense in this example, so freqMinBIC=FALSE is set.
> rep1 <- createReportFiles(leafs6, ana.setup, rep1,
+ ROCcolors=c("firebrick3","midnightblue"),
+ legendtext=c("RIS, BM1", "QDA, BM1"),
+ boxcolors=c("firebrick3", "midnightblue"),
+ freqMinBIC=FALSE)
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5.1.7 Report Generation
Finally, a report ﬁle is created (standard name is 'myreport.tex') where all output plots and
tables stored in the report object rep1 are included. The report is structured in sections
and subsections as deﬁned by the list structures in rep1. A name for the data set on
which the analysis was based and details about the author of the report are provided.
Then createReport generates a report ﬁle in tex format which is stored in the subfolder
'Report'. The full path of this ﬁle is returned by this method.
> createReport(rep1, dataname=ana.setup@data@name,
+ author="Mareike Kohlmann \\\\ DXRQB2 \\\\ Roche Diagnostics GmbH")
[1] "C:/AIDS2/Report/myReport.tex"
If necessary, the report can then be edited manually by adding comments or plots, re-
arranging or deleting output ﬁles etc. A tex compiler such as pdﬂatex is necessary to
compile the tex ﬁle to pdf. The resulting report ﬁle for this exemplary analysis is included
as Appendix A.
5.2 Software Design
The software for performing longQDA was implemented to provide a software solution
for the statistical evaluation of longitudinal biomarkers in clinical studies at Roche Diag-
nostics. The conceptual requirements are therefore a data-independent implementation
with a user-friendly handling, easy extensibility and a good run-time performance. A fur-
ther requirement is to support a comfortable reporting of the analysis results. With this
implementation, the user may apply univariate longQDA, multivariate longQDA and mul-
tivariate QDA to real as well as to simulated data. All classiﬁcation analyses are based on
the resampling method Monte Carlo cross validation to ensure a reliable estimation for
small sample sizes as well.
To meet all these needs, an object-oriented design was chosen which is facilitated by
the S4 system in R. This system provides functionality that allows OOP with classes and
methods within the functional R language. The idea of OOP is a close mapping from the
reality to the programming in a modular fashion. A class, the main component of this
concept, deﬁnes a new data type comprising a speciﬁc set of attributes called slots. E.g.
for a class Data, slots may be the name of the data set, the column number of the patient
identiﬁcation number etc. Objects are generated as instances of a class. Computations on
these objects consist of invoking methods on them. A method is speciﬁcally deﬁned for one
class and therefore objects are part of the method's arguments and are frequently returned
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as well. Exemplary methods are show or plot which determine the class-individual printing
resp. plotting. Methods need to be declared as generic functions in R. Via this mechanism,
S4 is compatible with the functional requirements of R.
Further, classes may be related to each other by class hierarchies, i.e. classes inherit
class properties of the base class and are extended by speciﬁc properties. In longQDA, for
example, the classes LongData for longitudinal data and XsecData for cross-sectional data
are derived classes of the base class Data. Both are designed for objects which include
a named data set and, for example, a column for the patient identiﬁcation number, but
LongData has its own attribute id2rows which is a matrix matching the row numbers
to each patient's observations. Objects of class XsecData do not need this attribute as
there is always only one row per patient in cross-sectional data.
Classes can be abstract, i.e. the class cannot be instantiated. The opposite is a concrete
class. Abstract classes are designed as base class and the speciﬁc functionality is then
implemented in the derived classes. The class hierarchy supports the extensibility as other
data structures can be easily incorporated. A user-friendly handling, an easy maintenance
and a fast debugging are further advantages of OOP due to the sparse representation
of complex relations. For example, methods are invoked on objects corresponding to the
classes of the method's arguments. Thus, if-statements in methods are avoided to direct
the proper, class-speciﬁc execution.
The user-friendly handling is furthermore enhanced by an intuitive guidance following
the typical process of a statistical analysis: ﬁrst the explorative and descriptive analy-
sis of the longitudinal data, followed by the evaluation and comparison of the biomarker
performance under various model assumptions by longQDA. Up to a basic level, these
tasks can be performed with the knowledge of only few central methods which are
LongData, AnalysisSetup, analyze, MccvSummary, selectResultLeafs, Report and
createReportFiles. The corresponding documentation is given in Appendix B, the rela-
tions between the functions and a more detailed description follow in the next subsection
which is 5.2.1.
Throughout the entire analysis, a template for the report can be created continuously.
At some points, namely for the descriptive and exploratory analysis and for the
comparison of the models, the user can select either the predeﬁned default analysis or
the customized analysis or can even combine both options. The ﬁrst is accomplished
by createReportFiles, the latter by using directly the methods included in
createReportFiles, these are ,for example, plotLongMarkers, boxplotLongMarkers,
scatterVisitTimes, autoCorr and optionally self-written functions or methods to
explore the longitudinal data. A combination of both options is used in Section 5.1
where plotLongMarkers has been used with another transparency value in addition to
the default output. The report can be complemented by comments or any plot during
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the analysis. The output format is a tex ﬁle which can be compiled to pdf, allowing an
easy editing of the template by adding text or rearranging parts after the completion of
the data analysis.
5.2.1 Software Architecture Overview
In the following, the presentation of the software architecture of longQDA is restricted
to the components that are needed for the analysis of real, univariate biomarker data
sets. The other components are described in Section 5.3 where the extensibility for the
evaluation of multivariate biomarker panels as well as for the analysis of simulated data
are demonstrated.
Since 1997, uniﬁed modelling language (UML) has been the standard approach for a
structured object-oriented software development (Born et al., 2004). One of the key
diagrams of UML is the class diagram depicting the class structure with its relationships.
At the moment, R does not support the creation of class diagrams from the code (back-
ward engineering), but there are plans to incorporate such a functionality in the future,
called Ruml (R Foundation for Statistical Computing, 2008). First steps towards back-
ward engineering are done by the package classGraph (Maechler and Gentleman, 2008).
A class diagram includes usually the classes with their attributes and methods as well as
the relationships between the classes. For the sake of a condensed presentation, the class-
speciﬁc attributes and methods are omitted in the class diagram for longQDA (Figure 5.4).
They are described exemplarily in the next subsection. Two sorts of class relationships
are visualized: Every arrow joins the derived class with its base class (e.g. LongData and
XsecData inherit from Data), a line labelled with its description symbolises an undirected
relationship (the method toXsec converts an instance of class LongData to an instance
of class XsecData with a cross-sectional data structure, for example). Note that only the
most important relations are included. Abstract classes are printed in italics.
The software architecture reﬂects the steps of a typical statistical analysis and is hence
quite general and could be easily adopted for other software implementations: There are
classes for data objects (on the top right of Figure 5.4), for the analysis setup (in the
middle on the top), classes involved in the discriminant analyses (down right), classes
containing the raw or summarized results of the analyses (on the left) and the Report
class deﬁning a standardized output (down left). We continue by presenting the class
diagram, following that order as far as possible, and start with the initial step, the data
import. In the upper right corner, all classes for structural data mapping are shown. They
have already been partly described above to explain possible class relationships. The user
operates only on objects of class LongData which are created from the user-provided raw
data sets and which are used to set up the analysis by AnalysisSetup. Objects of class
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XsecData are used only internally for tasks that require a cross-section data structure,
e.g. for performing QDA or creating plots (in autoCorr, for example).
Figure 5.4: UML class diagram of the R package longQDA, omitting attributes and meth-
ods. Created with Enterprise Architect (SparksSystems, 2008)
Objects of class AnalysisSetup specify all subanalyses that should be performed, includ-
ing information about the MCCV design and global precision parameters. Based on the
paths attribute of AnalysisSetup describing the subanalyses, AnalysisPath objects are
internally set up. These objects determine the instantiation of objects of class QdaAlgo
(for QDA) or LongDaUnivAlgo (for the univariate longQDA) during the execution of
the method analyze. Besides the determination of the required data structure for the
algorithms, the statistical analyses are performed as follows when calling analyze.
The evaluation of the biomarker performance is split up into three steps: the estimation
of the group-speciﬁc parameters for the quadratic discriminant rule with the training data
sets, the prediction of the posterior probabilities by (long)QDA with the test sets and
at last, the evaluation of the performance measures. The ﬁrst step is accomplished by
the method fit, deﬁned for the classes determining the algorithms for the discriminant
analysis. In the case of longQDA, for example, objects of class RiAlgo, RisAlgo or
Ricar1Algo deﬁne the estimation of the means and the covariance matrices by mixed
models. For QDA, the functionality of the R package MASS (Venables et al., 2008) is
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used. For the univariate longQDA with an RI or RIS structure, the estimation is done by
lme4 (Bates et al., 2008) whereas nlme (Pinheiro et al., 2008) is used for the RICAR1
structure2. For the second step, the evaluation of the discriminant rule, predict2 is
called. The method is deﬁned for objects of class LongDaUnivModel and returns a list
containing the estimated posterior probabilities amongst others. The classes RiModel,
RisModel and Ricar1Model are derived classes of LongDaUnivModel which is in turn,
as QdaModel, a derived class of LongDaModel. The same structure underlies the classes
describing the corresponding algorithms. The third step involves the calculation of the
performance measures by the constructor PerformanceMeasures. It uses the returned
list of predict2 as input and returns an object of class PerformanceMeasures. The
returned values of those three methods are stored in an instance of class ResultTree
which is created within analyze.
These results are not yet summarized, they contain the results for each MCCV sam-
ple. The method mccvSummary accomplishes this task by modifying the object of class
ResultTree to consist of objects of class MccvSummary. To constrain the results for com-
parison, the method selectResultLeafs returns a smaller version of class ResultList.
It is recommended to create an instance of class Report at the beginning of a data analysis
session. At the end of the analysis, the main parts of the report comprise the output
which was generated by the method createReportFiles (for objects of class LongData,
AnalysisSetup, MccvSummary or ResultList) or by the method save2Report for more
individualized output.
5.2.2 Description of Central Classes and Methods
The architecture of longQDA at the class level comprises the classes with its attributes
and methods. As already explained, they are usually part of the UML class diagram. In
R however, this issue is not realised graphically but at least textually by the documentation
of the classes in the help ﬁles. For S4 classes, the attributes of a class are stored in so
called slots of an object. The slots as well as the methods are documented for each class.
As an example, the help ﬁle for the class MccvSummary is included here. Except the method
show, all methods are documented separately. The method createReportFiles is given
and serves furthermore as an example for the sparse but ﬂexible OOP approach. It is
not only deﬁned for objects of class MccvSummary but also for objects of class LongData,
AnalysisSetup and ResultList. For further class and method descriptions, the reader
is referred to the help ﬁles in Appendix B.
2According to the author of lme4, this package is superior to nlme with regards to its execution time
and stability. But as models with an RICAR1 structure are only available in nlme, both packages had
to be used in longQDA.
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MccvSummary-class Class 'MccvSummary' with Summarized Analysis Results of
all MCCV samples
Description
All important analysis results are summarized over all MCCV loops allowing to produce
graphical as well as numerical summaries of the results by the provided methods.
Objects from the Class
Objects are created by calls of the form MccvSummary(nMCsamples, pmnames,
cvnames, roctemp, id2group), but these objects are only created internally.
Therefore the arguments are not documented here.
Slots
modelEstimates: Object of class 'list', the length equals to the number of groups.
Each list entry contains
estimates: Object of class 'matrix' containing the model parameters esti-
mated by MCCV. Each row correspondes to one MCCV sample (with names
"CV 1", "CV 2", . . . ), each column to one of the model parameters. The
model parameters have names and their number diﬀers, depending on the
estimated model.
BIC: Object of class 'numeric' containing the BICs of all MCCV samples (with
names "CV 1", "CV 2", . . . ).
modelparams: Object of class 'list' containing the following mixed model
parameters
covstr: Object of class 'character' giving the covariance structure. Can
be either "RI" (random intercept), "RIS" (random intercept and linear
slope) or "RICAR1" (random intercept and continuous AR(1) residual
structure) for univariate longQDA.
timestr: Object of class 'character' giving the maximum order for the
ﬁxed eﬀect(s) of the time variable. Terms of lower order are automati-
cally included. Can either be "linear" or "quadratic".
roccv: Object of class 'performance-class' in package ROCR. The slots x.values,
y.values and alpha.values are lists, each of length nMCsamples; v. the
documentation of ROCR for details.
pmmatrix: Object of class 'matrix' containing all MCCV estimates of twelve per-
formance measures. Each row corresponds to one MCCV loop (with names "CV
1", "CV 2", . . . ), each column to one of the performance measures (with names
"auc", "bs", . . . ).
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posterior2: Object of class 'data.frame'. Each row corresponds to one patient.
The ﬁrst column contains the numeric group according to the Gold Standard, the
second the predicted posterior probabilities for the latter speciﬁed group when
creating the LongData object of the ﬁrst MCCV loop, the third the predicted
posterior probability of the second MCCV loop and so on. The names of the
rows equal to the patient identiﬁcation numbers, the ﬁrst column has the name
group, the others the number of the MCCV loop.
analysisPath: Object of class 'character' containing the name of the analysis
path. It is a concatenation of the path number, the involved visits and the
biomarker(s) and will be used for ﬁle names of plots and tables, for example.
Methods
createReportFiles: signature(object = 'MccvSummary'): createReportFiles
plotROC: signature(summary = 'MccvSummary':): plotROC
pmHist: signature(summary = 'MccvSummary'): pmHist
pmQuantiles: signature(summary = 'MccvSummary'): pmQuantiles
post2CalCurve: signature(summary = 'MccvSummary'): post2CalCurve
post2Hist: signature(summary = 'MccvSummary'): post2Hist
show: signature(object = 'MccvSummary'): deﬁned as str(object, 3).
summaryModelEstimates: signature(summary = 'MccvSummary'):
summaryModelEstimates
Author(s)
Mareike Kohlmann hlongQDA@web.dei
Examples
showClass("MccvSummary")
data(AIDS2)
d <- LongData(AIDS2, "AIDS2", c("BM1"), c(0,2,4,8,16,24)/52,
c('non-resistant'=1, 'resistant'=2), timename="SDURN")
d2 <- completeCases(d, visits=6)
asetup <- AnalysisSetup(d2, nMCsamples=5, ratiotrain=2/3,
paths=list(
list(isLongitudinal=TRUE, isMarkerComb=FALSE,
whichVisits=(1:ncol(d2@id2rows)),
modelparams=list(covstr="RI",
timestr="quadratic"))))
tree <- analyze(asetup)
summary.tree <- mccvSummary(tree, asetup)
80 5.2 Software Design
node.leaf <- summary.tree[[1]][[1]][[1]]
class(node.leaf)
str(node.leaf,4)
createReportFiles-method
Creates Pre-Conﬁgured Output Files for the Report
Description
At any stage of the analysis, pre-conﬁgured output ﬁles can be created and saved
for a later inclusion into the report. This method calls various other methods for
creating graphical and/or numerical output and serves as default output. If modiﬁed
or additional output is desired, the user has the possibility to call those inner methods
separately and to add their graphical output to the report by save2Report. There is
also an option enabling the user to preview the corresponding part of the report with
the generated output ﬁles.
The following output generating methods are called within createReportFiles():
For objects of class 'LongData': plotLongMarkers,boxplotLongMarkers,
scatterVisitTimes, autoCorr.
For objects of class 'AnalysisSetup': str.
For objects of class 'ResultTree': createReportFiles for each leaf of class
'MccvSummary'.
For objects of class 'MccvSummary': summaryModelEstimates, pmQuantiles,
plotROC, pmHist, post2Hist, post2CalCurve.
For objects of class 'ResultList': plotROC, compPerfMeasures, freqMinBIC,
compPostProbs, compModelEstimates.
The execution of some of the methods can be controlled by the user, e.g. by setting
plotpmHist=FALSE for objects of class 'MccvSummary' or 'ResultTree'. Some
methods are automatically only executed for simulated data, e.g. compPostProbs for
objects of class 'ResultList'.
Usage
For objects of class 'LongData':
createReportFiles(object, analysis=object, report,
includeVisitTimes=TRUE, compile=TRUE)
For objects of class 'AnalysisSetup':
createReportFiles(object, analysis=object, report, compile=TRUE)
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For objects of class 'MccvSummary':
createReportFiles(object, analysis, report, MEaveragefn="mean",
MErounddigits=3, ROCaveragefn="mean", plotpmHist=TRUE,
pmrange=NULL,
PMrounddigits=c(2,3,3,2,2,2,2,2,2,3,0,3,0),
pmnames=c("$\mbox{AUC}$","$\mbox{BS}$", "$\mbox{BS}_C$",
"$\mbox{BS}_D$", "$\mbox{BS}_{D_M}$",
"$\bar{pp}_{(2)[z_{(2)}=1]}-\bar{pp}_{(2)[z_{(2)}=0]}$",
"$\bar{pp}_{(2)[z_{(2)}=1]}$", "$\rho_{{z_{(2)}},pp_{(2)}}$",
"$\Delta\sigma^2_{pp_{(2)}}$","$\sigma^2_{pp_{(2)},min}$",
"$\Delta\sigma^2_{pp_{(2)}}/\sigma^2_{pp_{(2)},min}$",
"$\mbox{Cal}_L$","$\mbox{Sensitivity}$"), onlyROCaverage=FALSE)
For objects of class 'ResultTree':
createReportFiles(object, analysis, report, MEaveragefn="mean",
MErounddigits=3, ROCaveragefn="mean", plotpmHist=TRUE,
pmrange=NULL,
PMrounddigits=c(2,3,3,2,2,2,2,2,2,3,0,3,0),
pmnames=c("$\mbox{AUC}$","$\mbox{BS}$", "$\mbox{BS}_C$",
"$\mbox{BS}_D$", "$\mbox{BS}_{D_M}$",
"$\bar{pp}_{(2)[z_{(2)}=1]}-\bar{pp}_{(2)[z_{(2)}=0]}$",
"$\bar{pp}_{(2)[z_{(2)}=1]}$", "$\rho_{{z_{(2)}},pp_{(2)}}$",
"$\Delta\sigma^2_{pp_{(2)}}$","$\sigma^2_{pp_{(2)},min}$",
"$\Delta\sigma^2_{pp_{(2)}}/\sigma^2_{pp_{(2)},min}$",
"$\mbox{Cal}_L$","$\mbox{Sensitivity}$"), onlyROCaverage=FALSE,
compile=TRUE)
For objects of class 'ResultList':
createReportFiles(object, analysis, report, ROCaveragefn="mean",
ROCcolors, legendtext, boxcolors, PMlabels=NULL, xTickLabels=NULL,
freqMinBIC=TRUE, existStarModel=FALSE, PPaveragefn="mean",
PPlinealpha=1, PPyliml=c(0,1), PPylimb=c(-60,100), MEbiaslimits=list(),
PProunddigits=0, compile=TRUE)
For objects of class 'SimulationSetup':
createReportFiles(object, analysis=object, report, compile=TRUE)
For objects of class 'SimulationResult':
createReportFiles(object, analysis=object@analysisSetups[[1]],
report, ROCaveragefn="mean", plotpmHist=FALSE, compile=FALSE,...)
Arguments
object = 'LongData': Contains the data set and corresponding metainformation.
object = 'AnalysisSetup': Contains metainformation about the analysis.
object = 'MccvSummary': Contains the summary of results over all MCCV samples.
object = 'ResultTree': Contains all analysis results based on real data.
object = 'ResultList': Contains user-selected analysis results.
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object = 'SimulationSetup': Contains metainformation about the simulation.
object = 'SimulationResult': Contains all analysis results based on simulated
data.
analysis: Default: object for 'LongData' (actually not necessary - just included
for compatibility) and 'AnalysisSetup'. Object of class 'AnalysisSetup'
containing metainformation about the analysis.
report: Object of class 'Report' to which the output ﬁles are added.
compile: Default: TRUE; exeption: FALSE for objects of class SimulationResult.
If TRUE, the corresponding part of the report is generated as a preview ﬁle in
the folder "Report" with name "myreport.pdf". This option does not exist for
objects of class 'MccvSummary'.
Additionally for objects of class 'LongData':
includeVisitTimes: Default: TRUE. If FALSE, scatterVisitTimes is not executed.
Additionally for objects of class 'MccvSummary' or 'ResultTree':
MEaveragefn: Default: "mean". Character vector giving the function for summariz-
ing the model estimates of all MCCV samples.
MErounddigits: Default: 3. Numerical number of decimal places to which the model
estimates are rounded.
ROCaveragefn: Default: "mean". Character vector giving the function for summa-
rizing the ROC curves of all MCCV samples.
plotpmHist: Default: TRUE. If FALSE, pmHist is not executed.
pmrange: Default: NULL. Matrix containing the ranges for the histograms of the
performance measures. Each column has two rows and contains the range of
one measure. If it is not provided by the user (default), the ranges of the
performance measures present in the data are taken.
PMrounddigits: Default: c(2,3,3,2,2,2,2,2,2,3,0,3,0). Numeric vector of
decimal places to which the performance measures are rounded.
pmnames: Default: c("$\mbox{AUC}$","$\mbox{BS}$", "$\mbox{BS}_C$",
"$\mbox{BS}_D$", "$\mbox{BS}_{D_M}$",
"$\bar{pp}_{(2)[z_{(2)}=1]}-\bar{pp}_{(2)[z_{(2)}=0]}$",
"$\bar{pp}_{(2)[z_{(2)}=1]}$", "$\rho_{{z_{(2)}},pp_{(2)}}$",
"$\Delta\sigma^2_{pp_{(2)}}$","$\sigma^2_{pp_{(2)},min}$",
"$\Delta\sigma^2_{pp_{(2)}}/\sigma^2_{pp_{(2)},min}$",
"$\mbox{Cal}_L$","$\mbox{Sensitivity}$").
Names of the performance measures, used for labelling the columns of the
output table and need to be formatted as LaTeX code.
onlyROCaverage: Default: FALSE. If TRUE, only the ROC curve based on the sum-
mary of all MCCV samples is plotted. Otherwise, an additional plot with an ROC
curve for every MCCV sample is generated.
Additionally for objects of class 'ResultList':
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ROCaveragefn: Default: "mean". Character vector giving the function for summa-
rizing the ROC curves of all MCCV samples.
ROCcolors: v. colors in plotROC.
legendtext: v. legendtext in plotROC.
boxcolors: v. boxcolors in compPerfMeasures.
PMlabels: Default: NULL. Character vector containing the labels of the performance
measures, used in compPerfMeasures.
freqMinBIC: Default: TRUE. Should freqMinBIC be executed or not?
existStarModel: Default: FALSE. If TRUE, the data analysis is based on simulated
data, compPostProbs and compModelEstimates are executed to assess the bias.
PPaveragefn: Default: "mean". v. averagefn in compPostProbs.
PPlinealpha: Default: 1. v. linealpha in compPostProbs.
PPyliml: Default: c(0,1). v. yliml in compPostProbs.
PPylimb: Default: c(-60,100). v. ylimb in compPostProbs.
MEbiaslimits: Default: list(). v. boxlimits in compModelEstimates.
PProunddigits: Default: 0. v. rounddigits in compPostProbs.
Value
Object of class 'Report'. The list entries contain the names and the location of the
output ﬁles.
Author(s)
Mareike Kohlmann hlongQDA@web.dei
Examples
### Example for object of class "LongData"
myreport <- Report(folder=getwd())
data(AIDS2)
d <- LongData(AIDS2, "AIDS2", c("BM1"), c(0,2,4,8,16,24)/52,
c('non-resistant'=1, 'resistant'=2), timename="SDURN")
# compile=TRUE does not work in Rcheck
myreport <- createReportFiles(object=d, report=myreport, compile=FALSE)
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5.3 Examples for Extending longQDA
Extensibility is an important quality aspect in software development. The package
longQDA already contains two extensions to the basis functionality for analyzing
univariate biomarker data. One is the incorporation of multivariate mixed models
to evaluate biomarker panels, the other is the generation and analysis of simulated
univariate biomarker proﬁles. Both serve as examples to demonstrate how fast longQDA
is extended by few additional classes and how easy the user can cope with the minor
visible changes implied.
5.3.1 Multivariate longQDA
So far, an implementation has been described for analyzing univariate models. To demon-
strate the extensibility, we illustrate in the following how multivariate models are included.
The presentation is restricted to multivariate mixed models with correlated random eﬀects
as deﬁned in Subsection 4.2.2 as the models with uncorrelated random eﬀects (presented
in Section 4.2.1) as well as the Kronecker Product models (Subsection 4.2.3) are anal-
ogously implemented in longQDA. In general, to extend the software by a new model, a
class for the model containing the group-speciﬁc estimates and a class for the algorithm
containing the necessary information for the estimation of the models need to be deﬁned.
For the present example, this is accomplished by the classes LongDaMvModel and
RcMvAlgo. These classes as well as all other necessary changes, which will be described
in the following, were added to the UML class diagram of Figure 5.4 and marked
in blue (see Figure 5.5). The class RcMvAlgo has the newly deﬁned base class
LongDaMvAlgo to cover also the other algorithms for the multivariate models. This is in
turn a derived class of the already existing LongDaAlgo.
For the multivariate mixed models with correlated eﬀects, models with and without random
slopes are distinguished, so there are the following classes derived from LongDaMvModel:
RiCorrModel with correlated random intercepts, RisCorrModel with correlated random
intercepts and slopes3. The class LongDaMvModel is derived from LongDaModel like
QdaModel and LongDaUnivModel.
The estimation of the models with the correlated random eﬀects is carried out by the
function lme of the R package nlme with its ﬂexible options to specify the random ef-
fects. The function requires a data structure implemented in an additional class, called
LongMvData, which is derived from Data. Objects of this class are internally created by
3There are actually additional derived classes which are RIuModel and RIuSuModel. As they are im-
plemented for models with uncorrelated random eﬀects (Section 4.2.1), further details are omitted
here.
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the method toLongMv which is part of the class LongData. The data structure comprises
a blown-up data set in that there is
 one biomarker vector (called response) where the observations of the single
biomarker variables are stacked blockwise
 one dummy variable for each marker indicating which observation of response is
from which marker (called marker1, marker2, ...) to model the random inter-
cepts
 one time variable for each marker (called time1, time2, ...) containing the
study time if the observation of response is from that marker and otherwise zero
to model the random slopes.
The multivariate outcome variables are structured in the same way as if only a univariate
variable was analyzed and a set of dummy codes are created to "ﬂag" the outcomes
accordingly. This recast has been proposed several times, for R users (Lockwood et al.,
2003; Doran and Lockwood, 2006) as well as for SAS users (Thiébaut et al., 2002;
Hamlett et al., 2003). For a mixed model with correlated random intercepts and slopes
with two biomarkers (speciﬁed as covstr="RISFull") in longQDA), the R syntax is
lme(response~-1 + marker1 + marker2 + time1 + time2,
random=~-1 + marker1 + marker2 + time1 + time2|patid,
data=mydataset, method="REML")
and yields an object of class RisCorrModel.
Objects of class RiCorrModel can be obtained by modifying the random statements as
follows
random=~-1+marker1+marker2|patid
Biomarker-speciﬁc residual errors are speciﬁed by setting
weights=varIdent(form=~1|marker2)
in the lme statement.
By extending the method analyze to select the new RcMvAlgo if requested by the user,
all necessary changes are done. At the user-level, the multivariate mixed model is cho-
sen by setting isMarkerComb=TRUE, giving the number of biomarkers to be combined in
markerCombLength and the correlation structure in the list of the model parameters in
covstr. The available correlation structures are "RIc" and "RISFull" 4.
4There are additional correlation structures implemented in longQDA as a RisCorrModel, these are
"RIcSu", "RIuSc" and "RIcSc". It is not recommended to ﬁt models with these correlation structures
as the random intercepts and slopes within the biomarker are uncorrelated (cf. Chapter 2, p. 7 for a
discussion of this issue). The necessary extensions to ﬁt all possible correlated intercepts and slopes
combinations are not available in R due to the restriction that correlation structures for each biomarker
can only be combined by pdBlocked in nlme which is used internally in the package longQDA.
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Figure 5.5: Extended UML class diagram of the R package longQDA, omitting attributes
and methods. The necessary extensions for the multivariate longQDA are
marked in blue, those for the simulated data in red.
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To update a previously deﬁned analysis setup (called oldSetup) by a bivariate mixed
model with correlated random intercepts, the user calls
ana.setup1 <- updateAnalysisSetup(oldSetup,
paths=list(list(isLongitudinal=TRUE, isMarkerComb=TRUE,
markerCombLength=2,
whichVisits=(1:ncol(data@id2rows)),
modelparams=list(covstr="RIc",
timestr="quadratic"))))
5.3.2 Generation and Analysis of Simulated Data
The second example, which shows how easy the functionality of longQDA is extended,
comprises all necessary changes to perform the simulation study of Chapter 3. This
applies to the following two tasks which need to be performed: the generation of the
data and their analysis. As both of them are repeatedly executed, the software design is
extended to be also compatible with parallel computing. All additionally deﬁned classes
and the new associations are marked in red in Figure 5.5.
The generated data are based on given model parameters for a speciﬁed covariance struc-
ture as well as on distributions for the individual visit times and they need to comply
with the structure of a real data set. For this purpose, the class SimulationSetup has
been designed. Within the constructor function SimulationSetup, data sets of class
LongData are simulated by the method generateData which takes as input:
 a model of class RiModel, RisModel or Ricar1Model, set up by the user by means
of the constructor methods RiStarModel, RisStarModel or Ricar1StarModel
 the distribution functions of the individual visit times (speciﬁed in simRandomVisits
in the example below)
 and further parameters as the number of visits (nvisits) or the number of patients
in each group (ngroups).
The number of simulated data sets corresponds to the number of speciﬁed simulation
repetitions (simreps). In addition, the paths of the analysis tree to be included in the
simulation are speciﬁed in the argument paths of SimulationSetup, analogously to the
AnalysisSetup for real data.
Here is one example for an exemplary setup of a simulation scenario:
# definition of the RIS* model
risStar <- RisStarModel(group1=list(beta=c(4.0,-4.5),
DCovstar=matrix(c(0.40, 0.39, 0.39, 16.1),
ncol=2, byrow=FALSE),
5. Software Implementation: The R package longQDA 89
R=c(sigQuad=0.56)),
group2=list(beta=c(4.0,-1.4),
DCovstar=matrix(c(0.23, 0.46, 0.46, 15.8),
ncol=2, byrow=FALSE),
R=c(sigQuad=0.39)), timestr="linear")
# functions needed for the generation of individual visit times
rmixnorm <- function (nsample, object){
mu <- object$mu
sd <- sqrt(object$sig2)
nj <- rmultinom(n = 1, size = nsample, prob = object$w)
return(sample(unlist(sapply(seq(along = nj), function(j) rnorm(nj[j],
mean = mu[j], sd = sd[j])))))
}
rmixnorm.v1 <- function(n){
return(rmixnorm(nsample=n, object=list(mu=c(0.05,0.5,0.95),
sig2=c(0.001,0.05,0.001),
w=c(0.12,0.76,0.12))))
}
# [some function definitions are omitted here...]
rnorm.v5 <- function(n){
return(rnorm(n, 0.45, sqrt(0.0045)))
}
# generation of individual visit times
simRandomVisits <- list(list(fn=rmixnorm.v1,range=c(0.02,0.05)),
list(fn=rnorm.v2, range=c(0.02, 0.08)),
list(fn=rmixnorm.v3, range=c(0.04, 0.12)),
list(fn=rnorm.v4, range=c(0.10, 0.22)),
list(fn=rnorm.v5, range=c(0.12, 0.19)),
list(fn=rnorm.v5, range=c(0.12, 0.19)),
list(fn=rnorm.v5, range=c(0.12, 0.19)),
list(fn=rnorm.v5, range=c(0.12, 0.19)),
list(fn=rnorm.v5, range=c(0.12, 0.19)))
# definition of analysis paths
testpaths <- list(list(isLongitudinal=TRUE, isMarkerComb=FALSE,
whichVisits=(1:6),
modelparams=list(covstr="RI", timestr="linear")),
list(isLongitudinal=TRUE, isMarkerComb=FALSE,
whichVisits=(1:6),
modelparams=list(covstr="RIS", timestr="linear")),
list(isLongitudinal=TRUE, isMarkerComb=FALSE,
whichVisits=(1:6),
modelparams=list(covstr="RICAR1", timestr="linear")),
list(isLongitudinal=FALSE, isMarkerComb=FALSE,
whichVisits=(1:6),
isSingleVisit=FALSE))
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# definition of all simulation settings
sim.setup <- SimulationSetup(starModel=risStar, simreps=25, paths=testpaths,
nvisits=10, ngroups=2*c(95, 37),
grouplabels=c("non-resistant", "resistant"),
priors=c(292, 64)/356,
randomVisits=simRandomVisits,
fixVisits=NULL, nMCsamples=50, ratiotrain=2/3,
stepcut=0.01, bmtransform="log10")
The analysis of simulated data according to the speciﬁed paths is carried out as for real
data by means of fit, predict2 and PerformanceMeasures within a MCCV design by
the already deﬁned method analyze (cf. p. 76). However, for the ...StarModel, the
ﬁrst step (the estimation of the group-speciﬁc group parameters) is skipped as the model
was fully speciﬁed by the user and does not need to be ﬁtted. The other two steps are
executed to estimate the biomarker performance, which is achieved by the ...StarModel,
as this serves as direct benchmark for the ﬁtted models. This is accomplished by the newly
created method analyzeStarModel.
The user does not need to care about this distinction as just the method analyze, which
has been adapted for objects of class SimulationSetup, is called to perform the analysis.
The returned object full.simtree is of class SimulationResult and contains a list
of objects of class AnalysisSetup and a list of objects of ResultTree, each of length
simreps. Then the results are summarized over the MCCV samples by the method
mccvSummary and afterwards over all simulation repetitions by simSummary:
full.simtree <- analyze(sim.setup)
mccv.sumsimtree <- mccvSummary(full.simtree, sim.setup)
sim.sumsimtree <- simSummary(mccv.sumsimtree)
The results of the subanalyses can be compared in the same way as for the analysis of
real data by selectResultLeafs and createReportFiles. For this purpose, the output
function createReportFiles has been adapted to the simulation setting, thus featuring
options to assess the introduced bias when assuming an incorrect model structure.
Finally, the computation times are an issue. Suppose we go for 28 simulation repetitions,
50-fold MCCV, 4 model structures to be compared, biomarker proﬁles of length 6 and
have 2 patient groups in a simulation. This results in 25  50  5  2=12500 models for one
...StarModel and all computations took 56 minutes on a PC with an Intel Xeon X5450
3 GHz processor and 3 GB RAM. As the data analyses of simulation repetitions are inde-
pendent, the computing performance may be enhanced by deploying multiple processors
in parallel. In this example, one mother process spawns 7 parallel child processes which
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ﬁnished in 11 minutes. This implementation is based on the R package Rmpi which is
one of the highly recommended packages by Schmidberger et al. (2009). The neces-
sary conﬁguration steps are described in the vignette "Parallel Computing in longQDA by
Rmpi" of longQDA. The user-handling is easy. The required setup for the parallel comput-
ing is performed by the method parInit, followed by invoking the equivalent method of
analyze for parallel computing which is parAnalyze. The parallel session is terminated
by using parFinalize. Here is the syntax for an example with seven child processes:
parInit(nslaves=7, name="logOfSlave")
full.simtree <- parAnalyze(sim.setup)
parFinalize()
Remark
Some ideas for the software design originated from a cooperation between Roche Diagnos-
tics and Manuel J. A. Eugster and Friedrich Leisch of the Ludwig-Maximilians-University,
Munich.

6 Conclusion
6.1 Summary
Discriminant analysis is a widely used statistical method for classiﬁcation purposes. The
extension for longitudinal data, proposed by Marshall and Barón (2000) and Tomasko
et al. (1999), is achieved by plugging the marginal estimates of linear mixed models into
the discriminant rule. This approach expands the search space for the best classiﬁca-
tion performance by a further dimension. Not only uni- or multivariate cross-sectional
measurements may yield the highest performance, also a single or multiple longitudinal
data proﬁles come into consideration. This moves the focus to modelling issues as model
selection and the need for parsimonious parametrization that are less relevant issues for
cross-sectional data. Besides those two research aims, an additional goal was a software
implementation in R that fulﬁlls quality criteria as user friendliness, fast extensibility and
time eﬃciency. All those issues of the dissertation were motivated by and adopted to
biomarker data from medical diagnostics. The proposed methods were applied to clas-
sify patients as resistant or non-resistant to a given therapy based on their longitudinal
biomarker measurements.
First, the longitudinal quadratic discriminant analysis (longQDA), a classiﬁcation method
for longitudinal data, was reviewed. It is a two-step approach in that the longitudinal mea-
surements are modelled by linear mixed models to yield empirical means and covariances
for both classes. These estimations are then plugged into the discriminant rule known
from quadratic discriminant analysis for cross-sectional data. To avoid an underestima-
tion of the classiﬁcation performance, Monte Carlo cross validation (MCCV) was used,
performing the ﬁrst step of longQDA on the training data and the second on the test
data. For a summarized assessment of the classiﬁcation performance, commonly used
performance measures in diagnostic medicine as the area under the ROC curve (AUC)
were complemented by the Brier score (BS) with its various decompositions to overcome
their shortcomings to evaluate only the discrimination. The BS and its decompositions
allow a more profound evaluation as they take the probability into account with which a
person is classiﬁed and are not based on the less informative discretised membership to
one of the classes. The application of the methodology to univariate biomarker data (RNA
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proﬁles) from patients that are and are not resistant to HIV therapy revealed an increased
performance by a longitudinal instead of a cross-sectional design.
The high ﬂexibility of linear mixed models induced the research question for an appropriate
model selection criteria in longQDA, especially for not well separated classes. Compared
to analysis goals where the mean parameters of the mixed model are of main interest, in
longQDA, both, the mean and the covariance parameters are important for the discrimi-
nant rule. In Chapter 3, this issue was investigated by comparing two diﬀerent selection
criteria in a simulation study: One strategy was to choose the mixed model which had
yielded the best classiﬁcation performance, also considering by which performance mea-
sure the classiﬁcation was assessed. The alternative strategy was to choose the mixed
model with the smallest Bayesian information criterion (BIC). We examined linear mixed
models with only a random intercept as true model, one with a random intercept and a
random slope and one with a random intercept and a continuous AR(1) process for the
residuals. All three structures and QDA were ﬁtted and the length of the longitudinal
proﬁles varied between 3 and 10. The simulation results showed that the BIC performed
much better than the performance measures, selecting the correct mixed model structures
in the broad majority of the MCCV loops. For most of the scenarios, especially those
with shorter biomarker proﬁles, the performance measures were very similar providing no
broad selection basis. Additionally, if they diﬀered, only few of them as AUC, BS and the
biserial correlation were able to select the correct model. As expected, the choice of the
correct model structure becomes more and more important for models with more than
about 5 visits and/or those that assume a time-variant longitudinal data structure. Then
the misspeciﬁcation eﬀects do not only occur at the individual in form of incorrectly low
or high classiﬁcation uncertainty but also at the global assessment level in the form of
underestimated performance measures.
In Chapter 4, the multivariate extension of longQDA was proposed. The challenge con-
sisted in ﬁnding parsimonious multivariate mixed models. The subsequent proceeding of
longQDA was the same as for the univariate case. The presentation was restricted to
the bivariate case with two biomarkers. In the following section containing the outlook,
it will become clear why this is an advisable starting point for any multivariate longQDA.
Besides a fast ad-hoc solution for independent biomarkers, two multivariate mixed model
classes were proposed in this dissertation. These are multivariate random eﬀects models
and covariance pattern models with a Kronecker product structure that may cope with
cross-sectional correlations as well as the additional time-dependent cross-correlations in
multivariate longitudinal data. Provided the data set is transformed appropriately, the
estimation of the random eﬀects models may be carried out with statistical software
written for the univariate case. For the estimation of covariance pattern models, a nu-
merical constraint optimization without the need of computer-intensive calculations for
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the information matrices was proposed. Not computing the information matrices and
the parsimonious parametrization of Kronecker product models led to computational ad-
vantages. In the application to a diagnostic study with seven longitudinal biomarkers,
assessed for resistance to one rheumatoid arthritis medication, the multivariate random
coeﬃcients models were preferred to the Kronecker product models according to the BIC.
A gain in classiﬁcation performance by pairs of biomarker proﬁles could not be achieved,
a single longitudinal biomarker was the best option. However, exemplary simulated data
settings were included to illustrate various potential gains through the combination of
longitudinal biomarkers.
For a wide-spread application of statistical methods, an implementation in a state-of-the-
art software environment like R is indispensable nowadays. The R package longQDA was
therefore developed. Its application and implementation were presented in Chapter 5. The
package provides a general framework for executing quadratic discriminant analysis with
longitudinal data, including univariate, multivariate longQDA and multivariate QDA, with
real as well as with simulated data. All models for longitudinal biomarker data that are
proposed in this dissertation are implemented. Based on the resampling method Monte
Carlo cross validation, the estimation of the group-speciﬁc parameters is performed with
the training datasets and the evaluation of the classiﬁcation performance with the test
datasets. The software solution was created to be used for clinical biomarker studies
with a longitudinal design at Roche Diagnostics. Therefore, conceptual requirements
as a data-independent implementation with a user-friendly handling, easy extensibility,
a good run-time performance and a comfortable reporting determined the design. The
implementation of the software follows the modern object-orientated concept with S4
classes and comprises functionality for the entire data analysis process, from the descriptive
and explorative analysis of longitudinal data up to the comparison of results under diﬀerent
model structures and data settings. Due to the broad generality, the key ideas may also
serve as a source for the implementation of other statistical methods in R. The usefulness
of the object-oriented approach in terms of fast extensibility was exemplarily demonstrated
for the multivariate version of longQDA and for the generation and analysis of simulated
data. For the latter, a short computational time was achieved by using parallel computing.
6.2 Outlook
Our presented approach for evaluating biomarker panels is not restricted to the bivariate
case. Our results indicate that for biomarker variables reﬂecting complex biological pro-
cesses, the restrictive proportionality property of Kronecker product structures is often
too simplistic. When increasing the dimension of a biomarker panel, these strong implied
assumptions get more and more implausible to hold. Therefore multivariate random ef-
96 6.2 Outlook
fects models should be favored. Fieuws and Verbeke (2006) and Fieuws et al. (2007)
propose an approach for q > 2 which extends directly the bivariate modelling presented
above. As computational problems occur more frequently when increasing the dimension
of the joint covariance matrix of the random eﬀects, their approach consists of ﬁtting
all possible bivariate models and joining them afterwards by pseudo-likelihood arguments.
Biomarker-speciﬁc parameters are estimated in more than one model and are therefore
averaged. Pair-speciﬁc parameters as for example the covariance between two random
eﬀects are estimated in exactly one model and thus there is no need for averaging those
parameters. Standard errors are obtained via a speciﬁcally constructed covariance matrix.
The matrix contains entries of the pairwise information matrices, each weighted by the
resulting coeﬃcients from the averaging step.
There is a further point to consider with a longitudinal multivariate assessment. An
optimization of the performance with respect to p, the number of measurements over
time, has diﬀerent implications than an optimization with respect to q, the dimension
of the biomarker panel. Increasing q yields a much higher dimensional problem than an
increase in p. In the ﬁrst mentioned univariate case, the dimension increases from p to p+1
but it increases directly from p q to p (q+1) in the multivariate case. That is, combining
longitudinal biomarkers is associated with a more challenging density estimation. Due to
this rapid increase in dimension, the disadvantageous curse of dimensionality may become
a serious problem. This is because the volume of a space increases exponentially by a
linear increase in dimension, yielding mostly empty spaces. This leads to less precise
plug-in estimators or even non-estimability. Van Ness (1976) ﬁnds in a comparison of
several classiﬁcation methods for cross-sectional data that QDA is especially sensitive to
this phenomenon.
An alternative approach to longQDA might be based on functional data analysis. James
and Hastie (2001) ﬁt B-splines to univariate longitudinal biomarker data and plug the
resulting mean and covariance functions into the standard discriminant rule. Multivariate
measurements might be modelled by multivariate B-splines as Brown et al. (2005) did
with biomarker data of the same HIV therapy resistance study that we used. As long
as the groups are not very well separated, the classiﬁcation performance might depend
on the appropriateness of the group-speciﬁc models. Therefore, it is advisable to check
in each application the sensitivity of the performance with respect to various modelling
approaches.
Müller (2005) proposes functional principal component analysis as a dimension reduction
technique for longitudinal data prior to the classiﬁcation. The resulting functional principal
component scores, derived from all patients, are then used as explanatory variables in a
functional binary regression with the group membership as dependent variable. However,
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applying PCA prior to classiﬁcation is not regarded as the best approach. The principal
components represent the highest within-group variation whereas the discrimination aims
at the highest between-group variation. This does not necessarily lead in the same direc-
tion (Jolliﬀe, 2002). These functional data approaches might be further investigated and
contrasted with longQDA in the future.

A Report for Dataset AIDS2
In Section 5.1, we illustrated the use of the R package longQDA for the therapy resistance
data of HIV patients (The data served also as application dataset for the univariate
longQDA in Chapter 2.). Here, we include the automatically generated report of our
exemplary analysis1. It serves as a quick overview of all the results and was not
designed with the intention to be as beautifully formatted as a ﬁnal report. It
contains all the results gathered throughout the analysis and may be a starting point
when preparing a report of the results. The LaTeX format enables easy editing.
1The original format is one-sided.
Results of dataset AIDS2demo
(complete cases)
Mareike Kohlmann
DXRQB2
Roche Diagnostics GmbH
11th June 2008
1 Exploratory Analysis
1.1 AIDS2demo (complete cases)
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Summary of visit times for each visit:
$‘1‘
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Min. 0 0
1st Qu. 0 0
Median 0 0
Mean 0 0
3rd Qu. 0 0
Max. 0 0
$‘2‘
non-resistant resistant
Min. 0.01918 0.01918
1st Qu. 0.02603 0.03288
Median 0.03836 0.03836
Mean 0.03812 0.03793
3rd Qu. 0.04932 0.04384
Max. 0.05479 0.05479
$‘3‘
non-resistant resistant
Min. 0.05753 0.06027
1st Qu. 0.07123 0.07397
Median 0.07945 0.07808
Mean 0.08033 0.07777
3rd Qu. 0.09315 0.08219
Max. 0.10680 0.09589
$‘4‘
non-resistant resistant
Min. 0.1151 0.1151
1st Qu. 0.1575 0.1562
Median 0.1699 0.1603
Mean 0.1665 0.1615
3rd Qu. 0.1726 0.1726
Max. 0.1890 0.1863
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non-resistant resistant
Min. 0.2712 0.2685
1st Qu. 0.3096 0.3103
Median 0.3260 0.3178
Mean 0.3199 0.3158
3rd Qu. 0.3288 0.3253
Max. 0.3425 0.3397
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Variance of visit times for each visit:
$‘1‘
non-resistant resistant
0 0
$‘2‘
non-resistant resistant
0.0001522672 0.0001006972
$‘3‘
non-resistant resistant
0.0001670600 0.0000937223
$‘4‘
non-resistant resistant
0.0001843052 0.0002903244
$‘5‘
non-resistant resistant
0.0002323249 0.0002483364
$‘6‘
non-resistant resistant
0.0002196071 0.0001705386
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2 Analysis Setup
Formal class ’AnalysisSetup’ [package "longQDA"] with 4 slots
..@ data :Formal class ’LongData’ [package "longQDA"] with 17 slots
.. .. ..@ id2rows : int [1:85, 1:6] 1 7 13 19 25 31 37 43 49 55 ...
.. .. .. ..- attr(*, "dimnames")=List of 2
.. .. .. .. ..$ : chr [1:85] "2" "5" "6" "26" ...
.. .. .. .. ..$ : chr [1:6] "1" "2" "3" "4" ...
.. .. ..@ visitindex : int 3
.. .. ..@ timeindex : int 6
.. .. ..@ markerlabels : Named chr "BM1 (log10)"
.. .. .. ..- attr(*, "names")= chr "BM1"
.. .. ..@ markerindices : int 5
.. .. ..@ scheduledtimes : num [1:6] 0.0000 0.0385 0.0769 0.1538 0.3077 ...
.. .. ..@ rawdata :’data.frame’: 510 obs. of 8 variables:
.. .. .. ..$ PATID : int [1:510] 2 2 2 2 2 2 5 5 5 5 ...
.. .. .. ..$ TIMEDAY : int [1:510] 0 8 37 64 99 162 0 13 26 69 ...
.. .. .. ..$ VISIT : int [1:510] 1 2 3 4 5 6 1 2 3 4 ...
.. .. .. ..$ CENSOR : int [1:510] 1 1 1 1 1 3 1 1 1 1 ...
.. .. .. ..$ BM1 : num [1:510] 5.24 4.61 2.46 2.27 1.69 ...
.. .. .. ..$ SDURN : num [1:510] 0.0000 0.0219 0.1014 0.1753 0.2712 ...
.. .. .. ..$ GROUP : int [1:510] 1 1 1 1 1 1 1 1 1 1 ...
.. .. .. ..$ GROUPVAR: Factor w/ 2 levels "non-resistant",..: 1 1 1 1 1 1 1 1 1 1 ...
.. .. ..@ name : chr "AIDS2demo (complete cases)"
.. .. ..@ groupindex : int 7
.. .. ..@ grouplabels : chr [1:2] "non-resistant" "resistant"
.. .. ..@ groupcodes : num [1:2] 1 2
.. .. ..@ groupcolors : chr [1:2] "black" "red"
.. .. ..@ groupsymbols : num [1:2] 1 2
.. .. ..@ grouppriors : num [1:2] 0.694 0.306
.. .. ..@ fixedgrouppriors : logi FALSE
.. .. ..@ idindex : int 1
.. .. ..@ markertransformfn: chr "log10"
..@ MCsamples :List of 10
.. ..$ :List of 2
.. .. ..$ train: int [1:58] 2 5 6 33 35 52 57 68 72 88 ...
.. .. ..$ test : int [1:27] 26 27 37 46 60 66 67 74 78 102 ...
.. ..$ :List of 2
.. .. ..$ train: int [1:58] 6 26 27 33 35 37 46 52 57 60 ...
.. .. ..$ test : int [1:27] 2 5 66 88 104 115 123 126 139 141 ...
.. ..$ :List of 2
.. .. ..$ train: int [1:58] 5 6 27 33 37 46 52 57 60 66 ...
.. .. ..$ test : int [1:27] 2 26 35 72 74 88 104 139 141 143 ...
.. ..$ :List of 2
.. .. ..$ train: int [1:58] 2 5 6 26 27 35 60 66 67 72 ...
.. .. ..$ test : int [1:27] 33 37 46 52 57 68 74 123 130 131 ...
10
.. ..$ :List of 2
.. .. ..$ train: int [1:58] 2 5 6 26 27 33 35 37 52 57 ...
.. .. ..$ test : int [1:27] 46 72 74 115 120 139 162 164 170 179 ...
.. ..$ :List of 2
.. .. ..$ train: int [1:58] 2 6 26 27 33 37 52 57 60 66 ...
.. .. ..$ test : int [1:27] 5 35 46 88 104 112 131 143 162 187 ...
.. ..$ :List of 2
.. .. ..$ train: int [1:58] 2 5 26 27 33 35 37 52 57 66 ...
.. .. ..$ test : int [1:27] 6 46 60 67 68 74 78 88 104 115 ...
.. ..$ :List of 2
.. .. ..$ train: int [1:58] 2 5 6 26 27 33 37 52 60 66 ...
.. .. ..$ test : int [1:27] 35 46 57 68 78 102 112 153 164 168 ...
.. ..$ :List of 2
.. .. ..$ train: int [1:58] 2 6 26 27 33 35 46 52 57 60 ...
.. .. ..$ test : int [1:27] 5 37 72 78 104 112 126 162 186 189 ...
.. ..$ :List of 2
.. .. ..$ train: int [1:58] 2 5 6 26 27 35 37 46 57 60 ...
.. .. ..$ test : int [1:27] 33 52 66 74 78 88 120 131 139 143 ...
..@ paths :List of 2
.. ..$ :Formal class ’AnalysisPath’ [package "longQDA"] with 4 slots
.. .. .. ..@ whichVisitsModel:List of 1
.. .. .. .. ..$ : num 1
.. .. .. ..@ modelfn :Formal class ’QdaAlgo’ [package "longQDA"] with 1 slots
.. .. .. .. .. ..@ reshapefn: chr "toXsec"
.. .. .. ..@ modelparams : list()
.. .. .. ..@ biomarker :List of 1
.. .. .. .. ..$ : chr "BM1"
.. ..$ :Formal class ’AnalysisPath’ [package "longQDA"] with 4 slots
.. .. .. ..@ whichVisitsModel:List of 1
.. .. .. .. ..$ : int [1:6] 1 2 3 4 5 6
.. .. .. ..@ modelfn :Formal class ’RisAlgo’ [package "longQDA"] with 1 slots
.. .. .. .. .. ..@ reshapefn: chr "minimize"
.. .. .. ..@ modelparams :List of 2
.. .. .. .. ..$ covstr : chr "RIS"
.. .. .. .. ..$ timestr: chr "quadratic"
.. .. .. ..@ biomarker :List of 1
.. .. .. .. ..$ : chr "BM1"
..@ performanceMeasuresParams:List of 1
.. ..$ stepcut: num 0.01
11
3 Analysis
3.1 Path 1 Visit(s) 1 Markers BM1
$group1
mu1 V11
4.702 0.479
$group2
mu1 V11
4.518 0.324
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Path 1_Visit(s) 1_Markers BM1
1−specificity for non−resistant (mean)
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3.2 Path 2 Visit(s) 1;2;3;4;5;6 Markers BM1
$group1
(Intercept) SDURN I(SDURN^2) DInt DSlope D_IS
4.438 -13.172 18.863 0.479 8.286 0.315
sigQuad
0.314
$group2
(Intercept) SDURN I(SDURN^2) DInt DSlope D_IS
4.270 -7.908 13.557 0.290 5.109 0.203
sigQuad
0.263
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longQDA includes 6 biomarker measurements per patient.
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4 Comparisons
4.1 Baseline vs. all 6 visits
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Baseline vs. all 6 visits
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B Selected Help Files of the R Package
longQDA
As supplementary material to Chapter 5, the documentation for the most important
functions are included in the form of help ﬁles. The following selection comprises those
functions that are needed to perform a "standard" longQDA, containing the output
as predeﬁned in createReportFiles. Beside the class MccvSummary and the method
createReportFiles of which the help ﬁles were included in Subsection 5.2.2, the
classes Report, LongData, AnalysisSetup and the methods analyze, mccvSummary
and selectResultLeafs are required.
Report-class Class 'Report' Contains Paths of Output Files
Description
An object of class 'Report' contains a list with elements called "Exploratory Analysis",
"Analysis Setup", "Analysis" and "Comparisons" as well as the path of the report
folder where all output ﬁles are stored. Every list entry contains the paths of the
output ﬁles which have been generated in the corresponding part of the analysis.
Graphics are saved in pdf format, tables and text in tex format.
Objects from the Class
Objects are created by calls of the form Report(folder).
folder: Object of class 'character'. Path of the folder where all analysis output
is saved which is later included in the report. If the folder does not exist yet, it
is automatically created. If the folder exists, its content is updated.
Slots
.Data: Object of class 'list' which contains the ﬁle names of the plots and tables
to be part of the report, structured by the following list elements:
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expl: Output for report section "Exploratory Analysis" - further subsections
possible.
anasetup: Output for report section "Analysis Setup".
analysis: Output for report section "Analysis" - further subsections possible.
comp: Output for report section "Comparisons" - further subsections possible.
(All subsections are created within createReportFiles with the result that the
corresponding list entries above may contain again lists (as documented above).)
folder: Object of class 'character': Path of the report folder where analysis out-
put to be included is saved.
Extends
Class 'list', from data part. Class 'vector', by class 'list', distance 2.
Methods
createReport signature(report = 'Report'): createReport
save2Report signature(report = 'Report'): save2Report
Author(s)
Mareike Kohlmann hlongQDA@web.dei
See Also
save2Report to add plots or text (comments) to the report, createReportFiles
to generate pre-deﬁned output for one analysis step and createReport to create the
report in tex (and pdf) format.
Examples
showClass("Report")
myreport <- Report(folder=getwd())
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LongData-class Class 'LongData' containing longitudinal data and metain-
formation
Description
Contains the longitudinally structured data set as well as metainformation (e.g. group-
speciﬁc colors and column indices of marker variables). For each subject, the data set
contains so many rows as there are individual repeated measurements.
Objects from the Class
Objects are created by calls of the form LongData(rawdata, name, markerlabels,
scheduledtimes, groups, priors, visitname, timename, groupname,
groupcolors, groupsymbols, idname).
rawdata: Object of class 'data.frame'. Raw data set in longitudinal structure, read
in beforehand by read.table, for example.
name: Object of class 'character'. Name of the data set, used i.a. as name of the
folder where for the output of the analysis is stored. As it will also be displayed
in the header of the report ﬁle in tex format, the character string should *not*
contain '_'.
markerlabels: Object of class 'character'. Names of the columns in rawdata
containing the biomarker variables.
scheduledtimes: Object of class 'numeric'. Vector containing scheduled times of
the visits.
groups: Object of class 'numeric'. Vector with levels of group variable. The group
labels need to be provided as names of the vector.
priors: Object of class 'numeric'. Default: c(0,0). Prior probabilities for group
membership. If they are not speciﬁed by the user (default), they are estimated
by the group proportions present in the data. Otherwise, they are not estimated
and taken as ﬁxed throughout the analysis.
visitname: Object of class 'character'. Default: "VISIT". Name of the variable
in the data set containing the consecutively numbered visits.
timename: Object of class 'character'. Default: "TIME". Name of the variable
in the data set containing the continuous study time (i.e. the actual time since
baseline).
groupname: Object of class 'character'. Default: "GROUP". Name of the variable
in the dataset containing the numerically coded group membership according to
the Gold Standard.
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groupcolors: Object of class 'character'. Default: c("black", "red").
Colours that are used for plots to distinguish the two groups by color.
groupsymbols: Object of class 'numeric'. Default: c(1,2). Symbol numbers for
plotting points to distinguish between the two groups. For possible values, refer
to pch in the section "Details" of points.
idname: Object of class 'character'. Default: "PATID". Name of the variable in
the data set containing the unique numerical subject identiﬁers.
Slots
id2rows: Object of class 'matrix' containing the row numbers of the data set for
each subject and each visit. The names of the rows are the identiﬁcation numbers
of the subjects, the names of the columns are the visit numbers.
visitindex: Object of class 'numeric'. Column of the data set containing the
visits (see also visitname above).
timeindex: Object of class 'numeric'. Column of the data set containing the study
time (see also timename above).
markerlabels: Object of class 'character'. Vector containing the names of the
marker labels provided by the user. The names of the vector are the new stan-
dardized names of the markers in the data set which are "BM1", "BM2",...
markerindices: Object of class 'numeric'. Vector containing the columns of the
data set containing the marker variables.
scheduledtimes: Object of class 'numeric'. Vector containing the scheduled times
of the visits as provided by the user.
rawdata: Object of class 'data.frame'. Data set provided by the user in a standard-
ized structure, e.g. coded names of the biomarker variables (see markerlabels).
name: Object of class 'character'. Name of the data set provided by the user.
groupindex: Object of class 'numeric'. Column of the data set containing the
coded group membership (see also groupname above).
grouplabels: Object of class 'character'. Labels of the two groups, provided by
the user.
groupcodes: Object of class 'numeric'. Coded levels of the two groups, provided
by the user.
groupcolors: Object of class 'character'. V. groupcolors above.
groupsymbols: Object of class 'numeric'. V. groupsymbols above.
grouppriors: Object of class 'numeric'. V. priors above.
fixedgrouppriors: Object of class 'logical'. If TRUE, prior probabilities for each
were provided by the user and are therefore treated as ﬁxed. If FALSE, the priors
are estimated by the group proportions in the data set and re-estimated whenever
necessary (e.g. in completeCases).
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idindex: Object of class 'numeric'. Column of the data set containing the unique
subject identiﬁcation numbers (see also idname above).
markertransformfn: Object of class 'character'. Names of the functions used for
marker transformation, only ﬁlled after execution of transform for real data.
Extends
Class 'Data', directly.
Methods
autoCorr: signature(data = 'LongData'): autoCorr
boxplotLongMarkers: signature(data = 'LongData'): boxplotLongMarkers
completeCases: signature(data = 'LongData'): completeCases
createReportFiles: signature(object = 'LongData'): createReportFiles
fit: signature(algo = 'QdaAlgo', data = 'LongData'): fit,QdaAlgo,
LongData-method
fit: signature(algo = 'RiAlgo', data = 'LongData'): fit,RiAlgo,
LongData-method
fit: signature(algo = 'RisAlgo', data = 'LongData'): fit,RisAlgo,
LongData-method
fit: signature(algo = 'Ricar1Algo', data = 'LongData'): fit,Ricar1Algo,
LongData-method
minimize: signature(data = 'LongData'): minimize
plotLongMarkers: signature(data = 'LongData'): plotLongMarkers
predict2: signature(model = 'QdaModel', data = 'LongData'):
predict2,QdaModel,LongData-method
predict2: signature(model = 'LongDaUnivModel', data = 'LongData'):
predict2,LongDaUnivModel,LongData-method
scatterVisitTimes: signature(data = 'LongData'): scatterVisitTimes
selectIds: signature(data = 'LongData', ids = 'vector'): selectIds
selectVisitsMarkers: signature(data = 'LongData', visits = 'vector',
markers = 'vector'): selectVisitsMarkers
toLongmv: signature(data = 'LongData'): toLongMv
toXsec: signature(data = 'LongData'): toXsec
transform: signature(_data = 'LongData'): transform
updateColIndices: signature(data = 'LongData'): updateColIndices
updateId2Rows: signature(data = 'LongData'): updateId2Rows
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Author(s)
Mareike Kohlmann hlongQDA@web.dei
Examples
showClass("LongData")
data(AIDS2)
d <- LongData(AIDS2, "AIDS2", c("BM1"), c(0,2,4,8,16,24)/52,
c('non-resistant'=1, 'resistant'=2), timename="SDURN")
AnalysisSetup-class
Class 'AnalysisSetup' Containing the Analysis Settings
Description
All analysis settings are contained therein to enable logging and reproducibility. In
details, these are the data together with its metainformation, the Monte Carlo cross-
validation (MCCV) samples, the analysis paths containing details about sub-analyses
to be performed and the global precision parameters for evaluating the performance
measures. To compare results of various analyses, it is recommended to use the same
setup settings (the same data set, same MCCV samples and same performance mea-
sures parameters), diﬀering only with regard to the analysis paths deﬁning the models.
This is accomplished by saving the analysis setup of one analysis and updating it for
the other one by updateAnalysisSetup.
Objects from the Class
Objects are created by calls of the form
AnalysisSetup(data, nMCsamples, ratiotrain, paths, stepcut).
data: Object of class 'LongData'. Data set and corresponding metainformation.
nMCsamples: Object of class 'numeric'. Number of Monte Carlo crossvalidation
samples to be used for the analysis.
ratiotrain: Object of class 'numeric'. Subjects are randomized blockwise (i.e.
with all their repeated measurements) to the training set with a probability of
ratiotrain within each group. This sampling yields a ratio of the size of the
training to that of the test set equal to ratiotrain and is performed without
replacement.
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paths: Object of class 'list'. The list should contain the following knot selection
criteria to build up the analysis tree describing the sub-analyses to be performed.
For an illustration with 2 biomarkers and 3 visits see the vignette "longQDA-
Analysis".
isLongitudinal: Object of class 'logical'. If TRUE, longitudinal data struc-
ture is accounted for in the analysis, i.e. longQDA is used.
isMarkerComb: Object of class 'logical'. If TRUE, biomarkers are analyzed in
combinations.
markerCombLength: Object of class 'numeric' determining how many
markers are combined; only needed for multivariate (long)QDA, i.e. when
isMarkerComb=TRUE.
isSingleVisit: Object of class 'logical'. If TRUE, data of single visits are
used; only needed for classic QDA.
whichVisits: Object of class 'numeric' giving the vector of visits which are
included in the analysis. For longQDA, this vector should always have 1 as
ﬁrst entry and should be a consecutive sequence.
modelparams: Object of class 'list' containing the following mixed
model parameters and need to be therefore only provided by the user if
isLongitudinal=TRUE.
covstr: Object of class 'character' giving the covariance structure. Can
be either "RI" (random intercept), "RIS" (random intercept and linear
slope) or "RICAR1" (random intercept and continuous AR(1) residual
structure) for univariate longQDA.
timestr: Object of class 'character' giving the maximum order for the
ﬁxed eﬀect(s) of the time variable. Terms of lower order are automati-
cally included. Can either be "linear" or "quadratic".
stepcut: Object of class 'numeric'. Default: 0.01. Precision parameter for gen-
erating the ROC curve. It gives the step length for moving the cut-oﬀ along
the range of the predicted posterior probabilities. Lower values than the default
gives higher precision and vice versa.
Slots
data: Object of class 'LongData'. Data set and corresponding metainformation
as provided by the user. It is not modiﬁed, only saved to support reproducible
research.
MCsamples: Object of class 'list' having length nMCsamples and containing for
each MC sample a list with 2 entries:
train: Object of class 'numeric' containing the unique identiﬁcation numbers
of subjects sampled to the training set by MCCV.
test: Object of class 'numeric' containing the unique identiﬁcation numbers
of subjects sampled to the test set by MCCV.
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paths: Object of class 'list' containing the analysis paths of class
'AnalysisPath'. See there for details and their structure.
performanceMeasuresParams: Object of class 'list' containing the named preci-
sion parameter stepcut. (Note: The list structure was set up to allow further
extension with additional parameters in the future.)
Methods
analyze: signature(analysis = 'AnalysisSetup'): analyze
createReportFiles: signature(object = 'AnalysisSetup'):
createReportFiles
updateAnalysisSetup: signature(setup = 'AnalysisSetup'):
updateAnalysisSetup
Author(s)
Mareike Kohlmann hlongQDA@web.dei
See Also
'AnalysisPath'
Examples
showClass("AnalysisSetup")
data(AIDS2)
d <- LongData(AIDS2, "AIDS2", c("BM1"), c(0,2,4,8,16,24)/52,
c('non-resistant'=1, 'resistant'=2), timename="SDURN")
d2 <- completeCases(d, visits=6)
asetup <- AnalysisSetup(d2, nMCsamples=5, ratiotrain=2/3,
paths=list(list(isLongitudinal=FALSE, isMarkerComb=FALSE,
isSingleVisit=TRUE,
whichVisits=(1:ncol(d2@id2rows))),
list(isLongitudinal=TRUE, isMarkerComb=FALSE,
whichVisits=(1:ncol(d2@id2rows)),
modelparams=list(covstr="RI",
timestr="quadratic"))))
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analyze-method Performs All (long)QDA Analyses and Evaluates Classiﬁca-
tion Performance
Description
Every analysis comprises the following sequential steps: Data set preparation, group-
wise model ﬁtting by the appropriate algorithm on the training set, computation of
the marginal estimators of the mean vector and the covariance matrix to predict the
posterior probabilities by the quadratic discriminant rule on the test set and graphical
and numerical evaluation of the performance measures. This is done repeatedly using
each of the MCCV samples, each visit and each biomarker selection of the analysis
paths deﬁned by the user in the analysis resp. simulation setup.
For simulated data, this procedure is repeated for each of the simreps generated data
sets. To speed up the analyses, parallel computing can be used. See parAnalyze for
details.
Usage
For objects of class 'AnalysisSetup' or 'SimulationSetup':
analyze(analysis)
Arguments
analysis = 'AnalysisSetup': Object deﬁning all analyses to be performed with
real data.
analysis = 'SimulationSetup': Object deﬁning all analyses to be performed with
simulated data.
Value
Object of class 'ResultTree' for real data resp. of class 'SimulationResult' for
simulated data.
Author(s)
Mareike Kohlmann hlongQDA@web.dei
See Also
'AnalysisSetup', 'ResultTree','SimulationSetup', 'SimulationResult'
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Examples
### Using real data:
data(AIDS2)
d <- LongData(AIDS2, "AIDS2", c("BM1"), c(0,2,4,8,16,24)/52,
c('non-resistant'=1, 'resistant'=2), timename="SDURN")
d2 <- completeCases(d, visits=6)
asetup <- AnalysisSetup(d2, nMCsamples=5, ratiotrain=2/3,
paths=list(
list(isLongitudinal=TRUE, isMarkerComb=FALSE,
whichVisits=(1:ncol(d2@id2rows)),
modelparams=list(covstr="RI",
timestr="quadratic"))))
full.tree <- analyze(asetup)
str(full.tree, 8)
### Using simulated data (without making use of parallel computing):
risStar <- RisStarModel(group1=list(beta=c(4.0,-4.5),
DCovstar=matrix(c(0.40, 0.39, 0.39, 16.1),
ncol=2, byrow=FALSE),
R=c(sigQuad=0.56)),
group2=list(beta=c(4.0,-1.4),
DCovstar=matrix(c(0.23, 0.46, 0.46, 15.8),
ncol=2, byrow=FALSE),
R=c(sigQuad=0.39)),
timestr="linear")
testpaths <- list(list(isLongitudinal=TRUE, isMarkerComb=FALSE,
whichVisits=(1:6),
modelparams=list(covstr="RIS", timestr="linear")))
sim.setup <- SimulationSetup(starModel=risStar, simreps=2, paths=testpaths,
nvisits=6, ngroups=2*c(95, 37),
grouplabels=c("non-resistant", "resistant"),
priors=c(292, 64)/356, randomVisits=NULL,
fixVisits=c(0,2,4,8,16,24)/52,
nMCsamples=5, ratiotrain=2/3, stepcut=0.01,
bmtransform="log10")
full.simtree <- analyze(sim.setup)
mccvSummary-method Summarizes Analysis Results over MCCV samples
Description
The lowest level of the analysis tree, consisting of one node for each MCCV sample,
is summarized as one leaf node.
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Usage
For objects of class 'ResultTree' or 'SimulationResult':
mccvSummary(tree, analysis)
Arguments
tree = 'ResultTree': Tree with analysis results based on real data. The leaf nodes
with the results of the MCCV samples are summarized.
tree = 'SimulationResult': Tree with analysis results based on simulated data.
The leaf nodes with the results of the MCCV samples are summarized.
analysis: Object of class 'AnalysisSetup' containing metainformation about the
data. It is needed for a correctly structured summary of the analysis tree.
Value
Object of class 'ResultTree' with leaf nodes of class 'MccvSummary'.
Author(s)
Mareike Kohlmann hlongQDA@web.dei
Examples
### Example 1 with real data (results of class 'ResultTree')
data(AIDS2)
d <- LongData(AIDS2, "AIDS2", c("BM1"), c(0,2,4,8,16,24)/52,
c('non-resistant'=1, 'resistant'=2), timename="SDURN")
d2 <- completeCases(d, visits=6)
asetup <- AnalysisSetup(d2, nMCsamples=5, ratiotrain=2/3,
paths=list(
list(isLongitudinal=FALSE, isMarkerComb=FALSE,
isSingleVisit=TRUE,
whichVisits=(1:ncol(d2@id2rows))),
list(isLongitudinal=TRUE, isMarkerComb=FALSE,
whichVisits=(1:ncol(d2@id2rows)),
modelparams=list(covstr="RI",
timestr="quadratic"))))
tree <- analyze(asetup)
sum.tree <- mccvSummary(tree, asetup)
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selectResultLeafs-method
Selects Analysis Results of Speciﬁed Node Leafs
Description
Selects some or all of the analysis results speciﬁed by the user for comparison. In
addition, the complex hierarchical structure of the result tree is removed and a ﬂat list
is returned instead. For an easy identiﬁcation of the selected paths, it is recommended
to provide path names.
Usage
For objects of class 'ResultTree' or 'SimulationResult':
selectResultLeafs(tree, leafnumbers=NULL, compname=paste("leafnumbers:",
ifelse(is.null(leafnumbers), "all", paste(leafnumbers,
collapse="-"))), pathnames=NULL)
Arguments
tree = 'ResultTree': A tree containing all results of the analysis based on real
data in the leaf nodes.
tree = 'SimulationResult': A tree containing all results of the analysis based on
simulated data in the leaf nodes.
leafnumbers: Default: NULL. Vector with numbers of leaf nodes to be selected,
can be displayed by showLeafs. If no leafnumbers are speciﬁed (default), all
leafnumbers are selected.
compname: Default: paste("leafnumbers:", ifelse(is.null(leafnumbers),
"all", paste(leafnumbers, collapse="-"))). Name of the comparison,
used as name for the returned result list.
pathnames: Default: NULL. Names of the corresponding analysis paths of the selected
leaf nodes, used as list names of the returned result list.
Note
The result tree must have the structure as returned by mccvSummary. Otherwise, an
error message is generated and the execution of the function is stopped.
Value
Object of class 'ResultList' containing only the analysis results of selected leafs.
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Author(s)
Mareike Kohlmann hlongQDA@web.dei
Examples
data(AIDS2)
d <- LongData(AIDS2, "AIDS2", c("BM1"), c(0,2,4,8,16,24)/52,
c('non-resistant'=1, 'resistant'=2), timename="SDURN")
d2 <- completeCases(d, visits=6)
asetup <- AnalysisSetup(d2, nMCsamples=5, ratiotrain=2/3,
paths=list(
list(isLongitudinal=FALSE, isMarkerComb=FALSE,
isSingleVisit=TRUE,
whichVisits=(1:ncol(d2@id2rows))),
list(isLongitudinal=TRUE, isMarkerComb=FALSE,
whichVisits=(1:ncol(d2@id2rows)),
modelparams=list(covstr="RI",
timestr="quadratic"))))
tree <- analyze(asetup)
summary.tree <- mccvSummary(tree, asetup)
leafs6 <- selectResultLeafs(summary.tree, leafnumbers=c(1,7),
compname="Baseline vs. all 6 visits",
pathnames=c("QDA, Baseline", "RI, 6 vis."))
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